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EXECUTIVE
SUMMARY
BACKGROUND TO THE REPORT
This literature review of risk factors for dementia and cognitive decline was carried out
between January and November 2002. It has been written by research staff at the
University of Paisley. The project was commissioned and funded by the Public Health
Institute of Scotland (now NHS Health Scotland) in the light of concerns about the
expected dramatic increase in the numbers of older people in Scotland (as elsewhere) living
with dementia. The effects of the syndrome can cause considerable problems for those
affected and for others. At one time, dementia and cognitive decline were seen as
inevitable consequences of ageing. Now, however, as more is known about ageing and
about the brain, possible means of prevention and treatment are being investigated, with a
view to reducing the prevalence of dementia. However, although treatment may slow the
progress of dementia in some cases, the condition cannot be reversed or cured, and there
has been growing interest in the possibilities for averting or delaying the occurrence of the
condition. Although little is known about the causal processes that result in dementia,
epidemiological studies examining some of the factors which appear to increase or
decrease risk are being carried out around the world.  
It was hoped that a review of this research literature would suggest answers to the
following questions: Are there any prospects of preventing dementia in Scotland? What are
the prospects? How far away are we? And what are the implications for public health
practice in Scotland? The review was later extended to include ‘risk factors’ for cognitive
decline. There is a debate about whether dementia should best be seen as an extension of
‘normal’ age-related cognitive decline or as a qualitatively different disorder, and answers to
this question could have important implications for approaches to prevention.
The timescale of the project precluded a comprehensive and systematic review. The
literature is vast, and commentators on empirical work have drawn attention to the
difficulties of summarising the findings from existing research or making comparisons.
Because of these problems, this report draws largely on existing reviews of the literature,
book chapters, editorials and commentaries, although recently published studies have also
been included.  It is acknowledged that the report might be partial or incomplete, although
steps have been taken to ensure factual accuracy.  
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The report is intended for health professionals and policy makers in Scotland. It is
hoped that it might also be useful to academics, since references have been included
wherever possible. 
PART I - BACKGROUND TO EMPIRICAL WORK
Demography and trends
• Because of the general increase in life expectancy and the ageing of the ‘baby boomer’
generation, the number of older people in Scotland is projected to rise substantially, with
the oldest groups experiencing the largest relative increase.
• The number of people with age-related conditions such as dementia is rising, and will
continue to rise, particularly in the oldest age group.
• Applying recognised prevalence figures to projected population statistics, the number
of people living with dementia in 2040 could be over 100,000, i.e. one in fifty of
the population.
Implications for public health, and primary prevention strategies
• The increasing prevalence of dementia is an important public health issue, because of the
impact on individuals and on service provision.
• While the progress of dementia can sometimes be slowed, no cure is available.
• There would be immense benefits to public health if ways of reducing the incidence (as
well as the prevalence) of dementia and cognitive decline could be found. Since the rates
of incidence of dementia rise exponentially with age, raising the mean age of onset could
significantly reduce the prevalence.  
• A primary prevention approach rests on a knowledge of causal factors and appropriate
means of intervention.  
• The processes underlying the development of dementia and cognitive decline are not
fully understood. At the same time as more is known about changes in the brain,
epidemiological studies of potential risk and protective factors are being carried out.
Cognitive decline, dementia and types of dementia
• Dementia can broadly be divided into vascular dementia and dementia of the Alzheimer
type, but dementia with Lewy bodies and fronto-temporal dementia are now thought to
have been under-diagnosed in the past.
• There is increasing knowledge of types and sub-types of dementia, but also of the
overlap between types or categories. With increasing knowledge, terminology is evolving.
• Cognitive decline has been sub-divided into ‘age-associated cognitive decline’ (AAMI)
and ‘cognitive impairment no dementia’ (CIND).
• Diagnosis of both cognitive decline and dementia is difficult, but there are now
internationally agreed standards. 
• A number of hypotheses and models of dementia of the Alzheimer type have been
proposed, based on pathological and clinical criteria.
• There is interest in whether cognitive decline and Alzheimer's disease should be seen as a
continuum, or as qualitatively different conditions. This issue could have important
implications for approaches to prevention.
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Methodological issues
• In assessing the findings from epidemiological work, a number of methodological issues
concerned with definition and measurement, and the design of the study, have to be
taken into account.
• The presence of the disorder or type of disorder must be capable of being reliably
assessed, as must the strength of exposure to risk factors.
• The design of the study can strongly influence the findings. Early empirical research was
based on case-control studies of prevalence, but large longitudinal studies of incidence
are needed to distinguish between association and causality, and to examine
interactions between risk factors.
• There may be various explanations for some of the findings of epidemiological studies. 
PART II - RISK FACTORS FOR DEMENTIA AND COGNITIVE DECLINE
Age, gender, ethnic and national factors
• Cognitive function declines with age, although there are wide individual differences, and
also differences between domains in the rate of decline.
• Both the prevalence and incidence of dementia increase exponentially with age. Key
issues are the size (or relative importance) of ‘age’ as a risk factor, and explanations for
the effect of ageing.
• Age has generally been seen as the main risk factor for dementia, but there is debate
about whether the ‘cause’ should be seen in terms of ageing per se (in which case
everyone would develop dementia if they lived for long enough), or the ageing-related
increasing incidence of disease.
• There are gender differences in the prevalence of dementia, but whether these reflect
differences in incidence is still unclear.
• By contrast with other chronic disorders, cross-cultural studies have thrown little light on
causal factors. The difficulty of separating biological and environmental factors has been
widely acknowledged.
Genetic factors
• Early onset Alzheimer's disease is strongly related to family history, and three genetic
mutations associated with this disorder have been identified. Although cases of early-
onset Alzheimer's disease account for a small proportion of cases of dementia overall, a
high proportion of such cases are thought to be associated with these genes.
• One genetic mutation has been linked with some forms of late onset dementia including
Alzheimer's disease. This is the APOE 4 allele. However, the presence of APOE 4 is neither
necessary nor sufficient to cause Alzheimer's disease; only about half of affected
individuals carry the allele.  
• Other genetic factors are being investigated.
• At the moment, research findings have not suggested any means of prevention.  
• An increased knowledge of genetic factors has been seen as useful in gaining a better
understanding of the mechanisms underlying the development of dementia.
Pre-existing conditions
• A number of conditions can predispose to dementia of the Alzheimer type. These include
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Down’s syndrome and Parkinson’s disease. Some studies have found an association with
thyroid disease but others have not.
• Pathological and genetic associations between Down’s syndrome and Alzheimer's disease
have been found. The incidence of dementia of this type occurs 30 – 40 years earlier in
the population of people with Down’s syndrome than in the general population.  
• The prevalence of dementia in people with Parkinson’s disease is thought to be between
28 – 40%, i.e. considerably higher than in the general population.
Physical injury, illness and medication
• There is some evidence that brain injury increases the risk of cognitive decline.
• There is evidence to support a link between head trauma and loss of consciousness and
an increased risk of Alzheimer's disease, although not all studies show this.
• There is some evidence to suggest that herpes simplex type 1 virus (HSV1) may be a risk
factor in individuals who carry the APOE 4 allele. If this is the case, it is possible that
some cases of Alzheimer's disease could be prevented by vaccination.
• The link with aluminium suggested by some early studies has not been proved.
• A few studies have examined exposure to other toxins and pollutants, but the findings
are inconclusive.
• There is some evidence of a link between non-steroidal anti-inflammatory drugs (NSAIDs)
and a reduced risk of Alzheimer's disease, although this protective effect remains to be
confirmed by clinical trials. NSAIDs have a number of side effects that preclude their
widespread use.
Risk factors for vascular disease
• The risk factors for vascular dementia are relatively well understood. These include
cerebro-vascular disease, and risk factors for vascular disease, such as hypertension,
diabetes and obesity.
• An association has recently been found between vascular factors found in mid-life (e.g.
hypertension) and Alzheimer's disease. At the same time, low blood pressure has
sometimes been found among people with the disorder.
• Findings from recent large studies have indicated that high blood pressure measured in
mid-life is also a significant predictor of poorer cognitive function in later life.
• The long-term cognitive decline experienced by a minority of heart bypass patients is
being investigated.
Smoking, alcohol and drug use
• Smoking is a known risk factor for vascular dementia.  
• Findings from studies examining smoking and the risk of Alzheimer's disease have varied.
It has been concluded that any effect, in either direction, is likely to be small.
• High alcohol intake is linked with cognitive impairment, although the effects may be
reversible. It is also the commonest cause of Wernicke-Korsakoff syndrome, the main
feature of which is memory impairment.
• Alcohol use is thought to contribute to a significant proportion (10%) of cases of
dementia. A high intake of alcohol is associated with vascular disease and, hence, with
vascular dementia. Also, although alcohol per se might not cause dementia, it has
been seen as a contributory factor in conjunction with other factors, particularly
nutritional deficiencies.  
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• Although there is interest in the long term effect of recreational drug use on the brain,
drug use has not been examined as a risk factor.
Diet, nutrition and hormones
• Weight loss is commonly associated with Alzheimer's disease, and a number of possible
explanations have been suggested.
• Nutritional deficiency has been found to affect cognition, and associations with dementia
are being investigated.
• A deficiency of B vitamins (B12, B6 and folate) has been found to be correlated with
increased serum homocysteine (tHcy) concentrations. Low levels of B vitamins have been
associated with lower levels of cognitive function. Similarly, a high concentration of
homocysteine (or folate deficiency) has been associated with an increased risk of
dementia, particularly Alzheimer's disease.
• Clinical trials of vitamin B supplements for people with Alzheimer's disease are planned,
and these may be extended to people with mild memory impairment.
• High cholesterol levels are associated with an increased risk of vascular disease and hence
vascular dementia. There is evidence of an association between high levels of dietary
saturated fat, or high cholesterol level, in mid-life and an increased risk of cognitive
decline and dementia.  
• There is some evidence to suggest that regular consumption of foods rich in N-3
polyunsaturated fatty acids may decrease the risk of Alzheimer’s disease.
• Statins (one type of lipid-lowering agent) have been found to lower the risk of vascular
disease and mortality from all causes. There is also some evidence that they reduce the
risk of developing Alzheimer's disease. Clinical trials are under way.
• Clinical intervention studies are examining whether anti-oxidant vitamins might reduce
the risk of dementia. Findings have been contradictory, but tend to suggest that vitamins
from food sources are more effective than supplements.
• Some observational studies have suggested that oestrogen use in post-menopausal
women can have a beneficial effect on cognitive function. However, the evidence for a
protective role against the development of dementia is weak. The effects of oestrogen
and HRT use are being investigated, although long term trials have been halted.
• Reviewers of the literature have emphasised that nutritional factors should be considered
in conjunction with others, and that there may be a number of possible explanations.
To what extent, if any, might interventions currently targeted at vascular disease have
helpful impacts on dementia or cognitive decline?
• The fact that some dementia and cognitive decline is linked with vascular factors,
particularly hypertension, suggests that there is some scope for intervention.  Treatment
of hypertension has been established, and has been found to be effective in reducing the
risk of vascular events. Thus, vascular dementia may be preventable, to an extent, by
medication and/or lifestyle change.
• However, little is known about whether interventions targeted at vascular disease have
any impact on the incidence of dementia or cognitive decline.  
• The identification of those whose age, sex, smoking and blood pressure indicate a high
risk of vascular disease is felt to be worthwhile in relation to vascular risk, and may be
worthwhile in relation to dementia.
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Factors related to social context: Social class, occupation and education
• Factors relating to social context or class have a significant effect on health and on the
incidence of a number of disorders.
• Lower socio-economic status (as measured by income or occupation) has been linked to
lower cognitive function in later life.
• Lower socio-economic status is known to be associated with an increased risk of vascular
disease, and, hence, potentially with an increased risk of vascular dementia.
• Little is known, however, about the relationship between lower socio-economic status
and the risk of cognitive decline or dementia.  Few longitudinal studies examining social
class or poverty as a factor have been carried out.  In the US, education has been taken
as a proxy measure of social class, but education can have a number of meanings.
• Occupation can be a marker for a number of factors, in addition to social class (e.g.
exposure to toxic substances).
• Lower educational level is known to be associated with lower cognitive function later in
life, but there has been little examination of the nature of this association, or of links with
cognitive decline.
• There is evidence that lower educational level is associated with an increased risk of
vascular dementia.
• The findings from studies examining links between lower educational level and an
increased risk of dementia of all types or Alzheimer's disease are mixed.  Some studies
have found evidence of an association, but others have not.
• Education has often been taken as a measure of innate intelligence or mental stimulation,
either or both of which have been viewed as serving to enhance ‘brain reserve’.  It has
been suggested that brain reserve might protect the brain from degeneration, or might
mitigate against the effects, hence delaying a diagnosis of dementia or cognitive decline.
• Because of the many meanings of education, implications for prevention are unclear.
Physical, mental and social activity
• Research is beginning to examine relationships between physical, mental and social
activity – in mid-life and in old age – and the incidence of cognitive decline and
dementia. If associations are found, there may be implications for social policy, e.g. in
relation to retirement.
• The findings from some studies have indicated that the maintenance of cognitive
function in old age is associated with good physical health. Other research has not found
this, however.
• There is some evidence that pulmonary function (FEV1) in mid-life predicts cognitive
function in old age, although the mechanisms are unknown.
• Physical exercise has been linked with a reduced risk of vascular disease. However, links with
the incidence of cognitive decline and dementia have been little examined by research.
• There is some evidence that mental activity can enhance or maintain cognitive function,
or protect against a degree of decline, although there are wide variations.  Further
research is felt to be needed to establish whether cognitive activity could protect against
long-term cognitive decline or dementia.
• There is also some evidence that social activity, involvement and support can help to
maintain cognitive function. Preliminary findings which suggest a reduced susceptibility
to dementia are felt to warrant further investigation.
• Although there is some evidence that some forms of ‘activity’ seem to have a preventive
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effect on cognitive decline, caution has been expressed about ascribing a protective role
to ‘activity’, since those experiencing cognitive decline might be less likely to be active.
• There is felt to be enough evidence to take seriously the possibility that depression is a
risk factor for dementia and cognitive decline.
• There has been increasing interest in the role of stress in cognitive functioning, because
of the link with stroke, because prolonged exposure to a stress hormone (cortisol) is
known to affect mental performance, and because ageing can be viewed in terms of a
loss of adaptive capacity.
PART III - DISCUSSION AND CONCLUSION
Discussion
• Cognitive function declines with age, although such decline is not inevitable and not
always progressive. A ‘healthy lifestyle’, and measures to maximise mental and social, as
well as physical health, have been recommended as potentially protective against
cognitive decline.
• The risk factors for vascular dementia are relatively well understood; these include
cerebro-vascular disease and risk factors for vascular disorders. The risk of vascular
dementia may be reduced by lowering the risk of vascular disease, e.g. through the
control of hypertension.
• At the moment, the only risk factors for Alzheimer's disease confirmed beyond reasonable
doubt are old age, a family history of dementia (particularly for early onset dementia),
Down’s syndrome and the APOE 4 genotype. The evidence for other risk factors is
inconclusive. None of the known risk factors for Alzheimer's disease is felt to give scope
for preventive action. Also, because of the links with age and – perhaps - genetic factors,
the potential for primary prevention may always be relatively limited. However, an
association with vascular factors suggested by recent research has caused the dichotomy
between vascular dementia and (‘degenerative’) Alzheimer's disease to be questioned,
and has indicated that there may be some scope for prevention.  
• Although the causal mechanisms underlying the development of dementia and cognitive
decline are not fully understood, with increasing knowledge about the brain and the
findings from epidemiological studies of risk factors, progress is being made. There is felt
to be considerable potential for further research.
• Evidence suggests that there is often no single cause of dementia or cognitive decline,
and hence no single solution, but that there may be some limited scope for intervention.
Clinical trials of potentially benefical interventions are felt to be worthwhile.
• One key issue may be the relationship between age-related cognitive decline and
dementia. Some commentators (although not others) have suggested that the evidence
from risk factor research tends to support the view that cognitive decline and dementia
of the Alzheimer type should be seen as a continuum rather than as qualitatively different
conditions. If this is the case, then changes associated with ageing are of interest. 
• Reviewers of the literature have noted a number of limitations of current research. It has
been emphasised that the evidence base must be adequate before considering strategies
of prevention.
• Some environmental risk factors, particularly social class, have been little examined
by research.  
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• A focus on primary prevention has been criticised for an over-emphasis on individual and
biological ‘risk factors’, for promoting the view that such prevention strategies are
feasible and ignoring the role of age, and for increasing anxiety and pathologising mild
cognitive impairment. A focus on primary prevention has also been seen as shifting
priorities and diverting attention from solutions of care and the needs of those affected.
• One approach to a public health goal of ‘healthy ageing’ is to consider the extent to
which ‘compression of morbidity’ is achievable, by delaying the onset of certain
conditions or preventing their occurrence.  
• In moving from knowledge about risk factors to strategies of intervention, there are a
number of practical and philosophical issues to be taken into account. These include
questions of ethics, responsibility, feasibility and acceptability.
• At the moment, targeted strategies (based on ‘high-risk’ groups) seem to offer more
potential than those based on populations, with the further investigation of potential
protective measures felt to be worthwhile. Questions remain about screening as a
method of identifying those at high risk.
• An important issue is when strategies of intervention might be most effective or
beneficial. Some evidence that ‘mid-life’ risk factors may predict later cognitive decline,
and that initial neurodegenerative changes of Alzheimer's disease may occur up to 40
years before the first clinical symptoms, suggests that mid-life preventive measures might
be worthwhile.
Conclusion
The report concludes that at present there are very few immediate prospects for effective
action to reduce the incidence of dementia in Scotland, particularly dementia of the
Alzheimer type. However, prospects may be beginning to improve. Research into risk
factors and potential interventions is ongoing, and there is much that remains to be
investigated. Progress is being made. More factors may be found, and much more will be
learned about – for example - the relative importance of different factors, the ways in which
and the extent to which these factors interact, and the extent to which they can be
modified. The hope is that new knowledge, together with the increased understanding
about ageing and the brain, will contribute to a better understanding about the nature and
the causes of cognitive decline and dementia. This in turn may suggest possible methods of
primary prevention. Research findings tend to suggest that there is no one single ‘cause’ of
dementia, and hence no single solution. Although age is an important contributory factor
for dementia and cognitive decline, there may be some scope for preventive action,
particularly for the latter, perhaps in mid-life.  
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CHAPTER ONE
INTRODUCTION
Given the increasing numbers of older people in most western populations, there is
concern about the anticipated rise in the prevalence of ageing-related disorders such as
dementia. It has been predicted, for example, that by 2040 one in every fifty people in
Scotland could be living with this disorder. The effects of the syndrome can cause
considerable problems for those affected and for others. At one time, dementia and
cognitive decline were seen as inevitable consequences of ageing. Now, however, as more
is known about ageing and about the brain, possible means of prevention are being
investigated, with a view to reducing the prevalence of dementia.  
One approach to ‘prevention’ involves the early detection of a condition and intervention
to halt or delay its progress (secondary prevention). Another approach – primary
prevention - aims to avert or delay the occurrence of a condition by reducing exposure to
causative factors, i.e. by reducing risk. Although little is known at the moment about the
mechanisms or causal processes which result in dementia, or about when the degenerative
processes begin, progress is being made, and considerable research efforts are being
expended in investigating both primary and secondary approaches to dementia.  
However, although treatment may slow the progress of dementia in some cases, the
condition cannot be reversed or cured. There has been growing interest, therefore, in the
possibilities for primary prevention, since even delaying the onset of dementia could
dramatically reduce the numbers of people affected.  Epidemiological studies across the
world are investigating some of the factors which appear to increase or decrease the risk of
dementia (especially Alzheimer's disease). The findings from large longitudinal studies and
clinical trials are beginning to emerge, and some intervention trials have been instigated.  
A review of this epidemiological literature was commissioned by the Public Health Institute
of Scotland (now NHS Health Scotland). It was hoped that the review might suggest
answers to the following research questions: Are there any prospects of preventing
dementia in Scotland?  What are the prospects? How far away are we?  And what are the
implications for public health practice in Scotland? It was decided that the review would
focus on primary prevention, and on the results of studies investigating the evidence for
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‘risk factors’. Literature detailing the findings from treatment studies would be excluded,
except where such interventions were felt to prevent (rather than slow) the development of
dementia. The review was later extended to include evidence about ‘risk factors’ for cognitive
decline. There is a debate about whether dementia should best be seen as an extension of
‘normal’ age-related cognitive decline or as a qualitatively different disorder, and answers to
this question could have important implications for approaches to prevention.
The timescale of the project precluded a comprehensive and systematic review. The literature
is vast, and commentators on empirical work have drawn attention to the difficulties of
summarising the findings or making comparisons. Various methods have been used, and a
range of factors examined. In addition, studies examining cognitive decline have been
carried out by psychologists, interested in differences between domains, rather than by
epidemiologists. Diagnosing and defining dementia and cognitive decline is problematic,
and the terms ‘cognitive decline’ and ‘dementia’ have been used in writing up some of the
research. Because of these problems, this report draws largely on existing reviews of the
literature, book chapters, editorials and commentaries. However, the findings from recently
published studies have been included. It is acknowledged that the report might be partial or
incomplete, although steps have been taken to ensure factual accuracy. The report is
intended for health professionals and policy makers in Scotland. It is hoped that it might also
be useful to academics, since references have been included wherever possible.  
The first four chapters in Part I provide the background to current empirical work. They cover:
demography and trends, implications for public health and primary prevention strategies,
definitions of cognitive decline and dementia, hypotheses and models, and methodological
issues. Part II, the body of the report, reports on the evidence from empirical work which has
examined risk (or protective) factors for dementia or cognitive decline, and intervention
studies. This section is structured according to risk factors under the following headings: 
• Age, gender and ethnicity
• Genetic factors
• Pre-existing conditions
• Physical injury, illness and medication
• Classical [personal and lifestyle] risk factors: 
• risk factors for vascular disease
• smoking, alcohol and drug use
• diet, nutrition and hormones
• interventions targeted at vascular disease
• Factors related to social context: social class, occupation and education
• Physical, mental and social activity
In Part III, the discussion chapter summarises the findings from research. It also considers
what the evidence suggests about the nature of dementia and cognitive decline and the
relationship between the two. The limitations of existing empirical work are discussed, as
well as some critiques of a focus on primary prevention. Starting from the concept of
‘healthy ageing’, the chapter considers the feasibility of ‘compression of morbidity’. It
concludes by outlining the conclusions that can be drawn about public health strategies for
preventing dementia and cognitive decline.  
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The report concludes that at present there are very few immediate prospects for effective
action to reduce the incidence of dementia in Scotland, particularly dementia of the
Alzheimer type. However, prospects may be beginning to improve. Research into risk
factors and potential interventions is ongoing, and there is much that remains to be
investigated. Progress is being made. Much is being learned about risk factors, ageing and
the brain, and about the nature and causes of dementia and cognitive decline. The hope is
that this new knowledge will indicate possibilities for methods of prevention.
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PART ONE
BACKGROUND TO
EMPIRICAL WORK
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CHAPTER TWO
DEMOGRAPHY
AND TRENDS
The populations of most developed countries are ageing, leading to an increase in the
prevalence of age-related disorders such as cognitive decline and dementia. This chapter gives
the predicted increase in the numbers of older people in Scotland. Prevalence ratios derived from
a meta-analyses of European studies have been used to derive estimates of the number of
people in Scotland with dementia in 2002, and until 2040.
The populations of most developed countries are ageing. In Scotland, the older population has
been growing in absolute and relative terms throughout the 20th century, and this trend is
predicted to continue. Whereas in 2000, people aged 65 and over made up just over 15% of
the population, NHS Scotland (Information and Statistics Division) estimates that this group will
account for 24% of the population by 2031.1 (At the moment, women outnumber men in the
older age groups, but male and female life expectancies are predicted to become more similar.1)
The main reasons for the absolute increase in numbers are the ageing of the ‘baby boomer’
cohort, and a general increase in life expectancy or ongoing decline in mortality at older ages.
Declining birth rates contribute towards the relative growth in numbers of older age groups.
In 2000, there were approximately 787,000 people aged 65 and over in Scotland.  Of these,
approximately 347,000 were aged 75 and over and 84,000 aged 85 and over.1 Substantial
increases are predicted to occur over the coming 30 years, with the oldest age group
experiencing the largest relative increase.1 Government Actuaries Department figures based on
the Registrar General’s estimates suggest that the number of people aged over 65 in Scotland
is expected to grow from 787,000 in 2000 to 1,238,000 in 2040, an increase of 57%.2
As the number of older people in the population increases, the prevalence of impairment is
also expected to increase, since rates of limiting longstanding illness and disability increase
dramatically with age.1;3 A number of age-related disorders relate to mental health and
cognitive function. Hence, the increase in life expectancy observed over the last decade has
particular relevance for conditions such as cognitive decline and dementia.4 These
conditions can detract from an individual’s quality of life, and reduce their ability to live
independently, with consequences for others, particularly family members, and for health
and social services.
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THE PREVALENCE OF DEMENTIA
Knowledge of the prevalence (number of cases) of given conditions within a population is
important for the provision of services. It has been estimated that, in the UK, about
600,000 people have dementia, and that over 300,000 of these have Alzheimer's disease.5
No large-scale studies of the prevalence of dementia have been carried out in Scotland,
although Gordon and Spicker have estimated that, in 1994, 6.9% of the population aged
65+ in Scotland had dementia, and that 55% of these people were resident in the
community, rather than in care homes or hospitals.6 Numbers can be estimated by applying
prevalence ratios to local populations.  
Prevalence ratios depend on the definition of terms, criteria for diagnosis and methods of
measurement, as well as on the study population. The most satisfactory overall prevalence
ratios for dementia are felt to be those which were derived from the European Community
Concerted Action on the Epidemiology and Prevention of Dementia (EURODEM), which re-
analysed original data from 12 prevalence studies of dementia conducted in eight countries
in Europe between 1980 and 1990.7-9 Although the EURODEM estimates of prevalence
could now be seen as dated, they have been seen as the most useful available for people
aged 65+ for three reasons:6
• they only included data from studies with rigorous inclusion criteria - those studies which
had used a DSM III or equivalent definition of dementia and had ascertained a
dementing illness by individual examination; 
• they are based on studies which included institutionalised populations; and
• they provide details of prevalence ratios according to age group and gender.
Although widely differing prevalence ratios for dementia have been reported for different
countries, these variations have generally been considered to be due to methodological
differences in study design, the diagnostic criteria employed, or differences in mortality.7;10-12
The EURODEM collaborative analyses found that, among European studies using similar
methodologies and diagnostic criteria, there were only trivial differences in the age-specific
prevalence of dementia7 and Alzheimer's disease.8 Similarly, a recent UK study (MRC CFAS)
employing the same methodology in multiple centres (with sufficient sample size to detect
differences large enough to be of public health or epidemiological interest) has found no
regional differences in the prevalence of dementia across five centres in England, despite
known differences in vascular risk and cardiovascular mortality.3;10
The EURODEM estimates indicated gender differences in prevalence, as have a number of
other studies.1;7;10;13 In addition, studies throughout the world have shown that the
prevalence of dementia increases dramatically with age,7;11;14-16 although the condition is
uncommon before the age of 65 years.1 The EURODEM estimates have suggested that
prevalence nearly doubles with every five years of increase in age.7
There are relatively few studies on the prevalence of dementia which include people below
the age of 65 years.  Many of the studies combined in EURODEM omitted young onset
dementia.17 A more recent study by Harvey (see Table 2.1 below) is felt to provide the
most satisfactory prevalence ratios for younger people with dementia (those aged between
30 – 64 years).17 Table 2.1 shows the prevalence ratios for dementia by age group and
gender, derived from both the EURODEM analysis and the Harvey study.
TABLE 2.1 Prevalence ratio (%) of dementia by age group & gender
Applying the above prevalence figures to the population of Scotland gives the following
estimates of the number of people with dementia, by age group and gender. It is
emphasised that the numbers in Table 2.2 below are estimates only.
TABLE 2.2 Estimate of the number of people with dementia in Scotland in
2002, by age group and gender
ESTIMATED POPULATION WITH DEMENTIA - 2002
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AGE GROUP BOTH SEXES WOMEN MEN
30-64 0.067
65-69 1.4 1.1 2.2
70-74 4.1 3.9 4.6
75-79 5.7 6.7 5.0
80-84 13.0 13.5 12.1
85-89 21.6 22.8 18.5
90-94 32.2 32.2 32.1
95-99 34.7 36.0 31.6
Source for rate 30-64: Harvey R (1998) Young onset dementia: epidemiology, clinical symptoms, family burden, support and
outcome. London: Dementia Research Group, Imperial College School of Medicine. Source for rates 65+: Hofman A, Rocca
WA, Brayne C, Breteler MMB et al (1991) The prevalence of dementia in Europe: A collaborative study of 1980-1990 findings.
Int. J. Epidemiology, 20(3), 736-48. (EURODEM)  Reproduced with permission from ‘Needs Assessment Report on Dementia’,
NHS Health Scotland, 2003.18
Source: EURODEM and Harvey prevalence figures applied to Government Actuaries Department (GAD) projections based on
the Registrar General’s estimate of the population at mid-2000. Reproduced, with permission, from ‘Needs Assessment Report
on Dementia’, NHS Health Scotland, 2003.18
AGE GROUP BOTH SEXES WOMEN MEN
30-64 1,321
65-69 3,732 1,395 2,337
70-74 8,587 4,486 4,101
75-79 9,892 6,600 3,292
80-84 12,950 8,852 4,098
85-89 12,540 9,466 3,074
90+ 8,299 6,512 1,786
Total 57,321
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Little is known about the prevalence of age-related cognitive decline,19 although there is
known to be a range of individual differences and a wide variation among older people.20
The UK study mentioned above (MRC CFAS) has been designed to estimate and compare
the prevalence and incidence of dementia in five centres, to examine the natural history of
cognitive decline and dementia in the population and to evaluate the degree of disability
associated with any decline.21
STUDIES OF INCIDENT CASES
Another way of examining the rates at which disorders develop and the pattern of their
development is to study incidence rates, i.e. the rate of new cases developing in a
population over a specified period. Investigating the incidence rates for cognitive decline
and dementia is problematic because of the gradual onset and the difficulty of diagnosis,
and because of the need for large studies. (For example, in Scotland, GP consultations have
been proved to be unsatisfactory as a marker for incidence.1) Existing studies of incidence
have not presented a consistent picture.14;17 Alzheimer Scotland - Action on Dementia has
stated that the results of existing research support a cautious assumption that there might
be 200 new cases of dementia per year per 100,000 people.17 Rates of incidence of a
dementing disorder rise exponentially with age.16 Launer and colleagues have suggested
that about 2.5 new cases per 1000 person-years develop at age 65; and about 85.6 new
cases per 1000 person years after age 90 years.22
THE PREDICTED INCREASE IN THE PREVALENCE OF DEMENTIA
Given the demographic trends of increasing numbers of older people (since more people
are living into old age, and life expectancy is increasing), the number of people with
dementia is rising and is expected to continue to rise. Some have argued that the
prevalence of Alzheimer's disease will double over the next 50 years.23  Also, because the
rates of incidence of dementia rise exponentially with age, people in older age groups are
increasingly likely to be living with this condition.
The results of applying prevalence figures (Table 2.1) to the projected population of
Scotland at intervals until 2040 are given in Table 2.3 opposite. This table shows the
projected estimates of the numbers of people in Scotland expected to have dementia. The
most rapid growth in the expected numbers of people with dementia is predicted to be in
the 75+ age group. 
TABLE 2.3 Projected estimates of numbers of people in Scotland with
dementia by age group and gender
From these figures, the number of people with dementia in Scotland is expected to almost
double over the next forty years. Even though they are estimates, these statistics suggest
that, by 2040, there could be more than 100,000 people with dementia in Scotland. The
numbers are high. The population of Scotland is currently around 5 million (and is predicted
to fall to around 4.5 million by 2040).2 100,000 people represents over one in fifty of the
population. In a street of 100 people, for example, two could be living with dementia.
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Source: EURODEM and Harvey prevalence figures applied to Government Actuaries Department (GAD) projections based on
the Registrar General’s estimate of the population at mid-2000. Reproduced, with permission, from ‘Needs Assessment Report
on Dementia’, NHS Health Scotland, 2003.18
2000 2005 2010 2020 2031 2040
Persons
30-64 1,321 1,408 1,492 1,616 1,438 1,284
Males
65+ 18,688 20,461 22,602 28,623 36,319 41,749
75+ 12,250 13,845 15,687 20,137 26,426 32,186
Females
65+ 37,311 38,028 39,241 44,437 54,160 62,992
75+ 31,430 32,221 33,330 37,334 45,988 55,011
Persons
65+ 55,999 58,489 61,843 73,060 90,479 104,741 
75+ 43,680 46,066 49,017 57,471 72,414 87,197 
POPULATION PROJECTIONS FOR PEOPLE WITH DEMENTIA IN SCOTLAND
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However, predicting trends in the overall numbers of people with dementia is a complex
matter, and others have recommended caution, since such projections are based on
assumptions, and these may turn out to be wrong. In addition, a number of unknown
factors, particularly environmental, might influence the development of dementia over the
next few decades. (Two long-term population studies found no significant change in the
prevalence ratios, over time, of dementia or types of dementia.12 These were not recent
studies, however.)
SUMMARY
• Because of the general increase in life expectancy and the ageing of the ‘baby boomer’
generation, the number of older people in Scotland is projected to rise substantially, with
the oldest groups experiencing the largest relative increase.
• The number of people with age-related conditions such as dementia is rising, and will
continue to rise, particularly in the oldest age group.
• Applying recognised prevalence figures to projected population statistics, the number
of people living with dementia in 2040 could be over 100,000, i.e. one in fifty of
the population.
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CHAPTER THREE
IMPLICATIONS FOR
PUBLIC HEALTH, AND
PRIMARY PREVENTION
STRATEGIES
The anticipated rise in the prevalence of dementia and cognitive decline is an important public
health issue.  Although progress has been made in assessing the needs of people with dementia,
and although treatment may slow the progress of dementia in some cases, nevertheless, the
costs of dementia for individuals and for services are high.  There has been increasing interest in
investigating primary methods of prevention.  An epidemiological approach can throw light on
‘risk factors’ for dementia.
The anticipated rise in the prevalence of age-related conditions such as dementia and cognitive
decline is an important public health issue. Cognitive function is a key determinant of quality of
life, and underlies nearly all daily living activities;24 it is linked with the capacity for self-care, and
the ability to take part in social activities, to exercise self-determination and to maintain
independence at older ages.25-27 Many people are frightened of a decline in cognitive function,
and particularly of developing a dementing disorder.28 The effects of dementia can cause
significant problems, both for those affected and for those caring for them. Hence, a predicted
increase in the prevalence of dementia is an issue of concern for public health, because of the
numbers involved, and because of the implications for individuals and for service providers.
Caring for people with dementia is enormously costly in terms of resources, and these costs
are likely to rise with an ageing population.29 The care required for those with moderate to
severe dementia is proportionately much greater than that required by the majority of older
people.30;31 Caring for people with dementia is highly labour-intensive, whether in the
formal or informal sector.  Studies have shown the heavy burden on informal caregivers in
terms of stress and strain.29;30 For example, one Scottish study which compared the needs of
the supporters of demented and non-demented elderly people found that among the
dementia group there was significantly greater use of mainstream day care services, and a
significantly higher level of unmet need, as well as some extra household expense.32
Dementia also causes significant costs for social care services and the health care system in
terms of the provision and financing of services and residential accommodation.30;31
Cognitive impairment is the main reason for long term institutional care in old age,33 and it
has been estimated that dementia accounts for 14% of the bed occupancy in psychiatric
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hospitals.34 Also, the number of people with cognitive impairment in institutional care is
predicted to increase considerably, because of the rising numbers of cognitively impaired
people aged 85 and over, the age group which is most likely to need residential or nursing
care.33 Estimates for the cost of care (which may be contingent on government policy)
vary.30 One recent review by the Audit Commission has estimated that dementia costs the
United Kingdom £6.1bn a year (at 1998-1999 prices), with £3.3bn of this direct spending
by health and social services.35 There would be immense benefits to public health,
therefore, if ways of reducing the prevalence of dementia could be found.
PUBLIC HEALTH APPROACHES TO ‘PREVENTION’
The goals of public health are broadly those of ‘health improvement’.  At the moment,
public health management is based on a ‘needs assessment’ approach.36 There may be a
number of conflicting priorities within public health, with fundamental questions about
how benefit should be measured. Costs and benefits are relative, and can be seen either in
terms of health outcomes (which can have a number of aspects) or in terms of resources
(human and financial). In addition, although populations include individuals, there are
questions about whether the recipients of health care are populations or individuals,36 how
to balance individual and more general ‘good’, and whether healthcare measures are to be
aimed at those at high risk or at populations.
There are three approaches towards ‘health improvement’, all of which may be
encompassed by a ‘needs assessment’ approach to public health.
• The aim of primary prevention is to reduce the prevalence of disease in a population by
averting or delaying the occurrence of conditions by reducing the risk of a condition
developing, e.g. by the avoidance of causative exposure. Primary prevention measures
require an understanding of the factors which cause a condition to develop, or which
increase risk, and about the means by which ‘risk factors’ may be modified.
• The aim of secondary prevention is to limit the progression and recurrence of disease in
people who already have it, by effecting a change in the natural history at an early stage.
Secondary prevention measures involve early detection, diagnosis and intervention, either
by treatment or lifestyle change, and they rely on an understanding of the mechanisms
underlying the progress of the condition.
• The aim of tertiary prevention is amelioration of the effects of disease, by containing
disability and dependency, and maintaining an acceptable quality of life.37 Tertiary prevention
measures mainly involve the provision of services and support, and are based on ways in
which the needs (including socio-psychological needs) of those affected might be met.
In relation to dementia, these approaches to ‘prevention’ tend to overlap.37 Until recently,
the emphasis – rightly - has been on tertiary prevention; considering the needs of those
affected, the ways in which the effects of the disorder might be ameliorated by increased
support or by treatment, and the quality of life for those affected and their carers
improved. The NHS Health Scotland report, ‘Needs Assessment Report on Dementia and
Older People’ (2003)18 gives a comprehensive outline of the main issues.
Now, however, as more is known about the central nervous system and about age-related
changes to the brain,28 and as neurodegenerative disorders are no longer assumed to be
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inevitable and natural accompaniments of ageing, there is considerable public health and
research interest in finding out more about the nature and the causes of dementia and
cognitive decline,10;28 and in considering ways in which the prevalence of these conditions
might be reduced.
An enormous amount of effort is being expended on the development of treatment
(secondary prevention) which might halt or delay the progression of disease in people with
mild dementia.37 Dementia (of the Alzheimer type) might seem to be a good candidate for
secondary prevention approaches because of its natural history – an extended pre-clinical
phase after which the severity increases gradually over a period of years.  Drugs such as
antidepressants, anti-psychotics and cholinesterase inhibitors have been found to alleviate
or stabilise some symptoms for a limited period of time.  However, although the progress of
dementia can sometimes be slowed, and although a small proportion of cases of dementia
are treatable, in general the condition cannot be reversed or cured.18;37 The difficulty of
detecting dementia at an early or ‘preclinical’ phase creates further problems for secondary
prevention measures.
Because of these difficulties, another approach has been to consider whether there are ways
of preventing or delaying the onset of dementia (i.e. reducing the age-specific incidence
rates) by primary prevention measures. Since the rates of incidence of dementia (especially
Alzheimer's disease) rise exponentially with age,16 raising the mean age of onset could
significantly reduce the numbers affected.38 It has been suggested, for example, that
delaying the onset by 5 years could halve the prevalence,39 or reduce it by at least a third.38
PRIMARY PREVENTION: AN EPIDEMIOLOGICAL APPROACH
A primary prevention approach to health improvement has been seen as appropriate,
especially where the possibilities for treatment or cure are limited.  Primary prevention has
also been seen positively, as having general, as well as individual, benefit.10  Primary
methods of prevention require some knowledge about the factors involved in causing a
condition to develop, or increasing individuals’ susceptibility, and about the means by
which these factors may be modified, or risk reduced.  
Strategies for primary prevention to reduce risk are limited; they include lifestyle change,
reduction in exposure to risk, ‘treatment’ (e.g. medical and dietary supplements),
vaccination and family planning. There are two main approaches to primary prevention;
those based on risk reduction in the general population (e.g. health promotion measures)
and those based on risk reduction in ‘high-risk’ groups.19;37 (The distinction between
individuals at high risk and those with pre-clinical disease - and hence between primary and
secondary prevention - is not always clear-cut.)  Approaches targeted at the whole
population aim to lower general levels of exposure, whereas those targeted at high-risk
groups aim to protect individuals by reducing their vulnerability.37 The anticipated benefit
of any intervention should outweigh possible harm, so that there are issues of ethics and
human rights, and about responsibility, as well as feasibility, to be taken into account, when
considering potential ‘strategies’.19 
Even if the processes leading to the development of a condition are not fully understoond,
a knowledge of risk factors might suggest possible strategies of prevention. A variety of
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factors – individual or social, biological or environmental, innate or acquired - can be
involved in the pathophysiological processes underlying the development of any disorder.20
Such ‘risk factors’ can interact in a variety of ways. Causal processes and risk (or protective)
factors can be suggested by hypotheses, theory or knowledge about the mechanisms
underlying the development of any disorder, or – in the case of age-related disorders – the
processes related to ageing. They can also be derived inductively, perhaps from observation
of treatment which has been found to slow the progress of a disorder, but particularly from
the evidence provided by epidemiological work.19
An epidemiological approach is based on statistical comparisons. For example, case-control
studies of populations with and without dementia (studies of prevalence) might suggest
characteristics or factors (either current or at earlier stages of life) associated more
frequently with the ‘case’ group. A preferable approach, however, which – although
expensive - can throw more light on causality, is to carry out large longitudinal studies of
incidence (new cases) over time.  
Within public health, the main focus of a primary prevention approach has been on
physical conditions, such as heart attack, stroke and cancer. Recently, however, there has
been an interest in investigating risk factors for non-fatal disorders, because of the potential
to reduce healthcare costs and improve public health.40 Maintaining mental health has been
little examined in epidemiological work. However, with the establishment of a European
Network for the Calculation of Health Expectancies (one of whose aims is the development
and promotion of mental health expectancies),4 and in the context that older people may
work for longer,41 commentators have noted an increasing interest in monitoring the
mental health of populations.
Strategies to prevent or delay the onset of symptoms of dementia, as well as to prevent decline
into the advanced stage, have been viewed as urgently needed.10;37;42;43 Because the causes of
dementia and cognitive decline, and the processes underlying their development are not fully
understood, possible preventive interventions are unclear.  However, at the same time as more
is becoming known about about age-related and ‘dementia-related’ changes in the brain,
epidemiological studies of potential risk and protective factors are being carried out. As Cooper
has noted, the public health challenge of dementia is beginning to be confronted.37
SUMMARY
• The increasing prevalence of dementia is an important public health issue, because of the
impact on individuals and on service provision.
• While the progress of dementia can sometimes be slowed, no cure is available.
• There would be immense benefits to public health if ways of reducing the incidence (as
well as the prevalence) of dementia and cognitive decline could be found. Since the rates
of incidence of dementia rise exponentially with age, raising the mean age of onset could
significantly reduce the prevalence.  
• A primary prevention approach rests on a knowledge of causal factors and appropriate
means of intervention.  
• The processes underlying the development of dementia and cognitive decline are not
fully understood. At the same time as more is known about changes in the brain,
epidemiological studies of potential risk and protective factors are being carried out.
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CHAPTER FOUR
COGNITIVE DECLINE,
DEMENTIA AND TYPES
OF DEMENTIA
An epidemiological approach rests on the ability to define and diagnose the conditions being
investigated, as well as on some understanding of causal processes. This chapter considers what
is meant by cognitive decline and dementia.  Dementia has been classified into types and sub-
types, and the diagnostic criteria are outlined, although there is increasing recognition of the
overlap between classifications. The chapter concludes by outlining some of the explanatory
models for Alzheimer's disease, some of which relate to debates about the nature of ageing
Potential risk and protective factors can be investigated by epidemiological studies of
disease cohorts, but the condition must be capable of being well defined and diagnosed.41
The decline of certain aspects of cognitive function with age has generally been
distinguished from dementia. Defining and diagnosing cognitive decline and dementia
(and ‘types’ of dementia) is problematic although, with increasing knowledge and
improvements in technology, standardised diagnostic criteria have been developed.  
Cognitive function is multi-dimensional, encompassing both memory and intelligence, both
of which have been seen as reflecting a number of cognitive domains.  Memory is
commonly divided into short term (STM) and long term (LTM), with LTM further
subdivided into declarative and procedural memory. The former refers to conscious
recollection and recall whereas the latter includes priming, conditioning and skill-based
learning.44 Two types of intelligence are often distinguished – crystallised and fluid.45 Fluid
intelligence, which can be seen in terms of mechanisms or processing resources,46 reflects
the ability to acquire or use new information.  Crystallised intelligence, or the knowledge
base, is taken to be the cumulative end product of information acquired by the activity of
fluid intelligence processes.47 Cognitive function is seen, therefore, as comprising crystallised
intelligence, fluid intelligence, declarative memory and procedural memory,44 and as also
including strategies, which are related to the concept of executive function.46
WHAT IS COGNITIVE DECLINE?
Cognitive performance declines with age,48 although there is known to be a range of
individual differences and a wide variation among older people.20 By the age of 70, most
people have a significant, although manageable, decline in cognitive abilities compared
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with their mid-life level.49 Studies indicate that many changes in cognitive function are
gradual and develop from early adulthood, the extent of decline depending on the type of
cognitive domain.44;48 There is general agreement that with age comes the increasing
likelihood of developing memory loss,27;50 although some abilities are more affected by age
than others, and fluid intelligence is more likely than crystallised intelligence to decline.27
The decline of certain aspects of cognitive function with age has generally been seen as
distinct from ‘pathological’ conditions such as dementia, in which there are disorders of
personality, memory, and other cognitive functions.51 Three broad states have generally
been distinguished (although various classificatory terms have been used): normal age-
related decline or age associated memory impairment (AAMI), cognitive impairment no
dementia (CIND) or mild cognitive impairment (MCI), and dementia.13;19;44;50;52 It has been
pointed out that - in common with other psychiatric diagnoses - there is no clear
distinction between ‘normal’ and ‘low’ cognitive function,20 and also that none of the
classificatory terms fulfils satisfactory criteria for clinical validity.44
Normal age-related decline in memory is often described as ‘benign senescent
forgetfulness’. It is ‘benign’ because it is not considered to be a harbinger of dementia.
AAMI is basically the same as ‘benign senescent forgetfulness’, except that it quantifies the
degree of memory loss required for the diagnosis, namely, performance at or below the
minus one standard deviation level for young adults on any standardised test of recent
memory for which adequate norms have been established.26 Some criteria also include self-
perception of memory loss.50 In addition, individuals should exhibit adequate performance
on dementia screening instruments and tests designed to assess intellectual function, and
they should be free of medical, psychiatric, or pharmacological factors that might confound
memory performance.26 Some have further sub-divided ‘normal age-related decline’ into
‘normal’ and ‘successful’.44 Little is known about the prevalence of age-related cognitive
decline,19 although some studies have suggested that, in the US, about 40% of people aged
65 and over have AAMI.50 Only a minority will develop progressive cognitive failure and
dementia;49 research has suggested figures between 1% per year50 and 9.1% over a 3.6 year
period.49 Attempts have been made to distinguish markers which might distinguish those
who are at risk of subsequent dementia from those whose cognitive impairments will
remain stable.49 Mild cognitive impairment (or CIND) defines a transitional stage between
normal age-related decline and dementia. The diagnosis is important (and can be described
as ‘transitional’) for two reasons. It helps clinicians to recognise – and take seriously - a
pathological (i.e. more than normal) degree of memory loss in older people, and it also
identifies a group of people who are at high risk of developing dementia. It is however a
heterogeneous condition, which suffers from heterogeneous definitions. It can be mild,
moderate or severe, and although it is not necessarily progressive,53 the annualised
conversion to dementia is quite high in most follow-up studies - between 10% and 15%.50;52
The condition is characterised by important memory deficits, similar to those in people with
very mild Alzheimer's disease, without functional impairment.50 Studies have suggested that
about 10% of people aged 65 years and over have this condition.50 In one recent
longitudinal study examining the evolution of CIND among subjects aged 75 years and
over, between baseline and a 6-year follow-up, 34% of subjects died, 35% progressed to
dementia, 11% remained stable and 25% showed cognitive improvement.53 Similar rates of
progession to dementia – which represent a threefold increase in risk over people without
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MCI - were found in the Religious Orders Study.54 Findings from other empirical work have
indicated that decline in specific cognitive domains might indicate reversible cognitive
impairment.55 The absence of a subjective memory complaint has been found to be
associated with improvement.53
WHAT IS DEMENTIA?
Dementia is a term used to refer to a variety of illnesses and conditions which affect the
brain. These conditions result in impairment of brain function and a multi-faceted decline in
cognitive functioning, including memory problems, personality changes and behaviour,
severe enough to cause impaired function in, and severe disruption to, everyday life.50 The
effects of the condition change over time, but the cognitive performance of people with
dementia is substantially worse than that of the normal elderly on crystallised and fluid
intelligence and declarative memory tasks.44 Dementia can be associated with a number of
conditions,56 and can occur as the result of a number of pathological processes.  
Dementia can be classified in a number of ways. One important distinction is between
progressive and treatable dementia. A small but significant proportion of those with a
dementing illness have a potentially treatable condition, such as Vitamin B12 deficiency,
normal pressure hydrocephalus or depression. Other possible ways of classifying dementia
are according to the effect on a person's ability to function and their need for care (mild,
moderate or severe), according to underlying pathology, or according to the age of onset.
Different classifications may stem from the reasons for classification. (While there may be
concerns about stigmatisation, a diagnosis of dementia, or type of dementia, can be
helpful in enabling needs to be addressed.) For service provision, a broad definition in
terms of the needs of the person or the severity of the condition may be most
appropriate. When considering possibilities for treatment, a more specific diagnosis and
prognosis can be helpful for patients and their families.57 For research, or in considering
the potential for prevention, dementia has been classified in terms of types and sub-types,
often based on pathology.  
Types and sub-types of dementia
There has been considerable progress in the ability to diagnose dementia and to distinguish
between types and sub-types.39 The most common types of progressive dementia are
Alzheimer's disease, vascular dementia, and dementia with Lewy bodies. Rarer types include
fronto-temporal dementia (including Pick’s disease) and Korsakoff’s syndrome. In addition, a
number of conditions, which include Down’s syndrome, Parkinson’s disease, Huntingdon’s
disease, Creutzfeld-Jacob disease, HIV /AIDS can predispose to dementia.  
At the same time, there is an increasing understanding of the heterogeneity of dementia,
and of the overlap between classifications.58 For example, although vascular dementia and
Alzheimer's disease are normally seen as characterised by different types of brain pathology,
it has recently been suggested that the evidence from empirical work makes the idea of a
dichotomy no longer tenable.19 It has also been noted that, with the increasing knowledge
about neurodegenerative disorders and improved diagnostic techniques, terminology is
evolving, and that in the future such disorders may be defined by the rogue proteins
responsible (and ultimately by their solutions).59
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Alzheimer's disease
Alzheimer’s disease is associated with progressively worsening memory, and a decline in
other intellectual functions including language, motor skills and perception.18 Frequently
there are changes in behaviour. The clinical diagnosis is based on the exclusion of other
causes of dementia, including vascular dementia.56;60 Alzheimer's disease mostly affects the
hippocampal area of the brain, and is characterised by the presence of neouropathological
features, including neuritic plaques, amyloid angiopathy, neuronal loss and neurofibrillary
tangles.43;56 A definite diagnosis can only be made after death. Evidence indicates that the
pathophysiology is very complex,61 and it has been suggested that there may yet be
different types of Alzheimer's disease.62 The causes of the condition are largely unknown.
Although Alzheimer's disease has always been seen as a degenerative disorder, there is
recent evidence to suggest an association with vascular disease.62;63
In the UK, the majority of people with dementia are thought to have Alzheimer's disease.
Large studies such as the EURODEM analysis8;9 and the MRC CFAS study3;10 have
investigated the relative prevalence of the various types of dementia, but there is no
consensus on a definitive breakdown of types. Research findings suggest that, of the cases
of dementia in those aged 65 and over, 55% will be Alzheimer's disease; 20% vascular
dementia, 20% Lewy body disease; and 5% other types.17 The prevalence of Alzheimer's
disease increases markedly with age,14 and a number of studies have suggested that the
prevalence is higher in women than in men.56
Vascular dementia
Vascular dementia is a complex disorder, characterised by intellectual impairment as a result
of cerebrovascular disease and ischaemic-hypoxic brain injuries.56;64 The symptoms are
similar to those of Alzheimer's disease, although periods of relative stability and sudden
decline occur more frequently in vascular dementia, frontal lobe damage appears earlier,18
and survival rates are lower.56 Again, diagnosis is difficult and can only be confirmed at
post-mortem.65 Diagnostic criteria rely on both clinical and radiographic criteria,26 i.e. the
presence of dementia and cerebrovascular disease or ischaemic white matter lesions
(evidenced by neuroimaging) and a temporal relation.56;57;65;66 The criteria for vascular
dementia allow for the possibility of sub-types,57 and clinical sub-types, including
Binswanger’s disease, have been recognised.56;65 The concept of vascular dementia as
resulting from ‘mini-strokes’ in the brain (hence multi-infarct dementia) has been replaced
by more sophisticated models, suggesting a spectrum of vascular causes,58;66;67 although the
causes are not easy to establish.66 Some have argued, therefore, that the term ‘vascular
dementia’ is now obsolete, and that a broader category, vascular cognitive impairment
(VCI) should be substituted.68
The prevalence of vascular dementia has been difficult to estimate, since different
diagnostic and pathological criteria have been used.65 Before about 1970, vascular
dementia was thought to be the most common form of dementia,67 but it is now felt that
the condition may have been over-diagnosed in the past.65 There is some evidence that
vascular dementia is more common in men than in women.56
Mixed dementing illness
It is possible to have a ‘mixed dementing illness’, i.e. Alzheimer's disease and vascular
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dementia, although the traditional separation between ‘senile dementia’ and
‘arteriosclerotic dementia’ is now being questioned.58;67;69 Magnetic resonance imaging and
neuropathological studies have shown that many individuals with dementia in old age have
more than one type of pathology.43 Indeed, a recent review of this topic argued that mixed
states are probably more common than ‘pure’ dementia syndromes.70
Dementia with Lewy bodies
Dementia with Lewy bodies (DLB) is now the preferred term for a variety of clinical diagnoses
used over the last decade, and current thinking suggests that there is a spectrum of disease.71
The condition is associated with tremor, rigidity and slowness of movement, delusions and
hallucinations and unexplained falls.18 The pathology is that of a primary degenerative
dementia with features resembling both Alzheimer's and Parkinson’s diseases.72 There are
microscopic changes, called Lewy bodies, in the nerve cells of the brain, similar to those in the
brains of people with Parkinson’s disease.73 A diagnosis of possible DLB can be made when
other causes of dementia or Parkinsonism have been excluded.71 Initially thought to be
uncommon, DLB is now thought to be the second most common pathological cause of
dementia, accounting for up to 20% of all elderly cases reaching autopsy.71 There could,
therefore, be approximately 11,000 people with DLB in Scotland.73
Fronto-temporal dementia
Fronto-temporal dementia (FTD) is the commonest clinical syndrome arising from
frontotemporal lobar degeneration (FTLD), a non-Alzheimer degeneration of the frontal and
temporal lobes.74 At first, personality and behaviour are more affected than memory; symptoms
include behavioural and emotional problems, disinhibition, apathy, inertia and loss of speech.18
The disease progression is usually slow. Clinical diagnostic criteria for FTLD syndromes have
been the subject of an international consensus,75 and the types of histology classified into three
main sub-types, including Pick type and motor neurone type. FTD is strongly familial, and in
some families the disorder mutations have been identified in tau sequencing on chromosome
17.76 FTD is thought to account for up to a quarter of patients presenting before the age of 65
with dementia due to primary cerebral atrophy. However, in other parts of the world the
condition is more widespread, and it is now felt that FTD has been underdiagnosed.74
Subcortical dementias
Subcortical dementias include dementia stemming from progressive supranuclear palsy, motor
neurone disease, Parkinson’s disease, Huntingdon’s disease and multiple sclerosis.18 Each is
associated with specific neurological changes. These dementias feature diminished initiative,
increased irritability, and difficulty processing and manipulating information, a pattern of
intellectual decline which is seen in multi-infarct dementia.26 The prevalence ratio for Parkinson-
related dementia has been estimated as 41.1 cases per 100,000 in those up to 50 years old,
and 787.1 cases per 100,000 in those 80 years or older.77 Progressive supranuclear palsy (PSP)
is clinically similar to Parkinson’s disease and tends to emerge in older populations. Up to 80%
of those who develop this disorder will ultimately show signs of moderate to severe dementia.26
Alcohol associated dementia
It has been estimated that alcohol may contribute to dementia of all types in about 10% of
cases.78 Alcohol-related brain disorders include a widespread impairment of mental function,
which has been termed ‘alcohol associated dementia’. There are severe problems with
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memory, and also with attention, despite retention of language.18 A heavy alcohol intake can
be associated with vascular disease, and with an increased risk of vascular dementia. In
addition, alcohol intoxication and withdrawal accompanied by thiamine deficiency is also
associated with the more specific disorder, Wernicke-Korsakoff’s syndrome, or Korsakoff’s
syndrome. There is contention about whether alcohol ingestion per se can cause dementia.79
Early onset dementia 
While dementia is largely a condition of old age, people aged under 65 years can develop the
condition. Common causes of dementia which occurs below the age of 65 include Down’s
syndrome and alcohol-related dementia, as well the more prevalent forms.17;18 Further
information about early onset dementia can be found in Cox and McLennan (1994)80 and the
SNAP report, ‘Huntingdon’s disease, Acquired Brain Injury and Early Onset Dementia’.81
DIAGNOSIS
In order to examine risk factors for dementia and cognitive decline, the presence of the
condition must be capable of being reliably assessed.41 However, diagnosis may be difficult for
a number of reasons. A certain threshold of severity has to be reached to justify a definite,
rather than probable, diagnosis, and in some cases of dementia, an accurate diagnosis can only
be made months or years after the first symptoms.39 Key problems have been seen as a lack of
consensus about the definition of ‘significant’ impairment, or the boundary between dementia
and cognitive impairment.11 A number of difficulties relate to psychological testing of mental
performance, since ‘normal’ scores of cognitive function vary widely and it may be difficult to
distinguish between impairment and decline without repeated re-examination, and because
testing methods may be unsophisticated.41
A number of concerns relate to the suitability and reliability of clinical tests of cognitive
function. Some have drawn attention to ethical considerations in administering such tests,
which can cause anxiety and distress, especially in people with dementia.11 (There is a view that
some older people might perform less well on certain tests of cognitive function because of
anxiety,41 and there is some evidence that practical problem-solving performance does not
show the same decline with age as traditional measures of intelligence.82) The most widely used
test world wide for global cognitive function or ability is the Mini-Mental State Examination
(MMSE)83 which tests a range of cognitive abilities and provides a total score of cognitive
function. An alternative is the Cambridge Cognitive Examination (CAMCOG).84 Other tests are
used to examine memory and intelligence. Questions have been raised, however, about the
extent to which measures of cognitive function are able to measure cognitive decline, and
whether they are sensitive to changes to a neuro-pathological grading.19 It has been noted, for
example, that the MMSE cannot be used to measure domain-specific change, since most
domains are represented by only one or two items, resulting in floor and ceiling effects and
insensitivity to change.55 The MMSE has also been seen as limited because it will not detect
subtle memory losses, particularly in those with more education.50 Although others have
argued that the MMSE has been shown to be sensitive to change in cognition over time,85 and
has been used to derive a tentative probability of dementia,10 the best tests of cognitive decline
are felt to be those with a range of measures.41
The diagnosis of dementia is notoriously difficult during life, partly because of the gradual onset
of the condition and because the early signs can be indicators of other diseases or life
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changes.60;62 Differentiating between different types of dementia can also be difficult because
the processes which result in dementia can be difficult to distinguish from one another
clinically, particularly at the early stages.57;65 Neuro-pathological confirmation of a diagnosis is
problematic, since changes in the brain can only examined after death. Identification methods
have varied considerably, but there are now sets of standardised clinical and neuropathological
diagnostic criteria,10;29;58;65 and improvements in diagnostic tools.17 A tentative probability of
dementia can be derived from the total MMSE score,10 but ICD-10 criteria for the dementia
syndrome require a decline in memory and in cognitive abilities, retained awareness of the
environment, and a decline in emotional or social behaviour, all present for at least six
months.10;66 Diagnostic methods include clinical tests, and biological markers in the fields of
neuropsychology, genetics and neuro-imaging,86 in particular magnetic resonance imaging
(MRI),57 and also measurement of brain electrical activity.41
The detection of dementia might not occur until the disease is quite advanced and there is
irreparable brain damage. Because of the possibilities for treating the symptoms of some types
of dementia in the early stages, and because those affected are entitled to information about
their condition, early detection and diagnosis is becoming more important.17;41;57 As a
consequence, ways of identifying dementia – in particular Alzheimer's disease - at the ‘pre-
clinical phase’ are being developed. At present, predictive testing is based on memory tests.
The findings from a number of studies have indicated that low scores in tests assessing delayed
recall are a better predictor of dementia than atrophy of the medial temporal lobe,86;87 and can
best discriminate between those with presymptomatic Alzheimer's disease and those who
remain non-demented.88 On the other hand, some have suggested that the changes in the
brain observed at autopsy in some older people without dementia represent a ‘pre-clinical
phase’ of Alzheimer's disease.39 Since brain changes can be detected by structural imaging, and
changes in brain activity by positron emission tomography (PET),89 it has been suggested that
these techniques will increasingly be used to aid the identification of Alzheimer's disease early
in its course.41;50;57 Other methods of evaluation are being investigated.
A number of ethical issues arise in relation to predictive or pre-symptomatic testing, which
can be seen as risk assessment or screening. These concern the accuracy of the test results,
and the degree of certainty of the eventual diagnosis, which may be expressed in terms of
probability or risk. For example, only half of those with ‘Alzheimer-like’ changes in the brain
detected by a PET scan will go on to develop Alzheimer's disease.90 Another concerns the
extent to which it might be felt beneficial or helpful to know of an early diagnosis of
dementia. Hence, the role of routine cranial imaging in the evaluation of dementia in older
people continues to be debated.26
HYPOTHESES, THEORIES AND MODELS
Despite the existence of criteria for diagnosis and classification, relatively little is known about
the nature of cognitive impairment and dementia, why and how these conditions develop,
i.e. what are the causal mechanisms or processes, or the factors associated with their
occurrence.19;20;61;66 This is particularly the case for Alzheimer's disease, the causes of which are
generally seen as being multi-factorial.91 Understanding the mechanisms might suggest
possible means of prevention, such as drugs, but the causes (and effects) are far from clear.41
A further reason for the difficulty of modelling a late-onset condition like Alzheimer's disease is
the uncertainty of the lag periods between putative exposure, disease onset and dementia
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presentation.92 Nevertheless, a number of hypotheses to explain the development of
Alzheimer's disease have been proposed, based on theories about the nature of ageing and
observed clinical and pathological changes.  
There are a number of theories of ‘ageing’.27;93 Ageing has been seen as due primarily to the
accumulation of defects.93 First, as the body ages, there is a limit to replication of cells, and
systems break down; these changes have been seen as genetically programmed to an
extent.27;94 From the ‘immune’ theory of ageing, the ageing body becomes more vulnerable to
damage. The work of Hayflick has suggested that the human organism appears less able to
maintain its own viability with increasing age.95 At the same time, damage to the cells or
organs of the body can occur by ‘insults’, injury, disease processes or chemical reactions.
Figure 4.1 below shows a model of the factors thought to contribute to disorders, such as
dementia, which have been seen as ‘ageing-dependent’ (see also the discussion on page 45).
Figure 4.1  A model showing the sequence of events resulting in
ageing-dependent disorders.
Source: Adapted from D.H. Solomon, “The role of aging processes in aging-dependent diseases”, figure 81, page 135, in
Bengston and Schaie (eds), Handbook of Theories of Aging, 1999.  New York, Springer Publishing.  Reproduced with
permission from Springer Publishing Company.
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Recently, much more has been learned about the brain, both at the general and the
molecular level,28 and about what happens to the brain in old age.41 Some hypotheses
about the processes causing dementia or cognitive decline are based on known changes to
the brain. For example, the brain of a 90-year-old weighs about 10% less than previously,
largely because of loss of neurons.26;27 There is some evidence that growing older, in itself,
leads to impaired cognition, and some have linked this cognitive decline with ‘age-related’
atrophy of the brain,26;27 and with a deterioration in the efficiency of important
neurotransmitter systems.27 In addition, the amyloid plaques and neurofibrillary tangles,
which have been seen as characteristic of Alzheimer's disease, have been found to occur
with greater frequency with age, even in otherwise normal older people.26;88
On the other hand, although age has been seen as the ‘cause’ of cognitive decline and
dementia, there is now increasingly a view that age is not the only cause. From the
assumption that dementia occurs in older people only in the presence of specific disease,26 the
term ‘senile dementia’, suggesting dementia as a natural consequence of ageing, has been
abandoned. It has been pointed out that older people are at greater risk of illness or disease,
so that the effects of age itself might not be separable from those of age-related disease.26;27 It
has also been noted that the hippocampus – the area of the brain thought to be responsible
for cognitive function – is vulnerable to insults such as head trauma, stroke, epilepsy and
chronic stress, as well as changes due to increasing age.96 From the view that Alzheimer's
disease is an extreme variant of brain ageing, one suggestion is that age-related changes in
the brain could upset the glucocorticoid balance and lead to hippocampal neuronal death.41
Some hypotheses about the causes of Alzheimer's disease are based on explanations for the
pathological changes to the brain. Brain damage may result from inflammation,97 injury or
disease (e.g. viruses)14 as well as from cerebro-vascular events. Also, although it is not
known whether amyloid plaques and neuro-fibrillary tangles should be seen as causes or
effects,41 there has been interest in the role of biological mechanisms, particularly protein
production, in their formation.98;99 Various mechanisms for the interaction of proteins,
pathological features, inflammation and neurons have been suggested.88 There has been
debate between those who have argued for a key role for ß-amyloid protein (‘bap-tists’)
and others (‘tau-ists’) who have offered explanations based on tau protein.88
Amyloid plaques are clumps of cellular debris containing amyloid protein, and are one of
the main – and earliest - changes in the brains of people with Alzheimer's disease.41;100
Amyloid deposits have been seen by some as a primary (necessary but not sufficient) cause
of Alzheimer's disease,38 the ‘amyloid hypothesis’ positing that these deposits result from
abnormal amyloid clearance.38 An increased synthesis of Aß (or ß-amyloid) protein, which
precedes symptoms of Alzheimer's disease, and which may be associated particularly with
the genes for early onset AD, has given support to this hypothesis.38;101 The ‘amyloid
cascade hypothesis’ proposes that the ß-amyloid plaques resulting from abnormal protein
production are toxic to neurons and also stimulate inflammation leading to tangles.88 It has
been pointed out that if amyloid plaques are present before the onset of Alzheimer's
disease symptoms, then treatment might usefully target plaque formation. However, if
amyloid itself impairs brain function or is cytotoxic, then such treatment would be
ineffective at best and could magnify brain damage.41
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The neuropathology of Alzheimer's disease also includes the formation of neurofibrillary
tangles. These tangles contain tau protein of various types in a phosphorylated state.41 Tau
protein is now known to be toxic,99 and some have argued that the key step in the
pathogenesis of Alzheimer's disease lies with tau protein and the breakdown of systems
preventing the formation of tangles.41;88
Another view is that brain ageing, or brain damage, is associated with free radical action.98
From the ‘oxidative stress hypothesis’, damage can be caused by the action of free radicals
or exposure to toxins. Free radicals, or oxidative stress, can be produced by (for example)
infection, smoking, a high intake of saturated acids, or a low intake of antioxidants.27;51;91
The observation that non-steroidal anti-inflammatory drugs (NSAIDs) can reduce the rates
of dementia has lent support to this hypothesis.41 The brain is thought to be low in anti-
oxidant substances (which can stop the free radical chain reactions).43 It has been
suggested that the free radical reactions generated by oxidation might contribute to both
vascular and Alzheimer's disease pathology;43 for example, the Aß protein of ‘senile plaques’
has been seen as evidence of an oxidative reaction.102 As knowledge about the pathways of
neuronal cell death that occur during oxidative challenges is increasing,102 one view is that
oxidative damage to lipid membranes can disrupt normal neuronal cell functioning, leading
to the formation of amyloid plaques and to neuronal cell death.103
However, research has shown that the occurrence of dementia is not always associated with
pathological changes in the brain.104 From a clinical perspective, explanations have focused
on neuronal changes, which have been seen as largely independent of amyloid
deposition,105 and particularly on the concept of ‘brain reserve’. It has been proposed that
individuals can vary in their ‘reserve capacity’ (a hypothetical concept related to the
‘amount’ of functioning brain tissue)62 because of genetic differences and exposure to
environmental factors. The reserve capacity is seen as being capable of being depleted by
injury, but also of being enhanced (or maintained) by intellectual stimulation.98 A clinical
diagnosis, therefore, might result from a combination of factors, including both
physiological and psychosocial processes.39 From this view, one hypothesis is that low pre-
morbid intelligence hastens the clinical diagnosis of dementia of the Alzheimer type.39
Another is that psychosocial factors might act to reduce the margin of intellectual reserve
to a level which results in a diagnosable dementia.39
Several authors have speculated that the brain has a form of neuronal ‘reserve’, such that it
can lose some of its functional capacity without degenerating dramatically.98 From this view,
the brain will start to demonstrate clinical degeneration if this reserve capacity is depleted,
with the onset of dementia once a ‘threshold’ (corresponding to the critical amount of
brain tissue at which normal cognitive function cannot be sustained) has been crossed.62;98
Figure 4.2 on page 38 illustrates the threshold model of dementia.
(A) indicates normal brain aging, where the threshold for dementia is not reached until
after normal life expectancy. (B) indicates attainment of the dementia threshold in middle
age because of an increased rate of loss of reserve capacity over the life course. (C)
indicates attainment of the dementia threshold in middle age because of a decreased
reserve capacity present at birth.
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Figure 4.2  Threshold model of dementia
There is continuing debate about the nature of cognitive decline and dementia, and the
relationship between the two, which relate to wider questions about the nature of ageing.44
One issue concerns whether cognitive decline should be seen as occurring as part of
‘normal ageing’.26;106 Keefover and Rankin have argued that the cognitive changes seen in
older people cannot be assumed to be benign just because they are common, and have
noted that severe cognitive decline, including significant memory loss and dementia,
almost always occurs only in the context of specific disease.26
A related unresolved question concerns the relationship between age-related cognitive
impairment and dementia,42;44 something which has been very little investigated by
research.49 One view is that the processes leading to dementia can be seen as similar to –
although more severe than - those resulting in cognitive decline.55 An alternative view is
that the deficits in dementia should be seen as qualitatively, as well as quantitatively,
distinct from those in normal ageing.44 This issue may have important implications for
approaches to prevention. If cognitive decline and dementia are seen as a continuum, with
Alzheimer's disease as an extreme variant of ageing, then, as Whalley has pointed out
(p125), “its proper study will rest firmly on the account of the neurobiology and
neuropsychology of the ageing process”, rather than on the study of disease cohorts.41
SUMMARY
• Dementia can broadly be divided into vascular dementia and dementia of the Alzheimer
type, but dementia with Lewy bodies and fronto-temporal dementia are now thought to
have been under-diagnosed in the past.
• There is increasing knowledge of types and sub-types of dementia, but also of the overlap
between types or categories.  With increasing knowledge, terminology is evolving.
• Cognitive decline has been sub-divided into ‘age-associated cognitive decline’ (AAMI)
and ‘cognitive impairment no dementia’ (CIND).
• Diagnosis of both cognitive decline and dementia is difficult, but there are now
internationally agreed standards. 
• A number of hypotheses and models of dementia of the Alzheimer type have been
proposed, based on pathological and clinical criteria.
• There is interest in whether cognitive decline and Alzheimer's disease should be seen as a
continuum, or as qualitatively different conditions. This issue could have important
implications for approaches to prevention.
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CHAPTER FIVE
METHODOLOGICAL
ISSUES
This chapter outlines the main methodological issues which need to be taken into account in
reviewing empirical work examining risk factors. These concern issues of definition and
measurement, the design of the study and interpretation of the findings.
Empirical work examining risk factors for dementia, particularly Alzheimer's disease, is being
carried out in a number of countries. Those reviewing empirical work have drawn attention
to a number of important methodological issues which need to be taken into account in
drawing conclusions from the findings or making comparisons between studies.10;11;107 It has
been emphasised that the data must be adequate for drawing conclusions about risk
factors,11 and that issues of bias should be acknowledged and addressed as far as possible.56
The main methodological difficulties can be seen in terms of:
• issues of definition and measurement
• the design of the study
• interpretation of findings.  
ISSUES OF DEFINITION AND MEASUREMENT
It has been pointed out that measurement error is an often unacknowledged but important
source of bias in epidemiological work examining risk factors.19 Both the presence of the
disorder and the exposure to risk factors have to be assessed.
Some reviewers have noted that estimates of the prevalence and incidence of dementia (or
type of dementia) are heavily influenced by the methods used to identify the syndrome.10
Certain criteria have been seen as unsatisfactory, either because the data would be
incomplete (e.g. only moderate to severe dementia is normally mentioned on death
certificates60) or because of the possibility of bias (e.g. carers’ diagnoses are subjective,
certain groups might be more likely to be admitted to hospital). It has also been claimed
that the rates reported can be affected by the efforts made to detect or identify cases,107
particularly in incidence studies,17 or that there might be tension between researchers and
clinicians about diagnostic categories.19
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With different diagnostic criteria being used in different countries,11 and in different
settings, methods of identification of dementia have varied widely across existing studies.10
Early work was hampered by the variety of definitions of dementia, assessment strategies
and population samples, but the introduction of reliable, internationally agreed clinical and
neuropathological diagnostic criteria has now made it more feasible for population-based
comparative studies to be carried out,64 or for the literature to be critically reviewed.108
Nevertheless, difficulties in diagnosing the presence of dementia continue to be noted. For
example, Whalley and colleagues have commented that the most important limitation of
their large study lay in the difficulty of reliably distinguishing between Alzheimer's disease
and vascular or ‘mixed’ dementias.92 Those reporting the recent MRC CFAS study have
drawn attention to the difficulties of collecting the complex information required for a
diagnosis of dementia over a long period of time and for very large population samples.10
There are also a number of difficulties in defining and measuring ‘risk factors’ or ‘protective
factors’.56 For example, how should the strength or level of exposure to the risk factor be
measured? By whom?  How long ago did the exposure occur?  For how long?  It has been
suggested that some of these issues can cause particular difficulties for case-control studies,
in which the assessment of exposure to the risk factor of cases (but not controls) may be
based on information from surrogates, or in which informants of patients (rather than
controls) might be better at recalling exposures such as head injuries.56
THE DESIGN OF THE STUDY
Reviewers of the epidemiological literature have drawn attention to the range of methods
used.  Many have pointed out that that methodological differences between studies have
caused difficulties in interpreting the results and in making comparisons between
studies.10;11;107 Important issues relate to whether studies examine prevalence or incidence,
the power of the study to test for risk factors, and the characteristics of the sample.
Prevalence or incidence studies
Early empirical work examining risk factors for dementia were case-control studies based
on prevalence. These studies, which were often small, compared the presence or absence
of certain ‘risk factors’ in the population with dementia and the population without.11;56
In some studies, e.g. the Canadian Study of Health and Ageing,109 the samples were
matched for factors such as age, gender, residence, although in others the populations
were unmatched.110
Prevalence figures (the number of individuals living with the condition) reflect survival as
well as new cases. One limitation of prevalence or case-control studies is that rates can be
biased by differences in survival, since differences in occurrence (incidence) and survival of
disease in a population cannot be distinguished.56 Hence, they cannot be used to
investigate either temporal effects or the complex interactions between risk factors.19
Epidemiologists have argued that research examining causal factors should be based on
large longitudinal studies of incident cases, ideally prospective (to examine variables before
the onset of disease) and preferably with a number of measurements over time,20;41 to
provide more reliable evidence, and to avoid the influence of variations in mortality, i.e. to
distinguish between association and causality.10;56
The confounding effect of survival is particularly important in considering risk factors for
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cognitive decline and dementia.  In the UK, cognitive function is strongly related to
survival, and has been seen as a marker for capacity for survival.111 Hence, the survival of
people with dementia for longer periods has enormous implications for prevalence
studies.112 Studies examining risk factors for dementia conducted before 1991, which
were mostly based on the comparison of prevalent cases of Alzheimer's disease with
control subjects, have been reviewed and re-analysed by the EURODEM Risk Factors
Research Group.7
Longitudinal or cohort studies, as well as being expensive and time-consuming to carry out,
are prone to potential problems of non-response, competing mortality and co-morbidity.56
Prospective studies, in which the exposure state is measured before the onset of the
disease, have been seen as preferable to retrospective studies,11;56 since, in the latter,
assessment of exposure to the risk factor may be prone to various kinds of bias. For
example, historical items may be based on recall measures, and data are more likely to be
influenced by selective memory.113 In the case of dementia or cognitive decline, longitudinal
studies may be hampered by difficulties with diagnosis, since the onset is hard to define.
Also, since the course of these disorders is gradual and slow, observation has to cover a
number of years.  
The power of the study to test for risk factors
Reviewers of the literature have noted that many early studies examining risk factors for
dementia have been small, and that risk factors can be rare.11;56 The point has been made
that one of the most important determinants of the identification of risk factors might be
the power of the study to confirm or deny a hypothesis.62 Large cohort studies are now
under way.
Characteristics of the sample
A major concern of any population study is the representativeness of the sample studied,
since the characteristics of the sample can profoundly affect the rates of prevalence or
incidence.10 The point has been made that, among the study population, there might be
sub-populations with – for example - high rates of illness or high frequencies of genetic
variants.11;107 It has been argued, therefore, that studies based on institutions, such as
nursing homes or hospitals, will indicate higher rates of dementia,11 although they will also
fail to identify a substantial proportion of those affected.107 Ideally, studies would be based
on institutional and community samples, but where this is not feasible, it has been
suggested that community studies are preferable.107
The method of sampling might also affect the numbers or characteristics of those who take
part.  Jorm and colleagues found that rates were lower when all of a community, rather
than a random sample, were studied.107 Sampling methods can be particularly important in
comparative studies, since there might be variations between groups in the proportion who
decline to take part.113
INTERPRETATION OF FINDINGS
Commentators on empirical work have stressed that, while studies can demonstrate the
consistency, or otherwise, of associations between the prevalence or incidence of
dementia and given risk factors, care must be taken in suggesting explanations. This is
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particularly important since the findings can be used to consider possible interventions.11 It
has been noted that an effect might not necessarily be causal, and that there could be a
number of explanations, e.g. the apparent variable might be a marker for another, or the
apparent association might be a measurement artefact.11 For example, the effects of
cardiovascular disease on cognitive maintenance might simply represent the results of
lifestyles that are unfavourable for both cardiovascular health and maintenance of
cognitive function.48 Many commentators have also emphasised the possible confounding
effects of pre-morbid cognitive ability on a diagnosis of dementia, especially when
examining education as a risk factor.108;114
SUMMARY
• In assessing the findings from epidemiological work, a number of methodological issues
concerned with definition and measurement, and the design of the study, have to be
taken into account.
• The presence of the disorder or type of disorder must be capable of being reliably
assessed, as must the strength of exposure to risk factors.
• The design of the study can strongly influence the findings. Early empirical research was
based on case-control studies of prevalence, but large longitudinal studies of incidence
are needed to distinguish between association and causality, and to examine interactions
between risk factors.
• There may be various explanations for some of the findings of epidemiological studies.
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PART TWO
RISK FACTORS FOR DEMENTIA
AND COGNITIVE DECLINE 
Empirical research examining risk factors for dementia, or cognitive decline, is being carried out in
many countries across the world. Because of the number and range of studies, this review draws
largely on recent reviews of empirical work, on book chapters, and on editorials and commentaries.
Details of recent empirical work have been included, among them some of the findings from papers
presented at the 8th International Conference on Alzheimer's disease and related disorders, held in
Stockholm, Sweden, between 20-25 July 2002.
The review is structured according to ‘risk factors’, under the following headings:
• Age, gender and ethnicity
• Genetic factors
• Pre-existing conditions
• Physical injury, illness and medication
• Classical [personal and lifestyle] risk factors: 
• risk factors for vascular disease
• smoking, alcohol and drug use
• diet, nutrition and hormones
• interventions targeted at vascular disease
• Factors related to social context: social class, occupation and education
• Physical, mental and social activity
Each section outlines the strength of the evidence for seeing the variable as a risk factor for dementia
and cognitive decline, possible interpretations of the findings and implications for prevention.
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CHAPTER SIX
AGE, GENDER,
ETHNIC AND
NATIONAL
FACTORS
Studies examining risk factors have conventionally been corrected for socio-demographic factors,
such as age, gender and ethnicity, education and occupation. However, there is increasing
interest in the extent to which these variables should be seen as ‘risk factors’. This chapter
outlines the evidence for risk due to age, gender and ethnic and national differences, and
considers the extent to which age should be seen as the main risk factor for dementia or
cognitive decline. Since these factors cannot be modified, the implications for strategies of
prevention rest on the relative importance of these risk factors.
AGE
Age and the risk of cognitive decline
Numerous psychological cross-sectional studies have shown age differences in cognitive
function,10;115;116 and in a recent two-wave study carried out in Cambridge, the incidence of
cognitive impairment at various cut-off points showed that age was a major influence on
MMSE score.10 There are also differences with age in the rate of cognitive decline. Findings
from longitudinal aspects of the Cambridge study showed that, with increasing age, the
mean drop in score increased.10;85
Schaie has made the point that cross-sectional studies do not take account of cohort
differences in experience, so that longitudinal studies are needed to examine cognitive
decline, both generally and in different domains.116 He has reported that the data from the
40-year Seattle Longitudinal Study does indicate age-related cognitive decline, although
not as great as that suggested by cross-sectional studies. The evidence from this study
suggests that cognitive decline below the age of 60 is not characteristic of normal ageing,
but neither is intact functioning at age 80. In a review of the literature, Fillit has observed
that the nature and extent of changes in cognitive function associated with ageing have
now been reasonably well defined.49 Cognitive decline is not universal nor are all aspects of
intellectual functioning equally affected.116 There is also some evidence that inter-individual
differences increase in old age.44;116 It has been suggested that older people may develop
coping strategies in order to maximise function and compensate for the loss of abilities in
specific areas.49
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There is general agreement, however, that with age comes the increasing likelihood of
developing memory loss, although some abilities (episodic memory, especially recall) are
more affected by age than others.27;50 Fluid intelligence is more likely than crystallised
intelligence to decline (although there is some evidence from longitudinal studies that such
decline may be cohort-related and may be decreasing over time).27 One recent study which
found significant decline in total CAMCOG score and all of the subscales over a 4-year
period in a 75+ age cohort found that greater decline in the perception subscale was
associated with older age.55 Certain cognitive domains, on the other hand, appear to be
particularly resistant to age-related deterioration.26 Schaie has found that decline is least in
magnitude and occurs later on verbal ability.116
Age and the risk of dementia
Studies throughout the world have shown that the prevalence of dementia increases
dramatically with age.11 While the condition is uncommon before the age of 65 years, the
prevalence of dementia, particularly Alzheimer's disease, increases exponentially with age,
at least up to age 90.7;14-16 Hofman and colleagues, reporting the estimates from the
EURODEM collaborative analysis, have noted that rates of prevalence nearly double with
every five years of increase in age,7 and the findings from the recent MRC CFAS study in the
UK show the same relationship.10
The incidence of dementia, particularly Alzheimer's disease, also rises dramatically with age.
The annual incidence of Alzheimer's disease has been estimated as approximately 1.4 per
1000 in the seventh decade, 6.4 per 1000 in the eighth decade and 20.5 per 1000 in those
aged 80 years of age or over.16 This describes a Gompertzian exponential (a linear
relationship between the log of age-specific incidence and chronological age) with a
doubling time of only 5 or 6 years from age 60 to age 90.16 There is some dispute about
what happens in very old age;14 some studies have suggested some levelling-off in the rise of
incidence in very old age.117 Others, however - the MRC CRAS study for example - have
found no levelling-off in the rise of prevalence in the 85 years and over age group.10
Interpretation of findings
Reviewers of the epidemiological evidence have concluded that ‘age’ (i.e. increasing age or
ageing) is the most important risk factor for dementia,15 at least on the basis of current
knowledge. However, there are debates about the reasons for the rise in incidence of
dementia (and cognitive decline) with age, and about the shape of the rise. These concern
the question of what it is about ageing that might explain the increased incidence of
cognitive decline and dementia, and whether increasing age, or ageing per se, can be
considered the most important risk factor.16;118
Solomon has suggested that a condition may be described as ‘age-related’ if a specific age-
range (e.g. 65-90) is most at risk, but that an ‘ageing-related’ disorder is one associated with
increasing age.41 He makes a further distinction between ageing-related and ageing-
dependent conditions,41 arguing that those such as cognitive decline and dementia, which
occur with increasing frequency as individuals age, i.e. the rates of incidence show an
exponential rise with increasing age, should be seen as ‘ageing-dependent’.16 (See also
Figure 4.1, page 35).  A linear rise would be expected if disease were the main cause. For
Solomon, the definition ‘ageing-dependent’ does not preclude the existence of other causal
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factors, but indicates that ageing seems to be more important than environmental factors.16
However, as many commentators have pointed out, neither the mechanisms of ageing nor
the mechanisms underlying the development of dementia or cognitive decline are
understood.93 It has often been suggested that ‘ageing’ should be seen as the accumulation
of changes that accompany age, whether these stem from the environment or from disease,
or from inborn processes of ageing.27;119 From this view, genetic and environmental factors
which influence ageing of the brain are thought to play a part in the development of
dementia or cognitive decline, i.e. the ‘causes’ may be several and may be interlinked.26;27;44;56
Starr and colleagues have concluded, for example, that cognitive decline should be
attributed to the effects of the interaction between age and disease on cognitive function.106
However, while many commentators have noted the difficulty of separating the effects of
increasing age from the effects of disease, some have argued that it is important to
distinguish between the two.26;106
From the view (held by Solomon) that the effects of ageing should be seen as the most
important factor increasing the risk of cognitive decline and dementia, Christensen and
O’Brien have suggested that the culmination of a biological ageing process might be an
acceleration of the rate of cell death, producing the characteristic neurological and cognitive
deficits of dementia.44
Others, on the other hand, have pointed to the fact that older people are at greater risk
of illness or disease, and have seen this increased vulnerability to certain risk factors,
physical events or age-associated disease as a more important factor.26;27 Keefover and
Rankin have noted, for example, that whereas cognitive decline has traditionally been
attributed to ‘normal ageing’, EEG literature shows that cognitive slowing virtually always
indicates an underlying pathological process.26 Similarly, in a study of healthy old people,
Starr and colleagues found that the mean decline in cognitive function over 4 years was
non-significant.106
It has been noted that, if the incidence of dementia continues to rise exponentially in very
old age, then logically, everybody will develop the disorder if they live for long
enough.14;16;44;118 If the incidence levels off, some individuals will never develop the disease
over a feasible life span, i.e. the disorder is not inevitable with increasing age.14;26 McGee and
Brayne have argued that a falling-off in the rise in prevalence with advanced age (as found in
some studies) gives support to the theory that age is one of several ‘risk factors’ for
dementia, rather than the condition being ageing-dependent.118 Other explanations, such as
slower rates of decline in capacity among a survival elite, have also been suggested.62 The
point has been made, however, that because so few people live beyond 85 years, it might
never be possible to prove or disprove the invariability of a relationship between old age and
cognitive impairment.26
Implications for prevention
Strategies of prevention depend on the extent to which risk factors can be modified. Where
disorders are strongly age-related, as is the case with cognitive decline and dementia, the
feasibility of prevention will be limited,118 unless ageing itself can be slowed.  From the
alternative theories of ageing, ageing-related decline might be delayed either by the
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avoidance or mitigation of damage, or by the boosting of capacity.  In rats, caloric
restrictions have been found to increase longevity, delay many of the signs of ageing, and
reduce the incidence of a variety of disorders.16 The possibility of preventing or even
reversing the damage to human brain cells implicated in mental decline has been discussed,
in particular by Whalley.41
A key issue is the strength, or relative importance, of age as a risk factor.  While there is a
view that age is the most important risk factor for dementia (and perhaps cognitive decline),
the evidence about variation in the age of onset of both conditions, together with views
about the influence of disease, warrants the investigation of other factors, those which are
modifiable and those which are not.
GENDER
The findings from a number of studies, including the Canadian Study of Health and Aging13
and the MRC CFAS study10 have indicated gender differences in the prevalence of dementia
in men and women, with higher prevalence estimates in women.1 (The MRC CFAS study also
found gender differences associated with MMSE scores of cognitive function, with men
scoring higher than women.10) The EURODEM collaborative reanalysis of individual studies
suggested that there were gender differences in the prevalence of dementia in different age
groups, with a slightly higher prevalence in men than in women among subjects aged under
75 years, but a higher prevalence in women among those aged 75 or over.7 There is also
some evidence that the major subtypes of dementia, Alzheimer's disease and vascular
dementia, might occur in different proportions in men and women, with Alzheimer's disease
more common in women and vascular dementia more common in men.56
The gender difference in the prevalence ratios of dementia and Alzheimer's disease has been
the subject of discussion.107 There are important implications of a higher prevalence in
women, since the majority of the very elderly population at the moment are women
(although this could change).10 Most commentators have speculated that the higher
prevalence in women is more likely to result from differential survival (i.e. women’s longer
life-expectancy and the larger number of women still alive at ages when Alzheimer's disease
is common), rather than from a higher incidence in women.10;14;107;120 Lower rates in men have
been suggested as being due to a healthy survivor effect,10 or to the fact that diagnostic
criteria for Alzheimer's disease rest on the absence of cerebro-vascular disease, a condition
more common in men.41 The reasons for the difference in prevalence remain to be
confirmed by large studies.10
Findings from incidence studies vary. In relation to vascular dementia, although EURODEM
pooled analyses found no gender differences in rates or risk,121 a number of studies have
found a higher incidence in men.56 Unusually, one US study indicated that men had a higher
incidence rate of ‘all-cause’ dementia than women.122 Regarding Alzheimer's disease, some
meta-analyses, including EURODEM, have found that female gender increases the risk of
Alzheimer's disease significantly,22;117 and that women tend to have a higher incidence rate
than men in very old age.22;123 However, one longitudinal study (the PAQUID project)
indicated that the incidence of Alzheimer's disease was higher in men than women before
the age of 80, although higher in women after this age.124 Other recent studies, however,
have found that the age-specific incidence of Alzheimer's disease did not differ significantly
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by sex,120;125 and – in a review of the literature - van Duijn has concluded that most studies
have shown a similar incidence in men and women.56
Any increased vulnerability to cognitive decline or dementia on the basis of gender is only of
relevance in relation to other potentially modifiable factors, e.g. vascular factors, alcohol
consumption. Any such evidence will be noted.
ETHNIC AND NATIONAL FACTORS 
If national and ethnic differences in the incidence of dementia could be found, they might
indicate important genetic or environmental differences in risk factors, or those endemic in a
given culture which might not be revealed by single-group studies.10;12;14;19 There might also
be different implications for ‘prevention’ among different cultural groups, and between
countries (e.g. developing, rather than developed, countries).12;126 There is increasing interest
in assessing the prevalence and the incidence of dementia or types of dementia among
different communities and groups, or in different locations or types of location.12;127;128 Studies
examining risk factors for dementia are also now being carried out in many countries,129;130
and, with standardised diagnostic criteria and improved techniques, cross-national and
multi-centre studies are under way.14
All commentators have drawn attention to the difficulties of comparing the findings from
different populations or carrying out cross-cultural work.131 Cultural background is a complex
matter, and the difficulty of distinguishing between environmental and biological, national
and ethnic, factors is well understood. People from different ethnic groups might differ in
their exposure to certain risk factors for a variety of reasons, such as diet, behaviour, or the
social context of their lives.
Early research suggested the possibility of wide variations in the prevalence of dementia or
types of dementia between countries and between ethnic groups.15;56;107 However, it has
generally been felt that these differences were explainable by differences in study design, the
diagnostic criteria employed, or differences in mortality.7;10-12 The consensus until recently,
from the results of European studies, was that there were no important regional differences
in the frequency of dementia or Alzheimer's disease which could not be explained by
differences in methodology.12 Commentators have called for longitudinal studies of incidence
to provide a better means of comparing rates.12;113
Recent studies have indicated some differences. One compilation of studies examining
dementia and cognitive decline has indicated some variations within and between ethnic
groups.126 There is some evidence, for example, that the highest proportion of dementia cases
among black individuals is attributable to vascular dementia.126 Also, a recent longitudinal
study in Manhattan, US, has found that the incidence rate for Alzheimer's disease was
significantly higher among African-American and Caribbean Hispanic elderly individuals
compared with white individuals.132 A trend for the age-related dementia prevalence estimates
to be lower in developing than in developed countries has also been noted.12;133 For example,
one recent study found significant lower age-adjusted prevalence ratios for Alzheimer's disease
and dementia among Nigerian Africans in Ibadan than in African Americans in Indianapolis,
using the same methodology.113 It has been pointed out, however, that there could be several
possible explanations for such differences, including differences in survival.12
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Findings from the existing studies of incident cases support the possibility that incidence
rates of dementia might be higher in some countries than others,14 although commentators
have highlighted the importance of making direct comparisons between countries or
between ethnic groups using standardised methodology, especially in relation to the
methods used to identify the syndrome.10;14 In a review of the literature, van Duijn has
concluded that there is some evidence of differences in the risk of vascular dementia
between populations, but that comparative studies are difficult to interpret because of the
lack of biological markers and unique clinical features for the subtypes of dementia.56 Cross-
cultural comparison of studies of Alzheimer's disease have suggested no evidence for the
existence of risk factors that are to be found predominantly in some populations but not in
others. Van Duijn has concluded that, by contrast with other chronic disorders, cross-cultural
research has not led to important clues about the causes of dementia or any of its subtypes.56
SUMMARY
• Cognitive function declines with age, although there are wide individual differences, and
also differences between domains in the rate of decline.
• Both the prevalence and incidence of dementia increase exponentially with age. Key issues
are the size (or relative importance) of ‘age’ as a risk factor, and explanations for the effect
of ageing.
• Age has generally been seen as the main risk factor for dementia, but there is debate
about whether the ‘cause’ should be seen in terms of ageing per se (in which case
everyone would develop dementia if they lived for long enough), or the ageing-related
increasing incidence of disease.
• There are gender differences in the prevalence of dementia, but whether these reflect
differences in incidence is still unclear.
• By contrast with other chronic disorders, cross-cultural studies have thrown little light on
causal factors. The difficulty of separating biological and environmental factors has been
widely acknowledged.
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CHAPTER SEVEN
GENETIC FACTORS
This chapter outlines the genetic factors which are thought to be associated with Alzheimer's
disease, both early onset and late onset.  Although genetic factors cannot be modified,
increasing knowledge about the mechanisms associated with genetic mutations might suggest
possibilities for intervention
Epidemiological studies have shown that about 30% of people with Alzheimer's disease have
a family history of the disorder, in that at least one first-degree relative is affected.38 It has also
been suggested that the association with various conditions, such as Down’s syndrome and
Parkinson’s disease might indicate a common genetic component or shared susceptibility, in
at least a sub-group of those affected.56 As knowledge about the human genome is increasing,
there has been interest in examining genetic factors. Since genes are thought to be associated
with protein production, the hope is that a greater understanding of genetics might throw
light on some of the mechanisms or processes underlying the development of dementia, and
might suggest possible methods of prevention, such as drugs.
GENETICS AND THE RISK OF EARLY ONSET ALZHEIMER'S DISEASE
Family history is an important risk factor for Alzheimer's disease, particularly early onset. The
occurrence of dementia of the Alzheimer type in specific families is well documented, and
the pattern of inheritance is consistent with autosomal dominant transmission with age-
dependent penetrance.62 Single gene mutations in three genes are known to be associated
with certain forms of early onset Alzheimer's disease. These are the amyloid precursor protein
(APP) located on chromosome 21, and genes for presenilin 1 and presenilin 2 located on
chromosomes 14 and 1 respectively.101 The mutations of the presenilin genes are thought to
disrupt the breakdown of APP.39
Although cases of early-onset Alzheimer's disease account for a small proportion of cases of
the syndrome overall, a high proportion of such cases are thought to be associated with
these genes.12;44 Mutations associated with APP are extremely rare, but the 50 or so
mutations associated with presenilin 1 are thought to explain up to half of all cases of early
onset Alzheimer's disease.101
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GENETICS, APOE, AND THE RISK OF LATE ONSET ALZHEIMER'S DISEASE
Most cases of late onset dementia are sporadic, rather than familial.38 A family history of
dementia has been associated with a higher risk in some studies,13;134-136 but not in others.22
At the moment, only one genetic factor has been indisputably linked with late-onset forms
of Alzheimer's disease; this is the 4 allele of the APOE gene on chromosome 19, which codes
for apolipoprotein E (ApoE),101 a lipoprotein thought to be involved in the development of
vascular dementia.41
Three common allelic variants of apolipoprotein E exist – 2, 3 and 4 - encoded on a single
locus on chromosome 19.101 A number of large cohort studies have provided evidence that
the presence of the APOE _ allele is associated with a higher risk of Alzheimer's
disease.125;137;138 The finding that the frequency of the APOE 4 allele among ‘cases’ was around
45-50% compared with around 16% among controls has been replicated in other studies.41
Research results have suggested an apparent ‘dose-response’ relationship, with individuals
who are homozygous for this allele (4/4) having a significantly higher risk of developing
Alzheimer's disease than those who are heterozygous for the allele, and higher again than
those without the gene.99 Recently, the APOE 4 allele has been shown to be associated with
other forms of dementia including vascular dementia, Lewy body disease and Creutzfeldt-
Jacob disease.56
However, the presence of APOE 4 is neither necessary nor sufficient to cause Alzheimer's
disease.12;101 Low concordance rates among monozygotic twins suggest a substantial
environmental influence.12 It is thought that, at most, only half of individuals with late onset
Alzheimer's disease carry the allele.12;41 Findings from one large study have suggested that the
presence of the apoliprotein E genotype predicts when – rather than whether – individuals
are predisposed to develop Alzheimer's disease.139 While most studies have indicated that the
APOE genotype is second only to age as a risk factor for dementia of the Alzheimer type,41;140
questions remain about the importance (or size) of the effect of the 4 allele relative to other
factors.  Commentators have called for large, population-based epidemiological studies to
evaluate the risk of developing cognitive decline and dementia.56;141
Several recent studies have investigated the extent to which other risk factors, such as
smoking,142 coronary artery surgery,143 gender, education or vascular risk factors might be
modified by the presence or absence of the APOE 4 allele. There is some evidence that
women who possess the APOE 4 allele appear to be at significantly greater risk of Alzheimer's
disease than men who are APOE 4 allele carriers.11 One recent longitudinal study in a biracial
community sample found that interactions with gender (being female) and with baseline
functional status predicted functional decline, although no relationship was found between
the APOE 4 allele and a decline in functional status overall.144 Findings from the Zutphen
elderly study in the Netherlands showed a significantly increased risk of cognitive decline
associated with a lower level of education in subjects without the APOE 4 allele. By contrast
there was no association between education and cognitive decline in subjects with the
allele.145 APOE 4 has also been shown to increase the risk of athero-sclerosis, which – it is
thought - might explain its association with vascular dementia.56;99 The findings from one
twin study showed greater vascular or degenerative damage among subjects with the APOE
4 allele.146
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There is some evidence that the APOE 2 allele may be associated with lower relative risk of
Alzheimer's disease and later onset.38;98 Additionally, it may well be that further
polymorphisms are associated with an increased risk of dementia of the Alzheimer type.
Other genetic risk factors have been and are being investigated.14
INTERPRETATION OF FINDINGS
The mechanisms by which proteins associated with genetic mutations are involved in the
development of Alzheimer's disease (and whether they are causes or effects) are not
known,41;88 but there are a number of hypotheses.98 Proteins are thought to be implicated in
the production of amyloid plaques and neurofibrillary tangles. They may also have a role in
neuronal damage and interaction with other mechanisms such as viruses.  
ApoE is a plasma protein thought to be involved in cholesterol transport and neuronal repair
(e.g. after head injury).14;41;98 A number of mechanisms by which the APOE 4 allele might
influence the development of dementia have been proposed.98 It has been associated with
higher levels of oxidative insults in Alzheimer's disease brains.147 The possibility of interaction
with the herpes simplex virus to increase risk has also been suggested.99 The genes for early
onset AD have been associated with the synthesis of Aß (or ß-amyloid) protein, involved in
the formation of amyloid plaques. Also, an inherited form of fronto-temporal dementia,
which is characterised by tau tangles, in the absence of amyloid plaques, is thought to be
associated with mutations of the tau gene.99 It has been suggested that APOE 3 prevents
tangles from forming, but that APOE 4 provides no such protection.88
IMPLICATIONS FOR PREVENTION
Because genetic make-up is not modifiable, if genetic mutations are important risk factors for
early onset Alzheimer's disease, then opportunities for prevention of this condition may be
limited. The mutations in APP, presenilin 1 and presenilin 2 allow for screening in suspected
cases of familial Alzheimer's disease with early onset, and for appropriate genetic counselling
and support.99 The point has been made that the numbers are far too small for family
planning to be considered as a method of prevention; in addition, family planning is only
effective when the pattern of occurrence indicates an autosomal dominant transmission.37
In the case of late onset Alzheimer's disease, there is less evidence, at the moment, for
genetic risk factors. The view has been expressed that, in the absence of disease-slowing
treatments, there is little justification for predictive testing.101 Also, using APOE genotyping
for this purpose has been seen as inappropriate;41 Eastwood and colleages have noted that
the current position on the place of APOE genotyping – which ‘may’ be used to assist an
already suspected diagnosis of Alzheimer's disease, but which may not be used to screen
healthy individuals for future risk – has been summarised in a consensus statement.19 Key
evidence on the scope for primary prevention, taking genetic factors into account, will come
from twin studies (which show low concordance), and from the incidence or prevalence of
Alzheimer's disease in different populations or sub-populations.  
Although genetic makeup is not modifiable, attempts are being made to develop a vaccine,
whose purpose would be to interfere with protein production in order to prevent, slow or
reverse the deposition of amyloid plaques in the brain (although amyloid plaques are not
necessarily a feature of Alzheimer's disease,88 nor has it been established that interfering with
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protein production would prevent dementia.) The findings from studies of mice have been
encouraging;41 transgenic mice that were given such a vaccine performed better on a
memory test than did unvaccinated mice.100 A vaccine has been developed for use with
humans, although the trial was abandoned in March 2002 after several patients developed
symptoms of brain inflammation.148
At the moment research findings have not suggested any means of prevention. There are
many unanswered questions about the relative importance of genetic factors and their
related effects. Most commentators have concluded that that there is much still to be
learned about the genetics of Alzheimer's disease (e.g. what gene products do, the correlates
with brain changes, and the interactions of APOE genotype and drug response) and that
more genetic factors will probably be found.19 It has been suggested by some that the
importance of genetic findings could be in throwing light on biological mechanisms of
Alzheimer's disease, and hence on therapeutic targets,19 and on aiding the search for non-
genetic factors.11 More work is felt to be needed to quantify genetic risk,19;56 and to
investigate possible interaction between genetic and other risk factors.11;19;56
SUMMARY
• Early onset Alzheimer's disease is strongly related to family history, and three genetic
mutations associated with this disorder have been identified.  Although cases of early-
onset Alzheimer's disease account for a small proportion of cases of dementia overall, a
high proportion of such cases are thought to be associated with these genes.
• One genetic mutation has been linked with some forms of late onset dementia including
Alzheimer's disease. This is the APOE 4 allele. However, the presence of APOE 4 is neither
necessary nor sufficient to cause Alzheimer's disease; only about half of affected individuals
carry the allele.  
• Other genetic factors are being investigated.
• At the moment, research findings have not suggested any means of prevention.  
• An increased knowledge of genetic factors has been seen as useful in gaining a better
understanding of the mechanisms underlying the development of dementia.
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CHAPTER EIGHT
PRE-EXISTING
CONDITIONS
A number of conditions are known to predispose towards dementia. Vascular disease, as a risk
factor for dementia of various types, is discussed in Chapters 10 and 13. This chapter outlines
the evidence for considering Down’s syndrome, Parkinson’s disease and thyroid disease, as risk
factors for dementia of the Alzheimer type.
DOWN’S SYNDROME
Cognitive and functional decline has long been recognised as a feature of ageing in people
with Down’s syndrome.149 One recent project found significant differences in cognitive
function between younger (30-44 years) and older (45+ years) subjects with Down’s
syndrome.150 Since the decline in function has usually been accompanied by changes in
personality and behaviour, links have been suggested with Alzheimer's disease. The findings
from one study have indicated that age-specific prevalence and incidence rates of
‘Alzheimer's disease’ and the pattern of cognitive decline were similar, although appearing
approximately 30-40 years earlier in life in the Down’s syndrome population.150 The
dramatic increase in life expectancy for people with Down’s syndrome - now about 50
years - has implications for the ageing of people with this condition, and there is interest in
finding out the prevalence of dementia among people with Down’s syndrome, and in
establishing whether such dementia should be seen as Alzheimer's disease.149
Numerous studies have found that there are ageing-related increases in plaque and tangle
formation in the brains of people with Down’s syndrome,151;152 and recent studies show that
virtually all people with Down’s syndrome have the neuropathological features of AD by the
age of 40 years.14 However, the prevalence of dementia in people with Down’s syndrome is
much less than 100% even by age 50.153 The reasons for the discrepancy between
pathology and function are not understood.14
Findings from a number of studies have suggested a shared genetic susceptibility to Down’s
syndrome and Alzheimer's disease.14 Links have now been found with the presence of
trisomy 21 (a genetic modification associated with Down’s syndrome),149 and it is thought
that the similar pathology is due to people with Down’s syndrome having an extra copy of
the amyloid precursor gene (APP) on chromosome 21.14 There is also some evidence that
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the presence of the APOE 4 allele increases the risk of Alzheimer's disease (in people with
Down’s syndrome),14;149 and one recent study has suggested that, after chronological age,
the APOE 4 genotype is the most important risk factor.150 It has been concluded that the
influences on the risk of developing Alzheimer's disease for people with Down’s syndrome
may be similar to those for people without Down’s syndrome, although whether or not the
mechanisms are similar is unclear.149
PARKINSON’S DISEASE
Parkinson’s disease (PD) is an ageing-related progressive neurodegenerative disorder, which has
been seen as essentially a profound disturbance of motor function.26 The condition typically
begins between the ages of 50 and 65 and exhibits a prolonged course of deterioration, so that
more than half of those with symptoms are aged over the age of 70.26 The condition is
associated with cognitive changes,26;154 particularly bradyphenia or ‘slow thought’,26 but there is
controversy about the prevalence and incidence of dementia within Parkinson’s disease.154
Like Parkinson’s disease itself, Parkinson-related dementia is strongly ageing-related; the
prevalence ratio increasing from 41.1 cases per 100,000 in those up to 50 years old to
787.1 cases per 100,000 in those 80 years or older.77 A review of cross-sectional studies
carried out since 1990 indicates that the prevalence of dementia in PD is in the range of 28
– 40%,154 i.e. well above the figures expected if the association between dementia and
Parkinson’s disease were coincidental. The authors of the review have noted an association
with older age of onset, rather than with illness duration.154
There is some evidence of higher rates of Parkinson’s disease among farmers. One study
carried out in France over 10 years found that, in a small sample of ‘dementia with
parkinsonism’ among women, eight cases were found among farmers.155 The authors have
recommended exploring this possible link further, suggesting that one possible explanation
could relate to exposure to environmental factors.
THYROID DISEASE AND NEURO-ENDOCRINE CONDITIONS
Thyroid disease is a hormonal disturbance widely recognised for its capacity to disrupt brain
function.26 Thyroid metabolism is complex, and a number of changes can increase or
decrease the production and utilisation of the active form of thyroid hormone.26 The
presence of thyroid disease appears to be relatively high in older people, with
hypothyroidism five to six times more common than hyperthyroidism. Both high and low
levels of thyroid hormone can produce cognitive or psychiatric behavioural change.  In
addition, older people appear to be prone to a form of thyroid dysfunction (apathetic
thyrotoxicosis) which may account for a number of cases of dementia in older people.26
Some empirical studies have indicated an association between Alzheimer's disease and
hypothyroidism,156 but others have not.135 Findings from one recent longitudinal study have
indicated a link between sub-clinical hyperthyroidism and Alzheimer's disease.157 An
association between Alzheimer's disease and autoimmune thyroid disease has been
reported in Down’s syndrome and familial Alzheimer's disease.56
It has also been suggested that, since there are two-way links between the brain and the
endocrine system, other neuro-endocrine mechanisms, for example those related to
hormones or to stress, may be relevant to cognitive function.96
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SUMMARY
• A number of conditions can predispose to dementia of the Alzheimer type. These include
Down’s syndrome and Parkinson’s disease. Some studies have found an association with
thyroid disease but others have not.
• Pathological and genetic associations between Down’s syndrome and Alzheimer's disease
have been found. The incidence of dementia of this type occurs 30 – 40 years earlier in
the population of people with Down’s syndrome than in the general population. 
• The prevalence of dementia in people with Parkinson’s disease is thought to be between
28 – 40%, i.e. considerably higher than in the general population.
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CHAPTER NINE
PHYSICAL INJURY,
ILLNESS AND
MEDICATION
As the pathological features of Alzheimer's disease are increasingly understood, there is interest
in the role of brain damage, injury and inflammation. This chapter summarises the evidence for
seeing brain injury, or exposure to viruses and pollutants, as risk factors. It also considers the
extent to which non-steroidal inflammatory drugs might protect against dementia.
The pathological features of Alzheimer's disease are increasingly well understood.102 There
has been interest in the role of brain damage, whether caused by biological or
environmental factors, i.e. trauma, inflammation or illness. Brain tumours represent one
cause of dementia. The incidence of aggressive tumours is rising in older populations, but
since the individuals affected seldom survive into very old age, less aggressive tumours
account for more cases of dementia in older people.26 Chronic inflammation is also thought
to have a key role in the abnormal processes related to ageing, possibly including
dementia,158 and a number of lines of evidence suggest that inflammatory mechanisms play
a significant role in the pathogenesis of Alzheimer's disease.159 Research has investigated
possible links between head injury, exposure to infection or toxins, and medications such as
non-steroidal anti-inflammatory drugs (NSAIDs) and the occurrence of dementia of the
Alzheimer type.
BRAIN INJURY
Head injury causing identifiable brain injury is thought to affect tens of thousands of
individuals in the UK per year,98 and is a major cause of disability.160 While most of those
injured are young people, and there are low rates in midlife, the risk of traumatic brain injury
rises again after age 60,161 and significantly after age 70, the most likely causes being falls
and road accidents.162 Postural instability is a physical characteristic of old age that increases
an individual’s tendency to falls.26 Although many of the effects of head injury are temporary,
there may be longer-term consequences.98 There is some evidence that traumatic brain
injury increases the risk of cognitive decline,163 although a review of the literature indicates
that older adults do not have a uniformly poor functional and cognitive outcome.164
Neuropathological signs similar to those found in Alzheimer's disease have been found in
the ‘punch drunk’ dementia pugilistica, which is associated with repeated blows to the
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head, but the extent to which the two conditions share a common pathogenesis is
unknown.56;98 Because of these links, there has been interest in the extent to which
traumatic head injury could be a risk factor for Alzheimer's disease.98
Reviewers of the literature have suggested that there is evidence to support a link between
a history of head trauma with loss of consciousness and an increased risk of Alzheimer's
disease.12;14;56;98 A 1991 meta-analysis, which included seven case control studies, found that
head injury with loss of consciousness increased the risk of Alzheimer’s - though the results
were significant only for males.165 A more recent meta-analysis of 15 case control studies
conducted since 1991 confirmed this finding.166 There is also some evidence from
prospective studies that individuals with a history of head injury with loss of consciousness
are more likely to develop dementia over a 2-year period.98 Greater severity of head injury
has been associated with greater risk of Alzheimer's disease,98 and  Mortimer’s 1991 meta-
analysis suggested that head trauma in the decade before onset of Alzheimer's disease was
more important than head trauma earlier in life.165 Also, Aß (or ß-amyloid) protein – one of
the hallmarks of Alzheimer's disease – has been found in the brains of head injury
fatalities,14;98 and there is some evidence that the presence of the APOE 4 allele may be
associated with a poorer recovery from brain injury.98 Several studies have found that the
association between head injury and Alzheimer's disease is stronger in males.98
However, not all studies have found a significant risk of Alzheimer's disease after head
injury, and some reviewers have concluded that the relationship remains uncertain.56;164
Many have commented on the possibility of bias in the studies. One reason is because of
the use of retrospective reporting of head injury, often by relatives, with consequent biases
of recall;56;98 another is because of the subjective definitions of head injury.14;98 Jorm has
reported that the findings from studies which used objective medical records of head injury
did not support an association.14 (One study indicated that head trauma was only a risk
factor for individuals who carried the APOE 4 allele.167) On the other hand, Morris98 has
drawn attention to a recent US study which verified the occurrence and severity of head
injury using medical records, and which found a clear relationship between severity of
injury and risk of Alzheimer's disease.168
EXPOSURE TO ILLNESS, INFECTION OR VIRUSES
Herpes simplex type 1 virus (HSV1)
It has been suggested that dementia may be associated with the presence of the herpes
simplex type 1 virus (HSV1) in the brain. HSV1 is harboured in latent form in the peripheral
nervous system of nearly all adults,5 and in the brains of elderly people with and without
Alzheimer's disease.5;169 When the virus is reactivated, it causes an acute infection which – in
some people – causes cold sores.  
Neuro-pathological studies have found that Alzheimer's disease patients who harbour the
virus are far more likely than those who do not to possess the APOE 4 allele.5 Results have
shown that those with the APOE 4 allele are not more susceptible than others to HSV1
infection. Itzhaki and colleagues have concluded, therefore, that HSV1 in the brain together
with the possession of the APOE 4 allele confers a high risk of developing Alzheimer's
disease, whereas neither factor on its own does so,5 i.e. that HSV1 is a risk factor in
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individuals who carry the APOE 4 allele.170 Evidence that a higher proportion of cold sore
sufferers than non-sufferers possess the APOE 4 allele lends support to this view.5 These
findings have been replicated in one study,171 but not in another, and the authors of the
latter have recommended the use of larger studies with attention to potential sampling bias
to investigate the reasons for discrepancies.172
Itzhaki and colleagues have postulated that the virus is present in the brain in latent form
and re-activates under certain conditions,14 and that limited reactivation of the virus causes
more damage in Alzheimer's disease patients than in other older people because of
differences between individuals.170 They have speculated about possible causal mechanisms,
suggesting a link with genetic factors. They have also noted, however, that, whatever the
mechanisms involved, if HSV1 is a risk factor for Alzheimer's disease, then some cases might
be preventable by vaccination, and anti-viral drugs might slow the course of the disorder in
those already affected.5
Human immunodeficiency virus type 1 (HIV)
Dementia has been associated with the human immunodeficiency virus type 1 (HIV).173 The
point has been made that little knowledge is available about HIV/AIDS in the elderly
population, although it has been estimated that 10% of all diagnosed cases in the US are in
people age 50 and over.174
Illness: delirium
Adults over age 75 years are particularly vulnerable to developing delirium during acute
illness and hospitalization.175 Dementia has been seen as an important risk factor in the
development of this multi-factorial syndrome. Delirium has traditionally been seen as
reversible, but Inouye has argued that an examination of the literature suggests that
delirium poses substantial risks for cognitive decline and dementia.175 The condition could
serve to unmask unrecognised dementia, but it might also lead to irreversible cognitive
decline and dementia, particularly in people with an underlying degree of cognitive
impairment. Inouye has suggested that any strategy to prevent cognitive decline in later life
should include efforts to prevent delirium in hospitalised older people.  
EXPOSURE TO TOXINS OR POLLUTANTS
Aluminium
There is some circumstantial evidence, which has accumulated over a period of decades,
linking aluminium with Alzheimer's disease.176 Early pathological research found increased
concentrations of aluminium in the brains of Alzheimer cases.14;62 In addition, aluminium has
been linked with the presence of plaques in the hippocampus, although not the plaques
and tangles characteristic of Alzheimer's disease.176 Aluminium has also been identified as
the cause of ‘dialysis dementia’, although people with this condition do not appear to
develop plaques and tangles in the brain.176 Some empirical research has suggested a
possible relationship between aluminium in drinking water and the occurrence of
Alzheimer's disease.14;56;62 However, reviewers have drawn attention to methodological
weaknesses in the studies and the strong possibility of bias,56;62 as well as to the small size of
the increased risk.176 They have concluded that there is no evidence that aluminium plays a
causative role in the development of the condition,176 and that more research is needed.62;177
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Other toxins and pollutants
Findings on occupational exposure to other toxins and pollutants have been
controversial.14;56 One case-control study has indicated an association with Alzheimer's
disease for men exposed to certain solvents,178 and another has found a similar
association with exposure to pesticides and fertilisers,179 and glues.109 However, reviewing
the evidence, van Duijn has argued that overall, the results are inconclusive, partly
because of the low frequency of exposure and the imprecise definition.56 Jorm has
concluded that the findings relating to other occupational hazards have generally been
negative, although an exception might be exposure to electro-magnetic fields.14
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
Inflammation has been seen as a response triggered by the interplay of a range of
factors.180 It has been hypothesised that Alzheimer's disease involves inflammation of the
brain,97 although the role of inflammation in the pathogenesis of the disease has been
debated.159 Non-steroidal anti-inflammatory drugs (NSAIDs) are often prescribed for
arthritis, and it has been estimated that at least 10 –15% of people over the age of 65
years in the US take these medications.181 It is known that high NSAID use may be
associated with a reversible impairment of cognition in the elderly,181 and a number of
other adverse effects of the drugs have also been noted.158;182
Some research has indicated, however, that the use of NSAIDs might slow the rate of
cognitive decline in patients with Alzheimer's disease.182 In addition, there is now evidence
from large longitudinal population-based studies, as well as from earlier observational and
small interventional studies, that the prolonged use of NSAIDs might prevent - to an
extent - the decline in cognition associated with ageing,181 and that the past use (i.e.
before the onset of disease) of such medications is associated with a reduced risk of
developing Alzheimer's disease.14;56;158;159;181-183 A recent meta-analysis of observational studies
has concluded that NSAID use does appear to lower the risk of Alzheimer’s disease –
though the appropriate dosage and duration of use are still unclear.184
The possible protective effects of NSAIDs remain to be clarified by clinical trials.56;185
Commentators have pointed out that the side effects of the drug make it difficult for
randomised controlled trials to be carried out,56 and that not all elderly patients are
candidates for NSAIDs.182 NSAIDs are currently being tested in clinical trials of patients
with Alzheimer's disease and cognitive impairment,11 but in the US a major prevention
trial (ADAPT) is now recruiting healthy participants who have a family history of
Alzheimer's disease.186 It has been stressed that the risks of NSAIDs must be shown to be
outweighed by the benefits before their use to reduce the risk of cognitive decline and
dementia is indicated,181;182 and that determining the definitive mechanism of action of
NSAIDs in the development of Alzheimer's disease might suggest alternative agents
which have similar pharmacological activity but which are associated with fewer side
effects.182 The point has also been made that, although the benefits of NSAIDs have
been seen from a patho-physiological perspective, it is not known whether the
protection comes from an anti-inflammatory effect that modifies pathways involved in
Alzheimer's disease, or is mediated by a platelet effect that decreases the risk of cerebro-
vascular disease.181
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SUMMARY
• There is some evidence that brain injury increases the risk of cognitive decline.
• There is evidence to support a link between head trauma and loss of consciousness and
an increased risk of Alzheimer's disease, although not all studies show this.
• There is some evidence to suggest that herpes simplex type 1 virus (HSV1) may be a risk
factor in individuals who carry the APOE 4 allele. If this is the case, it is possible that
some cases of Alzheimer's disease could be prevented by vaccination.
• The link with aluminium suggested by some early studies has not been proved.
• A few studies have examined exposure to other toxins and pollutants, but the findings
are inconclusive.
• There is some evidence of a link between non-steroidal anti-inflammatory drugs (NSAIDs)
and a reduced risk of Alzheimer's disease, although this protective effect remains to be
confirmed by clinical trials.  NSAIDs have a number of side effects that preclude their
widespread use.
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CHAPTER TEN
CLASSICAL (PERSONAL
AND LIFESTYLE) RISK
FACTORS I: RISK
FACTORS FOR
VASCULAR DISEASE
A number of factors are traditionally seen as increasing the risk of a wide variety of conditions.
These ‘classical’ factors, which can also be seen as ‘personal’ or ‘lifestyle’ factors, include
vascular factors, smoking, alcohol, diet, nutrition and hormones. This chapter examines the
evidence for seeing risk factors for vascular disease as also risk factors for dementia or cognitive
decline. Possible strategies for intervention are outlined in Chapter 13.
There is interest in vascular causes of dementia since, to the extent to which vascular
disease is preventable or treatable, the incidence rates of dementia might be reduced.12;20;56
Vascular risk factors for dementia include vascular disease, and risk factors for vascular
disease. Hypertension (high systolic blood pressure) is a main risk factor for vascular disease,
but there are many others, such as diabetes and atrial fibrillation. One important issue is
whether vascular risk factors measured in old age or in mid-life have a more significant
effect on the risk of cognitive decline or dementia.
VASCULAR FACTORS AND THE RISK OF VASCULAR DEMENTIA
Vascular dementia is thought to be caused by a disruption of the blood supply to the brain.
However, the concept of ‘mini-strokes’ in the brain (hence multi-infarct dementia) has been
replaced by more sophisticated models suggesting a spectrum of vascular causes.67 The risk
factors for vascular dementia (or vascular cognitive impairment [VCI]) are relatively well
understood, and are thought to be very similar to those for stroke and coronary artery
disease.68 They include cardio-vascular disease and risk factors for vascular disease, which in
turn include cerebro-vascular disorders (CVDs) and vascular risk factors such as
hypertension and diabetes.56;64-67 Erkinjuntti has listed the risk factors for vascular dementia
(see Table 10.1 on page 66).67 He has noted, however, that the individual roles that these
factors play in causation have not been identified in detail, nor is it clear which mechanisms
are of primary importance.
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Table 10.1  Different Aetiologies of Vascular Dementia
Hypertension
Hypertension or elevated blood pressure reportedly affects at least 50% of older people in
the US.26 It is well known that, if untreated, hypertension can contribute to the
development of cerebrovascular disease,20;187 and hence to conditions such as vascular
dementia which can occur as a consequence of stroke. Hypertension is one of the leading
causes of vascular dementia.188 (Much less frequently, severe hypertension has been
associated with characteristic changes in the brain, called white matter hyperintensities,189
and with acute or subacute global cerebral disturbance.26) Systolic blood pressure has been
found to be far more important than diastolic blood pressure in predicting the risk of
cardiovascular disease in those aged 50 and over.190
Cerebrovascular disorders
Large artery disease
Artery to artery embolism
Occlusion of an extra- or intracranial artery
Cardiac embolic events
Small vessel disease
Lacunar infarcts
Ischaemic white matter lesions
Haemodynamic mechanisms
Specific arteriopathies
Haemorrhages
Intercranial haemorrhage
Subarachnoid haemorrhage
Haematological factors
Venous diseases
Hereditary entities
Risk factors
Vascular
Arterial hypertension
Atrial fibrillation
Cardiac abnormalities
Myocardial infarction
Coronary heart disease
Diabetes
Generalised atherosclerosis
Lipid abnormalities
Smoking
Other
High age
Low education
Source: T. Erkinjuntti, “Vascular dementia: an overview”, table 48.1, page 624 in O’Brien, Ames and Burns (eds) Dementia,
2nd edition, 2000.  London: Hodder Arnold. Reproduced with permission from Hodder Arnold.
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Diabetes
The link between diabetes and cognitive impairment among older people is well
documented,191;192 and a recent BMJ editorial has noted that there is now evidence from
prospective longitudinal studies of an association between diabetes and cognitive decline.191
The majority of these cohort studies have found that diabetes is associated with an
approximate doubling of the risk of dementia, more often with ‘stroke mediated dementia’
than Alzheimer's disease.191 A recent Swedish study looking specifically at Type2 diabetes
found no association between diabetes and Alzheimer’s disease, though the risk of vascular
dementia increased twofold.193 It has been pointed out that there are numerous
mechanisms by which the complications of diabetes can alter mental status; for example,
vascular complications can contribute to the development of stroke and cardiac disease,
and renal failure can affect brain function.26
Obesity
There is increasing interest in obesity as a risk factor for cerebro-vascular conditions,194
since people with excess body fat have a greater risk of illnesses such as diabetes and
hypertension.50 One recent US study which followed participants in the Framingham heart
study found that, even when hypertension was controlled, obesity was still a risk factor for
heart failure.194 A similar finding has recently been reported for the association between
obesity and cognitive decline in the same cohort,195 though the link was found only in
men. Results from a recent 18-year Swedish study have also indicated that overweight and
obesity at high ages could be risk factors for the development of late-onset dementia,
particularly Alzheimer's disease. In this case, however, the association was found only in
women.196 Suggested mechanisms include a thickening of the wall of the heart, or a
cluster of symptoms known as the metabolic syndrome and characterised by insulin
resistance and dyslipidaemia.194
VASCULAR FACTORS AND THE RISK OF DEMENTIA OF THE ALZHEIMER TYPE
There is evidence from a number of recent studies of an association between vascular
disorders and risk factors (e.g. raised systolic blood pressure) and Alzheimer’s disease.12;63;197-
203 Skoog lists as evidence: the frequency of APOE 4 allele in middle aged individuals with
coronary heart disease and atherosclerosis; the increase in neurofibrillary tangles and senile
plaques in the brains of non-demented individuals with hypertension, and the increased
systolic and diastolic blood pressure before the onset of Alzheimer's disease.63;204 A recent
prospective, population-based study has suggested that raised systolic blood pressure and
high serum cholesterol concentration, and in particular, the combination of these risks, in
midlife, increased the risk of Alzheimer's disease in later life.188 Also, a recent large
population-based study has found that features of the insulin resistance syndrome were
associated with an increased risk of Alzheimer's disease independent of APOE 4
phenotype.205 Skoog has noted, however, that the mechanisms for the association between
vascular risk factors and dementia are unclear.63 He has suggested that they could include
shared pathogenic pathways of various sorts, environmental as well as individual. It has also
been pointed out that, although an increased risk of stroke or transient ischaemic attacks
has been implicated in inducing Alzheimer–type degenerative changes, the converse has
been suggested; i.e. that individuals with Alzheimer's disease may be at increased risk for
stroke and cerebral infarction, the main diagnostic features in vascular dementia.199
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Low blood pressure and Alzheimer’s disease
A number of studies have found low blood pressure among people with dementia,
including Alzheimer's disease,197;206-210 and in the years just preceding its onset.204 Some
commentators have concluded that low blood pressure might be a complication of the
disease process,197;200;206 or that low blood pressure might predispose a subpopulation to
developing dementia.197 Others, on the other hand, have suggested that the decrease in
blood pressure in the very elderly might stem from age-related changes in brain structure,
with low blood pressure in dementia disorders being a secondary phenomenon.208
There is some concern, therefore, about the safety of treatment for hypertension.211
However, the more general view, drawing on studies which suggest that treatment of
hypertension has no effect on cognitive function,212 is that low blood pressure is more likely
to be the result of dementia or the healthy survivor effect than its cause.213 More
longitudinal studies are felt to be needed to investigate cause and effect.206
VASCULAR FACTORS AND THE RISK OF COGNITIVE DECLINE
There was some early evidence that the cognitive function of individuals at risk of
cardiovascular disease tended to decline earlier than that of those not so affected.214 One
recent small cross-sectional study has found that cardiovascular risk factors are important
predictors of cognitive function among middle-aged and older African Americans.215
Reviewers of the literature20;189 have noted that a number of recent studies, including the
Rotterdam study, have shown evidence of a link between vascular risk factors and cognitive
impairment (and dementia).204;216-219
Some research has found that blood pressure values are related to cognitive performance
scores,220 and it has been suggested that blood pressure and hypertension might account
for variance in performance that might otherwise be attributed to ageing.220 Findings from
a number of studies have suggested that individuals with elevated blood pressure during
midlife exhibit lowered cognitive functioning in old age.221-223 Results from the Framingham
longitudinal community study of vascular risk factors have demonstrated that blood
pressure measured about 20 years prior to cognitive function testing was associated with
recent poorer function.209 These findings have been confirmed in the Honolulu-Asia Aging
Study (HAAS), in which midlife systolic blood pressure (SBP) was found to be a significant
predictor of reduced cognitive function in later life,216 even after controlling for a number of
factors and even when people with dementia were excluded from the analysis.189 The
authors have recommended that early control of SBP levels may reduce the risk of cognitive
impairment.189;216 In another longitudinal study of healthy old people in Edinburgh (the
HOPE study), Deary and colleagues found that blood pressure was related prospectively to
fluid intelligence but not to memory differences.224 A somewhat puzzling note has,
however, been struck by a Swedish longitudinal study which found the association between
hypertension and cognitive decline did not exhibit the expected dose-response
relationship.225 Individuals with blood pressure in the highest ranges showed a smaller
decline in cognitive performance than people with moderate hypertension.
White and colleagues have noted that, in the HAAS, diastolic blood pressure measured
during the same earlier time period did not predict later poor cognitive function.189 Neither
was current systolic or diastolic blood pressure related to cognitive function.189;226 In fact, it
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appeared that a relatively low systolic blood pressure was associated with the highest risk of
poor cognitive function.189 The authors have concluded that relationships between base
variables and outcomes are complex, but that it is possible that the identification of a risk
factor in mid-life might be a better indicator of exposure than identification of the same
factor in later life.189
Cerebral hypoxia and sleep apnoea
Some research has suggested that chronic disorders of blood gas regulation (e.g. sleep
apnea or breathing cessation during sleep) are associated with long-term cognitive
deficits,26 perhaps because of low levels of blood oxygen or high levels of carbon dioxide.
Sleep apnoea is a common medical disorder exhibiting an increased incidence with age,
and affected individuals can develop chronic cardio-vascular disorders, such as hypertension
and heart failure.26
Heart bypass surgery and cognitive decline 
There are clear signs of cognitive dysfunction immediately after coronary artery bypass
surgery (CABG) in about 75% of patients, although in the majority of cases the problems
are temporary. There is interest in whether there are more subtle, long-term, cognitive
deficits in a sub-set of patients, whether the effects of CABG can be separated from any
subtle cognitive effects that were present before surgery, and whether any cognitive deficits
seen before surgery in people with heart disease might be pre-clinical Alzheimer's disease.227
The findings from one recent study have indicated that a significant predictor of cognitive
decline after 5 years was cognitive function at discharge, and the authors have argued that
interventions to prevent or reduce short- and long-term cognitive decline after cardiac
surgery are warranted.228
SUMMARY
• The risk factors for vascular dementia are relatively well understood.  These include
cerebro-vascular disease, and risk factors for vascular disease, such as hypertension,
diabetes and obesity.
• An association has recently been found between vascular factors found in mid-life (e.g.
hypertension) and Alzheimer's disease.  At the same time, low blood pressure has
sometimes been found among people with the disorder.
• Findings from recent large studies have indicated that high blood pressure measured in
mid-life is also a significant predictor of poorer cognitive function in later life.
• The long-term cognitive decline experienced by a minority of heart bypass patients is
being investigated.
CHAPTER ELEVEN
CLASSICAL (PERSONAL
AND LIFESTYLE) RISK
FACTORS II: SMOKING,
ALCOHOL AND DRUG USE
This chapter summarises the strength of the evidence for seeing smoking and alcohol consumption
as risk factors for dementia or cognitive decline. These factors have been linked with vascular
disease and with other disorders. Recreational drug use has not been examined by research.
SMOKING
Smoking is a known risk factor for vascular disease, and the risk of vascular dementia has
been found to be increased for subjects who smoked.229 If smoking were found also to
increase or decrease the risk of cognitive decline or Alzheimer's disease, there would be
implications for public health campaigns, since smoking habits are potentially changeable.
Research investigating smoking and Alzheimer's disease has appeared to produce
contradictory findings.14;56;60;230 Early case-control studies110 and meta-analyses231 suggested
that smoking might be associated with a decreased risk of Alzheimer's disease. There is also
some evidence of a protective effect of smoking on early onset Alzheimer's disease,
although strongly modified by genetic factors.142 It has been suggested that smoking could
have a short term therapeutic effect on cognition, attention and reaction time.60 A
protective effect on Alzheimer's disease has also been seen as biologically plausible, since
smoking increases the density of nicotinic receptors in the cortex, and Alzheimer's disease
involves a loss of these receptors.14;60 Various alternative explanations have been offered,
however, including elderly smokers being a survival elite,232 and classification of demented
smokers as having vascular or mixed dementia rather than Alzheimer's disease.233 It has also
been pointed out that the diagnostic criteria for Alzheimer's disease exclude those with
vascular disorders and hence those more likely to have smoked early in life.60
Recent studies examining links between smoking and Alzheimer's disease have yielded more
equivocal results. Findings from longitudinal studies - the Rotterdam study,232 a community-
based study in Manhattan,234 the Kungsholmen project in Sweden235 and the Honolulu-Asia
Aging Study236 - have suggested that smoking is associated with an increased risk of
Alzheimer's disease, thus tending to confirm the findings from EURODEM pooled analyses
which showed that current smoking (more strongly in men), increased the risk of
Alzheimer's disease significantly.24 Doll and colleagues have concluded that the findings
from a long-term study of smoking and dementia in British doctors, taken together with
other longitudinal studies, suggest that persistent smoking does not substantially reduce
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the age-specific rate of dementia, but that any net effect on severe dementia – in either
direction – must be small.233 Others, however, have called for long-term prospective studies
to clarify the direction of any association.14;60 Commentators have noted that the findings
from within the Swedish study,235 and from a number of other studies, have highlighted
differences between cross-sectional and longitudinal analyses, perhaps due to the effect of
survival in the former.60;230
There are a number of difficulties in examining smoking as a risk factor, especially in
retrospective studies. Comparing current smokers, ex-smokers and non-smokers is
problematic, since the first two categories can cover a range of experience.60;233 Also, since
the presence of disease might change smoking habits, earlier smoking patterns have to be
examined, and a brief period of smoking might be more likely to be overlooked in cases
than controls.233 It has also been pointed out that, in any study carried out among hospital
patients, the prevalence of smoking among the controls is likely to be high.230;233
ALCOHOL
The lifetime incidence of alcoholism exhibits a bi-modal pattern, with the second peak
representing people in their 60s and 70s.26 It has been argued, therefore, that the
prevalence and the consequences – which can be cumulative - of alcohol abuse can be
seen as age-related.26
One reviewer of the literature has suggested that alcohol may make a contribution to
dementia of all types in roughly 10% of cases.78 Alcohol is known to affect the brain in a
variety of ways. There is some evidence that a significant proportion of heavy drinkers have
a degree of mental impairment on some tests, although an improvement has been found
with abstinence.237 There are also thought to be long-term effects of alcohol abuse on the
brain, since a proportion of chronic alcoholics develop dementia,79 and since scanning
evidence suggests that 50-70% have shrinkage of and damage to the brain.26;237 The
consequences of alcohol abuse were at one time included under the general term ‘Alcohol
related brain disorder’ (ARBD), but it is now felt that the effects should be seen as separate
conditions, rather than as a specific syndrome.26 These conditions include Korsakoff’s
syndrome (or Wernicke-Korsakoff syndrome) and a widespread impairment of mental
function, which has been termed ‘alcohol-associated dementia’.  
Alcohol abuse is the commonest cause of Wernicke’s encephalopathy, an acute syndrome
consequent on thiamine deficiency, whose features include memory impairment. A longer-
term consequence is Korsakoff’s syndrome, the main feature of which is amnesia, or
impaired recent memory. (For further details, see ‘Korsakoff’s syndrome and other chronic
alcohol related brain damage’ (2002).237) One post-mortem study of Korsakoff’s syndrome
patients indicated that some dementia was present in 34% of cases.238 It has been pointed
out, however, that many cases of pathologically proven Wernicke’s encephalopathy are
clinically aysymptomatic before death.79
The term ‘alcohol-associated dementia’ or ‘dementia associated with alcohol’ has been
used to describe the development of a dementia following prolonged and heavy ingestion
of alcohol, for which all other causes of dementia have been excluded. This definition
acknowledges that (although there is convincing evidence that alcohol is directly
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neurotoxic) the causal role of alcohol per se in dementia is controversial, and that some of
the medical effects of alcoholism are potentially reversible.79 Although some have seen
‘alcohol associated dementia’ as a more severe form of Korsakoff’s syndrome, there is no
recognised microscopic pathology,239 and no direct evidence linking the cognitive deficits of
alcoholics with subsequent findings at post-mortem.79 Much of the evidence for the
existence of the condition is based on neuropsychological tests and scanning.237
A high intake of alcohol is associated with vascular disease, and hence with an increased
risk of vascular dementia.18 On the other hand, there is also some evidence that light to
moderate alcohol intake is associated with a lower risk of coronary heart disease and
stroke,240 and the findings from two recent prospective studies have indicated that light to
moderate alcohol consumption might be associated with a lower risk of developing
dementia, including Alzheimer's disease,241 and vascular dementia.240 A slightly more
complex picture is suggested by results from the Copenhagen City Heart Study, which
found that the association between alcohol intake and risk of dementia depended on the
type of alcohol that was being consumed.242 Although alcohol intake (irrespective of the
type of alcohol) was not associated with reduced risk of dementia, regular consumption of
wine was associated with a lower risk. The authors have suggested that one explanation for
these results may lie in the antioxidant effects of the flavonoids in wine (absent in other
forms of alcohol). However, the results of studies linking light or moderate alcohol
consumption with a lower risk of dementia have been questioned. One commentator has
argued that, in the light of strong evidence associating alcohol with a significantly increased
risk of dementia and Alzheimer's disease, the findings from studies which do not find this
should, perhaps, be treated with caution, since cases with high alcohol intake might have
been excluded.56 There might also be other explanations for the effect, such as moderate
drinking being associated with a healthier lifestyle. 
In reviewing the literature, Joyce has concluded that there are several possible routes to
brain damage in alcoholics, that these are interlinked, and that a combination of
malnutritional and alcohol intake can give rise to a range of cognitive deficits from mild
cognitive impairment to severe dementia.79
RECREATIONAL DRUG USE
Some forms of dementia have been seen as drug-induced.59 There is increasing interest in
the long term effect of recreational drug use on the brain. At the moment, however,
epidemiological research has not examined recreational drug use as a risk factor.  
SUMMARY
• Smoking is a known risk factor for vascular dementia.  
• Findings from studies examining smoking and the risk of Alzheimer's disease have varied.
It has been concluded that any effect, in either direction, is likely to be small.
• High alcohol intake is linked with cognitive impairment, although the effects may be
reversible. It is also the commonest cause of Wernicke-Korsakoff syndrome, the main
feature of which is memory impairment.
• Alcohol use is thought to contribute to a significant proportion (10%) of cases of
dementia. A high intake of alcohol is associated with vascular disease and, hence, with
vascular dementia.  Also, although alcohol per se might not cause dementia, it has
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been seen as a contributory factor in conjunction with other factors, particularly
nutritional deficiencies. 
• Although there is interest in the long term effect of recreational drug use on the brain,
drug use has not been examined as a risk factor.
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III: DIET, NUTRITION
AND HORMONES
Until recently, research on nutrition and cognitive function in older people has been limited.
However, there has been increasing interest in examining the extent to which nutritional factors
can be considered as risk factors for dementia or cognitive decline, and at the recent 8th
International Conference in Sweden, a number of papers reported the results of studies of this
type. Diet and nutrition has a number of aspects. This chapter examines the strength of the
evidence for regarding weight loss, nutritional deficiency, B vitamins, cholesterol and anti-
oxidants – whether in midlife or old age - as risk or protective factors for cognitive decline and
dementia. The role of hormones such as oestrogen is also examined.
WEIGHT LOSS
Weight loss is commonly associated with Alzheimer's disease, and a number of possible
explanations have been suggested.91 The evidence is equivocal. However, although one
study found no association with malnutrition in early life,243 two recent long-term
prospective studies, including the Honolulu-Asia Aging study,244 have found a significant
correlation between previous weight loss and the subsequent development of Alzheimer's
disease, not explainable substantially by co-morbid disease.244;245
NUTRITIONAL DEFICIENCY
Older people might be at risk of nutritional deficiency for a number of reasons. The effects
of nutritional factors have been seen as important in the risk of heart disease, and there
has been increasing interest in investigating whether aspects of nutrition might have long-
term effects on cognitive function or might be implicated in the development of
dementia.  Food deprivation of varying degrees has been found to affect cognition,
although the size of the effects can be small.26;51 The central nervous system is known to
depend on glucose and almost all of the essential nutrients for effective functioning.246
Vitamins and minerals are thought to be crucially involved in the formation of certain
neurotransmitters, suggesting an explanation for links between deficiency and impaired
cognitive functioning.247
B VITAMINS: FOLATE, VITAMIN B12 AND LEVELS OF HOMOCYSTEINE
Deficiencies in B vitamins (folate, vitamin B12 and vitamin B6) are thought to be relatively
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common in the general population and in older adults in particular.26;246;248 Folate deficiency at a
cellular level can occur even with ‘normal’ serum folate values.249 Low levels of B vitamins have
been found to correlate with increased serum levels of homocysteine, an amino acid.61;249;250 It
has been has suggested that folate concentrations in serum and cerebrospinal fluid fall (and
plasma homocysteine rises) with age, perhaps contributing to the ageing process.251
There is evidence from a number of cross-sectional studies that folate intake and/or status,
either alone or in combination with vitamin B12, appears to be associated with cognitive
functioning,26;51;61;246;249 especially memory performance and measures of abstract
reasoning.246 Elevated plasma homocysteine levels have also been found to be associated
with poor cognition.252-254 However, the links between B vitamins and the incidence of
cognitive decline and dementia have been little examined.255
Low folate levels have been associated with an increased likelihood of vascular disease
including stroke.249 Similarly, a high concentration of plasma total homocysteine (tHcy) has
been identified as a major cardiovascular risk factor,61;91;250;252;255;256 (although recent studies
indicate that the risk might not be as high as was once thought257), as well as being
associated with some cancers and possibly multiple sclerosis.258
There is clinical and epidemiological evidence linking low (serum) levels of vitamin B12 and
folate to dementia,26;91;249 and to Alzheimer’s disease in particular.61;258;259 For example, the
Canadian Study of Health and Aging found that low folate levels were common in all types
of dementia and were associated with a history of weight loss, lower body mass index and
lower serum albumin concentrations.249 In the Nun study, serum folate deficiency correlated
significantly with neocortical atrophy found at postmortem.260 In addition, a number of
cross-sectional studies, including those carried out by Clarke and colleagues261 and
McCaddon and colleagues253 in the UK, have found evidence of raised homocysteine levels
in people with Alzheimer's disease.14;61;91;258;262 In the OPTIMA Project (Oxford Project to
Investigate Memory and Ageing), Clarke and colleagues found that low blood levels of
folate and vitamin B12, and elevated tHcy levels, were associated with Alzheimer's disease,
as diagnosed at autopsy.261
Some commentators have pointed out that it is unclear whether the observed levels of
homocysteine or folate are cause or effect of dementia or cognitive decline, since they
could reflect the reduced ability of people with dementia or cognitive decline to eat
properly.91;249;258 On the other hand, Clarke and colleagues have argued that the findings do
suggest homocysteine levels as a cause of disease and warrant further investigation. There
have been other calls for longitudinal studies.252 The findings from two recently reported
longitudinal studies have tended to confirm the associations found in early work.251 Results
from the Kungsholmen project have indicated an association with Alzheimer's disease,
especially among cognitively intact subjects, when both vitamin B12 and folate were taken
into account,259 and those from the larger Framingham Study have suggested that an
increased plasma homocysteine level is a strong, independent risk factor for dementia and
Alzheimer's disease.252
Various theories have been put forward about possible mechanisms by which
hyperhomocysteinemia (or elevated tHcy) might be related to cognitive decline, dementia
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and Alzheimer's disease.91;263 Since there is strong evidence that elevated tHcy is associated
with an increased risk of vascular, cardiac and cerebral pathologies, it has been suggested
that the cognitive impairment that occurs in older subjects might be mediated by
homocysteine-related cerebrovascular lesions.61 (With the recent evidence that
cerebrovascular disease might contribute to the risk of Alzheimer's disease, tHcy may again
be relevant.91;261) It has also been suggested that folic acid deficiency and homocysteine
might impair DNA repair in hippocampal neurons and sensitise them to amyloid toxicity,
something which has been demonstrated in mice.264
Implications for prevention
In considering strategies for intervention, there are issues of feasibility and ethics to be
considered. Interventions should be effective (and perhaps cost-effective), but should also
not cause harm. There are particular concerns about safety where people do not suffer
from a recognised disease, as is the case with cognitive impairment. B vitamins are found in
low concentrations in certain foods, such as broccoli, fruit and beans.258 They can also be
taken as supplements. Alzheimer Scotland – Action on Dementia (ASAD) has pointed out
that, at the doses found in commercially available supplements, taking B vitamins is not
normally harmful, although at high doses all vitamins can be dangerous and toxic.258
High levels of homocysteine in people with dementia can be reduced, relatively inexpensively,
by taking folic acid or vitamin B12 supplements.250;258 There have been suggestions that
vitamin B12 treatment might improve frontal lobe and language function in patients with
cognitive impairment,265 or might even offer a means of protection against cognitive decline
or dementia. There is as yet no consensus about screening for hyperhomocsyteinaeima, with
some reviewers arguing that tHcy levels should be monitored – with a view to treatment - in
all older people,259 and others recommending that only high-risk individuals (i.e older people
with cognitive impairment) be investigated.265;266 Another suggestion has been that flour
should be fortified with folic acid as a general population measure.248
One UK study in which baseline vitamin level correlated with cognitive function found that
vitamin supplements, while increasing blood vitamin levels, had very little effect on
performance.247 On the other hand, although few longitudinal studies have been carried
out,246 there is evidence that treatment with vitamin B12 has a positive (improving) effect
among patients presenting with cognitive impairment,265 and that supplementation can
enhance cognitive performance in older adults.246 Intervention studies with vitamin B
supplement are felt to be warranted.61;246 Clinical trials of homocysteine-lowering vitamins
for people with Alzheimer's disease are planned, and it has been suggested that these
should be extended to people with mild memory impairment.148 As to whether taking such
supplements might offer any protection against developing dementia, ASAD has noted that
longitudinal studies with a large number of participants, carried out over many years,
would be needed to determine this.258
CHOLESTEROL
There has been increasing interest in the role of dietary fat (saturated or unsaturated) in
dementia, and in the relationship between blood cholesterol levels and cognitive decline
and Alzheimer's disease. Cholesterol levels might be modifiable, either by changes in the
diet, or by medication.
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High blood cholesterol levels are associated with an increased risk of cardiovascular disease.
Low-density lipoproteins (LDLs) are the part of cholesterol that enables fats to attach to the
walls of arteries, narrowing and eventually blocking them. High-density lipoproteins (HDLs)
in contrast help to keep the arteries clear, so that blood can flow freely. If left untreated,
elevated LDL and cholesterol levels can increase the risk of stroke, heart attack and death.
There is some evidence that – for women – after the menopause, cholesterol and LDL levels
may rise and HDL levels may fall slightly.267
There is also accumulating evidence from epidemiological studies pointing towards a link
between cholesterol and Alzheimer's disease,91;268 and indicating that lower fat diets in mid-
life might reduce the risk for Alzheimer's disease decades later.50 Findings from the
Rotterdam study have provided some evidence that dietary saturated fat and cholesterol
measured at baseline increased the risk of cognitive impairment and dementia a few years
later,269;270 and those from a 21-year Finnish study have indicated that raised systolic blood
pressure and high serum cholesterol, and in particular the combination of these risks, in
midlife, increased the risk of Alzheimer's disease in later life.188  Another Finnish study has
found an association between blood lipid levels in mid-life and the amount of ß-amyloid
protein (Aß) seen in the brain at post-mortem, although the issue appears to be complex.271
Several recent studies have indicated similar links between cholesterol and cognitive decline
more generally.272-275 Longitudinal or prospective studies are felt to be needed to further
investigate these findings.276 It has also been argued that, since the risk from these treatable
factors appears to be relatively high, in relation to genetic factors for example, intervention
may be worthwhile.277
The fats that are strongly associated with vascular damage and may also be associated
with damage to the brain are rich in monosaturated fatty acids. Fats that are rich in
polyunsaturated fatty acids appear by contrast to offer a significant degree of protection
from cardiovascular disease, and there is now also some evidence to suggest that they
might benefit brain health (independently of their effect on vascular disease). In both the
Rotterdam Study and the Zutphen Elderly Study, moderate fish consumption (as a marker
of n-3 fatty acid intake) appeared to decrease the risk of Alzheimer's disease.269;270;278 More
recent reports from the longer PAQUID project, though here linked with the higher
education of regular consumers,279 and from a Chicago-based study280 have confirmed
these findings.  
Interpretation of findings
It is thought increasingly likely that cholesterol might play a role in the pathophysiology of
Alzheimer’s disease,91;268;281;282 although the mechanisms are unclear. It has been pointed out
that the epidemiological evidence linking dietary cholesterol intake to Alzheimer's disease is
stronger than the epidemiological evidence linking levels of serum cholesterol and
Alzheimer's disease.91 So, for example, a recent follow-up of subjects in the long-running
Framingham Heart Study found no association between serum cholesterol (measured at
various ages) and risk of Alzheimer’s disease.283 It has also been suggested that the
associations with cholesterol found by research could reflect differences or disturbances in
endogenous fatty acid metabolism.275
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Fatty acids could be involved in dementia through several mechanisms, including
atherosclerosis, thrombosis and inflammation,279 and various hypotheses have been
proposed. One suggestion is that the ApoE protein is involved in the transport of
cholesterol and other lipids between neurons.91 There is also growing evidence from studies
with animal models of a link between cholesterol and the accumulation of ß-amyloid in
specific regions of the brain (the common pathogenic event that occurs in all forms of
Alzheimer's disease).268;281;284 In addition, it has been suggested that a high intake of
saturated acids, or a low intake of antioxidants, can increase oxidative stress,51;91 causing
oxidative damage to the brain, changes which may contribute to both vascular and
Alzheimer's disease pathology.43 N-3 polyunsaturated fatty acids, on the other hand, might
reduce inflammation in the brain. Saturated fatty acids are associated with increased
atherosclerosis, and both inflammation and atherosclerosis are thought to be involved in
dementia pathogenesis.272 One view is that dietary fats might interact with genetic factors
to accelerate Alzheimer's disease pathology.285 Hence, lower fat diets during mid-life might
substantially reduce risk of Alzheimer's disease for those with the APOE 4 allele.276
Implications for prevention
Possible protective mechanisms related to cholesterol include (1) changes in diet, i.e.
reducing the intake of saturated fats, or replacing with unsaturated fats, (2) treatment with
lipid-lowering agents, or ‘cholesterol-busters’, and (3) increased intake of anti-oxidants.
Prospective clinical trials have been recommended, to evaluate the impact of specific
macronutrient intakes on age-related changes in cognitive function.273
Lipid-lowering agents
It has been suggested that large reductions in cholesterol concentrations might be easily
and safely achievable with the discovery of statins.286 (Early trials of cholesterol-lowering
agents were not found to be convincingly effective, because the available interventions -
drugs or diet - lowered cholesterol to only a modest degree, the interventions were not
well-tolerated, or the studies lacked statistical power.286) Statins are a group of cholesterol-
lowering drugs, the HmG-CoA reductase inhibitors, which are currently available clinically
and which are thought to have few side effects.268 The discovery of statins has led to a series
of trials, which have demonstrated benefits in selected populations.286 The results of a
recent 5-year randomised control trial (the MRC/BHF Heart Protection Study) have shown
that, for the group of patients taking a statin (simvastin), there were significant reductions
in the incidence of vascular disease and in mortality from all causes, and that there were
clear benefits, even from those high-risk patients considered to have ‘normal’ or ‘low’ blood
cholesterol concentrations.287 Because of the possibility that treatment with statins might
reduce the incidence of cognitive decline, the study included a test of cognitive status at
the final follow-up, but no significant differences were observed between groups.
However, the results of two other observational studies have indicated that statin therapy
can reduce the risk of developing Alzheimer's disease among patients with hypertension
and cardiac disease.288;289 Reviewers have commented that randomised controlled trials are
needed, but that statins appear to have other beneficial effects in addition to that on
cholesterol.282;290 Preliminary findings from one large study in Boston US, which includes a
large number of African Americans (a group known to have a higher risk of developing
Alzheimer's disease) have confirmed earlier indications of a reduction in risk.291
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Anti-oxidants
A high intake of saturated acids has been seen as increasing oxidative stress, and hence the
risk of brain damage.51;91 Evidence of oxidative reactions (e.g. Aß protein of plaques) has
come from neuropathologic studies of Alzheimer's disease.43;102 Conversely, it has been
argued that high plasma levels of anti-oxidants might correlate with cognitive performance
in healthy older individuals,51 or might mitigate against oxidative damage.  Anti-oxidants, or
‘free radical scavengers’ include vitamins A, E, C, ß-carotene and minerals such as zinc, as
well as ginkgo biloba, red wine flavonoids and oestrogen.  
Research has indicated that high levels of cognitive function are associated with higher levels
of vitamins A, C and E (as well as B1, B2 and B3),51 and that, conversely, a decrease in
cognitive test results is associated with sub-deficiencies of various vitamins and minerals,
including vitamins C and E.61 One case-control study, for example, found that lower vitamin C
plasma concentrations were found in Alzheimer's disease patients than in control subjects.292
In a review of the literature, Launer has concluded that, although there are a number of
methodological limitations in the existing studies and larger, better designed trials are
needed, there is increasing experimental data from observational studies and randomised
trials to implicate oxidative damage as a mechanism contributing to brain disease.43
There has been speculation that dietary vitamins with anti-oxidant properties might have a
role in the prevention or slowing of cognitive decline in patients with Alzheimer's disease,91
or that such lipophilic free radical scavengers might play a protective role against oxidative
toxicity.102 Launer has pointed out that trials can help in clarifying a role, if any, for anti-
oxidant therapy to reduce the risk of dementia, noting that many of the hypotheses
regarding the role of oxidation in neurodegeneration must remain speculative in the
absence of knowledge about the pathophysiology of neurodegenerative diseases. Ideally,
trials would be used to test a model or hypothesis, but the problem of finding possible
ways to prevent severe cognitive decline is such that trials have been instituted already.43
Anti-oxidants: intervention studies
Findings from empirical studies examining the relationship between anti-oxidants and
vascular disease have been seen as contradictory.158 The recent UK MRC/BHF Heart
Protection Study of antioxidant vitamin supplementation found that allocation of high-risk
patients to the vitamin regime markedly increased their plasma concentrations of a-
tocopherol, vitamin C and b-carotene, but no significant differences in mortality, nor in the
occurrence of major vascular events were found.293 These findings agree with those from
three other major trials.286
In relation to cognitive decline and dementia, one small cohort study in Australia found
that consumption of vitamin C supplements was associated with a lower prevalence of
more severe cognitive impairment, and the authors have concluded that vitamin C might
have a protective function.294 On the other hand, a small UK study found that, although
multivitamin supplementation increased blood vitamin levels, it had little effect on cognitive
function or mood.247
Some studies have found that anti-oxidant (e.g. vitamin E) supplements have a beneficial
effect on the cognitive function of people who have been diagnosed with early dementia.91
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Longitudinal studies and trials of putative protective agents among people with Alzheimer's
disease and people with cognitive impairment are now under way,11 and, in the US, a
clinical trial examining the prevention of Alzheimer's disease by vitamin E and selenium
(PREADVISE) is recruiting men aged 60 living in the community.295 Reviewers of intervention
studies have found that, overall, the evidence for a protective role of anti-oxidants on the
incidence of dementia is inconclusive.14;61;296 There is some evidence from the Honolulu-Asian
study that supplementary vitamin E might be protective against developing vascular
dementia.297 Also, findings from the recent US Cache County Study have suggested that the
use of vitamin E supplements is associated with a reduced prevalence and incidence of
Alzheimer's disease (and that the combination of vitamin E and C supplements might be
particularly advantageous).298 Interestingly, two recently reported longitudinal studies have
found that high dietary intake of antioxidants, especially vitamin E, from food sources may
reduce the risk of developing Alzheimer's disease.103;299 Findings from the Rotterdam study
have indicated that vitamins C and E may both be beneficial,300 while those from a study in
Chicago have suggested the protective nature of dietary vitamin E, an association only
observed among individuals without the APOE 4 allele.301 Neither study found a benefit
from consuming the supplement sources of vitamins, even though a higher dose was
available in the supplements.103;299
Again, any medical intervention has to be proved to be both safe and effective. Yusuf  has
argued that the data from the MRC/BHF study indicates that prolonged use of antioxidant
vitamins in Western populations without vitamin deficiencies could potentially lead to some
increase in vascular disease.286 Vitamin E is soluble in fat, and can accumulate in the liver
and cause poisoning. There has been interest, therefore, in other supplements with an anti-
oxidant effect. Certain fruits have a relatively high antioxidant capacity.50
Oestrogen
Another putative protective factor is oestrogen. There is some evidence that, for women,
after the menopause cholesterol and LDL levels might rise.267 Animal and in-vivo cell studies
have suggested that oestrogens can protect brain structures, including those related to
memory,302 and there has been interest in whether this might be the case in humans.  
A number of women in Western countries take either synthetic oestrogen or hormone
replacement therapy (HRT – oestrogen combined with progesterone) to treat menopausal
symptoms or to guard against osteoporosis. While oestrogen therapy has been found not
to slow the progress of Alzheimer's disease significantly in patients who already have the
disease,303 there has been interest in finding out whether oestrogen supplements might
have beneficial effects for women in delaying or averting cognitive or memory decline, or
the incidence of dementia.304 A higher prevalence of Alzheimer’s disease in women than in
men suggests a possible link with gonadal hormone levels. There is also increasing evidence
to support the view that oestrogen has a role in brain regions involved in learning and
memory, and in the protection and regulation of cholinergic neurons which degenerate in
Alzheimer’s disease.305 At the same time, there have been concerns about the safety of
taking oestrogen or HRT for long periods, since there are several known side effects. A
number of studies have been carried out, particularly in the U.S.  
Reviewers of the literature have concluded that evidence (from observational studies) for
the beneficial effect of oestrogen on cognitive function is inconclusive.267;296;303 There is
78 Risk Factors for Dementia and Cognitive Decline
CHAPTER TWELVE CLASSICAL (PERSONAL AND LIFESTYLE)
RISK FACTORS III: DIET, NUTRITION AND HORMONES
clearly quite a lot of data supporting the view that HRT has a positive effect on certain
aspects of cognitive performance in women with menopausal symptoms,303-307 but there
appears to be no evidence of benefit in asymptomatic women.296;303 There are, however, a
number of substantial methodological problems in some of these studies, most notably the
failure to control for the fact that women who take oestrogen tend to be better educated
and healthier than non-users.56;296;303 Although the findings from one large study in New
York, as well as the Cache County Study, have suggested that oestrogen use in
postmenopausal women might delay the onset and decrease the risk of Alzheimer's
disease,308;309 overall the evidence for a protective role against the development of dementia
has been seen as weak.56;61;296;310 A large UK case-control study based on the General Practice
Research Database found no reduction in risk even in patients who had taken oestrogen for
5 years or longer,311 and another recent study has indicated that oestrogen does not
prevent dementia in women with APOE 4.312 Results from the Cache County Study do,
however, suggest one possible explanation for this apparent weakness, namely that
oestrogen use within 10 years of the onset of disease yields little, if any, apparent benefit.309
In other words, oestrogen therapy may only have a protective effect if taken well in
advance of the onset of symptoms.
Two large clinical trials which were examining the long term effects of HRT and oestrogen
on healthy post-menopausal women were halted during 2002. The international WISDOM
trial was investigating the incidence of dementia (among other diseases), but it was felt
that the results, ten years hence, would be unlikely to affect clinical practice.313 Part of the
Women’s Health Initiative Study (WHI)314 was stopped early because of small increases in
the rates of breast cancer, coronary heart disease, stroke and pulmonary embolism among
the case group compared with controls.315 Further analysis of the results of the WHI study
found in fact that prolonged HRT use was associated with a small increased risk of clinically
significant cognitive decline.316 Another recent study has found that women who used
oestrogen-only replacement therapy, particularly for 10 or more years, are at significantly
increased risk of ovarian cancer.294 It seems clear that further trials, as well as much longer
follow-up of the women in studies like the WHI study, are needed in order to evaluate fully
the real long term risks and benefits of HRT.14;56;61;303
CONCLUSION: DIET, NUTRITION AND HORMONES
Reviewers of the literature have concluded that there is evidence to suggest that nutritional
factors can play a part in reducing the risk of dementia or cognitive decline.51;61;91 It has
been argued that eating a healthy diet – or changing to a healthier diet – can reduce the
risk of conditions such as diabetes and cerebrovascular disease, and hence the risk of
dementia.50 Nevertheless, more research is felt to be needed,91 and it has been noted that,
since nutritional effects are liable to be subtle, samples must be large enough to provide
adequate power.246 It has also been emphasised that nutritional factors should be seen as
interacting with other factors.61
Commentators have urged caution in suggesting explanations for empirical findings, or in
recommending interventions. For example, it has been stressed that research should
ascertain that the problem is not that people with declining cognitive function might not
eat properly.51 Also, in ascribing causality, the effect of body metabolism, and the possibility
that the ability to process foods might be at least as important as diet, should be taken into
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consideration.26;275 Reviewers of the literature have also emphasised the importance of
controlling for extraneous variables that might affect the absorption of vitamins (e.g.
smoking), and of identifying other background and demographic factors that should be
used as co-variates (e.g. way of life).246;318 At the same time, it has been noted that,
although low socio-economic status is often cited as a major cause of nutritional
deterioration in older people, other factors such as age-related physiological changes may
be more important.26
Some commentators have made the point that the interest in nutritional factors rests on
the assumption that nutrition can be modified, relatively cheaply and safely, by
supplementing (for those at high risk) or by changing the diet, perhaps in mid-life.51;246 It
has been noted, however, that, even where there is evidence linking nutritional deficiency
with an increased risk of dementia or cognitive decline, supplements might not necessarily
be beneficial.319 Also, although high intakes of folic acid are known to reduce plasma
homocysteine, there is no evidence from clinical trials that fortification of cereals reduces
cardiovascular disease.319 Riedel and Jorissen have discussed the fact that different
interventions (dietary enhancement, treatment with supplements, and treatment - of
patients - with drugs) may be more or less appropriate for different groups.51 There are
safety issues, in that drugs – and to a lesser extent supplements – can have side effects.
They have noted that, since cognitive decline is not a disease, medication would be
inappropriate, but that in fact anti-oxidant supplements appear to be equally beneficial.
These authors have concluded that a proper dietary composition with regard to the ratio of
carbohydrates to proteins, as well as the inclusion of micronutrients, seems to help in
maintaining cognitive function in the elderly.51
SUMMARY
• Weight loss is commonly associated with Alzheimer's disease, and a number of possible
explanations have been suggested.
• Nutritional deficiency has been found to affect cognition, and associations with dementia
are being investigated.
• A deficiency of B vitamins (B12, B6 and folate) has been found to be correlated with
increased serum homocysteine (tHcy) concentrations.  Low levels of B vitamins have been
associated with lower levels of cognitive function. Similarly, a high concentration of
homocysteine (or folate deficiency) has been associated with an increased risk of
dementia, particularly Alzheimer's disease.
• Clinical trials of vitamin B supplements for people with Alzheimer's disease are planned,
and these may be extended to people with mild memory impairment.
• High cholesterol levels are associated with an increased risk of vascular disease and hence
vascular dementia. There is evidence of an association between high levels of dietary
saturated fat, or high cholesterol level, in mid-life and an increased risk of cognitive
decline and dementia.  
• There is some evidence to suggest that regular consumption of foods rich in N-3
polyunsaturated fatty acids may decrease the risk of Alzheimer’s disease.
• Statins (one type of lipid-lowering agent) have been found to lower the risk of vascular
disease and mortality from all causes. There is also some evidence that they reduce the
risk of developing Alzheimer's disease. Clinical trials are under way.
• Clinical intervention studies are examining whether anti-oxidant vitamins might reduce
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the risk of dementia. Findings have been contradictory, but tend to suggest that vitamins
from food sources are more effective than supplements.
• Some observational studies have suggested that oestrogen use in post-menopausal
women can have a beneficial effect on cognitive function. However, the evidence for a
protective role against the development of dementia is weak. The effects of oestrogen
and HRT use are being investigated, although long term trials have been halted.
• Reviewers of the literature have emphasised that nutritional factors should be considered
in conjunction with others, and that there may be a number of possible explanations.
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CHAPTER THIRTEEN
CLASSICAL (PERSONAL AND
LIFESTYLE) RISK FACTORS IV: 
TO WHAT EXTENT, IF ANY, MIGHT
INTERVENTIONS CURRENTLY
TARGETED AT VASCULAR DISEASE
HAVE HELPFUL IMPACTS ON
DEMENTIA OR COGNITIVE DECLINE?
A number of the ‘classical’ risk factors described in the previous three chapters (e.g. vascular
factors, smoking, cholesterol levels) have been associated with an increased risk of vascular
disease. This chapter outlines the interventions currently targeted at vascular disease, and
considers whether there is any evidence that they lower the risk of dementia or cognitive decline.
There have been calls for more emphasis to be placed on the identification and appropriate
treatment of risk factors for cerebrovascular disease, with a view to reducing the incidence of
vascular dementia or ‘vascular cognitive impairment’ (VCI), as well as vascular disease.68;320
The results from the Systolic Hypertension in the Elderly Program (SHEP)321 have been seen
as confirming the need for active treatment of isolated systolic hypertension, and as
indicating measures which might help to reduce stroke and other complications of high
blood pressure including dementia.28 Along with control of hypertension (a major cause of
vascular dementia), it has been suggested that the control of hyperlipidaemia (raised blood
fat levels) and diabetes mellitus might have a stabilising effect, although evidence is lacking.66
Other modifiable factors include cigarette smoking, excessive alcohol consumption, obesity
and lack of exercise,66 although the interaction between social and behavioural factors (e.g.
between lower socioeconomic status and an increased likelihood of smoking and high
alcohol consumption) has also been pointed out.322
Several commentators have seen the potential for the effective treatment of vascular
disease or the control of vascular risk factors as very promising.68;286 Others, however, have
argued that in spite of the known association between high blood pressure and stroke,
effective means of prevention of stroke have not yet been identified.187 It has also been
noted that the adverse effects of antihypertensive medication use can negatively affect
mental state.189
Management of the risk of vascular disease relates to appropriate treatment, but also to
the promotion of potential protective factors and behaviour. Interventions currently
targeted at vascular disease include measures aimed at individuals at high risk, and those
aimed at the population as a whole. These have been seen as worthwhile in relation to
vascular events, and may be worthwhile in relation to dementia.
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HOW EFFECTIVE ARE CURRENT INTERVENTIONS IN REDUCING THE RISK OF
VASCULAR DISEASE?
The treatment of systolic hypertension (either by medication or by weight loss, decreased
salt intake and exercise) as a preventative approach has been established,66;321 and this has
been shown to be effective in the primary prevention of cerebrovascular disease among
hypertensive patients.158;189;286;323 It has been noted that there is evidence to suggest that
aspirin, b-blockers, ACE-inhibitors and lipid-lowering agents can lower the risk of future
vascular events (coronary heart disease and strokes) to a moderate but important degree, in
high-risk patients, the benefits of each intervention appearing to be largely independent.286
Medication measures have usually been combined with recommendations for lifestyle
change. Smoking cessation is thought to lower the risk of myocardial infarction by a half
after about two years.286 However, in general, the evidence for lifestyle or non-
pharmacological measures has been seen as inadequate at present, with large-scale trials of
long duration thought to be needed.324
Other approaches to prevention involve population-based strategies, either by means of
screening programmes or risk assessment, or by health promotion measures. Population
screening for individuals at high risk of coronary heart disease is an explicit objective in primary
care.325 The national service framework for coronary heart disease,326 and the joint British
recommendations on prevention of coronary heart disease,327 propose that all patients with a
10 year absolute risk of a coronary event of over 30% should be identified (by general
practitioners and primary healthcare teams) and should be offered appropriate advice and
treatment to reduce their risk.325 Some questions have been raised about the feasibility and
ethics of the proposed screening, and a recent BMJ editorial has argued that a scientific
evaluation of effectiveness and benefit should be carried out.325 The authors have suggested
that a more practicable approach might be to restrict cholesterol measurements to those
whose age, sex, smoking and blood pressure would indicate high risk. Concerns have also
been raised about how benefit should be assessed (given that individual and public health
values and goals might differ and given the consequences of being classed as ‘high risk’),328
how information is presented, and how decisions about interventions are arrived at, particularly
when there is little evidence to suggest the extent to which risk might be reducible.325
Health promotion measures aim to reduce the risk of vascular disease by encouraging a
moderate reduction in blood pressure among the population as a whole, through lifestyle
change.  Health education campaigns have emphasised the importance of exercise, diet
and weight control, smoking cessation and stress reduction. However, there are concerns
about the effectiveness of this approach, and one review has suggested that, although
weight reduction is potentially useful in controlling blood pressure, multiple risk factor
interventions may be ineffective in reducing mortality from cerebrovascular disease in the
general population of middle aged adults (as opposed to among hypertensive patients).329
IS THERE ANY EVIDENCE THAT INTERVENTIONS CURRENTLY TARGETED AT VASCULAR
DISEASE HAVE HELPFUL IMPACTS ON DEMENTIA OR COGNITIVE DECLINE?
There is some evidence that control of blood pressure in hypertensive patients and
cessation of smoking may improve cognitive function.330 Also, in one large double-blind
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placebo-controlled European study, treatment of mild systolic hypertension decreased the
incidence of dementia.331
However, findings from the UK Medical Council trial have suggested that treating moderate
hypertension in older people had no effect on subsequent cognitive function.212 Those
reviewing the literature have concluded that the evidence for any effect of either anti-
hypertensive treatment,37;67;158 or other interventions to modify cardiovascular factors,20 on
the incidence of dementia remains scanty and unclear, and that little is known, as yet,
about whether and how the general (or cohort) effects of cardiovascular and
cerebrovascular reduction will influence future rates of cognitive impairment.19 There have
been calls for further clinical trials.201;211
SUMMARY
• The fact that some dementia and cognitive decline is linked with vascular factors,
particularly hypertension, suggests that there is some scope for intervention. Treatment
of hypertension has been established, and has been found to be effective in reducing the
risk of vascular events. Thus, vascular dementia may be preventable, to an extent, by
medication and / or lifestyle change.
• However, little is known about whether interventions targeted at vascular disease have
any impact on the incidence of dementia or cognitive decline.  
• The identification of those whose age, sex, smoking and blood pressure indicate a high
risk of vascular disease is felt to be worthwhile in relation to vascular risk, and may be
worthwhile in relation to dementia.
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FACTORS RELATED TO
SOCIAL CONTEXT: SOCIAL
CLASS, OCCUPATION AND
EDUCATION
Findings from empirical work examining the prevalence and incidence of dementia have
conventionally been corrected for socio-demographic factors such as education and occupation.
Factors related to social context have been found to be a major influence on the incidence of
many other disorders. A number of studies have investigated the extent to which the risk of
cognitive decline and dementia might be affected by social class, occupation and education.
However, while education has been taken as a proxy measure of social class, it has also been
seen as a marker for ‘brain reserve’.
Factors related to social context may have a significant effect on health. There is a view that
more attention should be paid to these potentially important environmental factors in the
development of dementia and cognitive decline, and some recent studies are examining
social class as a risk factor.112;332 In the UK, occupation has often been taken as a marker for
social class, and research has generally distinguished between social class and educational
level.10 In the US, the number of years of education has often been used as a proxy measure
for social class. However, educational level has sometimes also been seen as a marker for
‘brain reserve’.
SOCIO-ECONOMIC STATUS 
Numerous studies, including some in Scotland,333 have found that social class is related to
health differentials, with lower socio-economic status (both in childhood and in adult life)
being associated with higher levels of mortality and with a higher incidence of certain
diseases.334-337 Lower socio-economic status is known to be associated with an increased risk
of cardiovascular disease,338 and is an established risk factor for cerebro-vascular disease.92;322
It might be expected, therefore, that lower social class or socio-economic status might be
associated with a higher risk or incidence of dementia and of cognitive decline. Any evidence
of such a relationship would have important implications for policy, since this would suggest
that the rates might be lowered if deprivation or poverty could be reduced.332
There are a number of possible ways of measuring social class, and it has been noted that
the choice of index of deprivation can influence the findings of research.31 Deprivation can
be seen in either absolute or relative terms, and can be measured in terms of individual or
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area characteristics. Individual deprivation – which can relate either to the individual or to
the head of the household - can be assessed in terms of income or employment status (or
sometimes education). Other measures of deprivation are provided by local area (e.g. the
social deprivation index,339 or Scottish Area Deprivation Index), or by the housing council
tax band.  
Where subjects are retired, using income or occupation may be problematic, but when
social class is examined as a risk factor for late-onset conditions, there are additional
questions about the stage in life at which it should be measured (even though there is little
upward mobility). There are also particular difficulties in using educational level as a proxy
measure of social class when examining differences between age-groups (since the age of
leaving school might be cohort-specific)108 and when examining cognitive function late in life
(since there is a known association with that in early life).48 The point has also been made
that occupation can be a surrogate marker for a number of factors, such as premorbid
intelligence, cognitive stimulation, but also level of medical care and attitude to health,
psychosocial characteristics, or exposure to chemicals or other environmental factors.155
Lower socio-economic status and the risk of cognitive decline
A number of studies have found that lower socio-economic status – whether measured
currently, in mid-life or in childhood – is associated with lower cognitive function in later
life.10;92;115;340-342 The same relationship has been found using occupation as the variable; there
is evidence from a number of cross-sectional studies to indicate that cognitive impairment
in old age varies across occupational groups.343 In one Australian study, these differences
held even when age, education and language fluency were statistically controlled.343
The findings from one recent UK study (the Cambridge City Over-75 Cohort Study) have
suggested that a greater decline in the Attention /Calculation sub-scale is associated with
manual social class.55 Other longitudinal studies, however, have found no association
between socio-economic status and cognitive decline,343 although this relationship has in
fact been little examined.
Lower socio-economic status and the risk of dementia
The findings from the few studies which have investigated lower socio-economic status as a
risk factor for dementia are inconclusive. Where an association has been found, it has
usually been with vascular dementia. For example, one small longitudinal study in Germany
found significant associations between socio-economic status (as measured by former
occupation) and vascular dementia, whereas Alzheimer's disease was evenly distributed.344
Similarly, a study in Iceland found no significant association between education and
occupation before old age and the incidence of Alzheimer's disease.345 A study carried out in
Central Scotland indicated that, using records from mental hospitals, vascular dementia was
associated with deprivation, although early onset Alzheimer's disease was not. Using death
certificate records, however, there was a clear trend towards a higher incidence of dementia
(from all causes, and in all age groups) among those in the most deprived categories.346
Similarly, a US study has found that people who had been in low status jobs had a higher
risk of dementia, even where education was controlled.347 Rather different findings have
emerged from another US study which found that three markers of low socio-economic
status, including education, predicted the risk of developing incident Alzheimer's disease.332
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Others studies, however, have found no relationship between lower socio-economic status
or occupation and the incidence of dementia.343 One UK study found no difference in risk of
dementia between high and low status occupations,348 and a Greater Glasgow Health
Board (GGHB) report has stated that, whereas for most mental health problems there is a
strong link with deprivation, dementia appears to be the exception, since no link is
apparent.349 Similarly, a large 10-year longitudinal study in France found that occupational
category had no major impact on the risk of Alzheimer's disease, findings which contrasted
with the strong relation found at the baseline screening phase of the cohort between
cognitive performance and principal lifetime occupation.155 The authors have commented
that the findings seem unusual at first sight, given that an association is often found
between cognitive ability and education, but they have suggested that the results could be
explained by the fact that occupational category can be a marker for a number of factors.
Jorm and colleagues, however, have concluded that cross-sectional differences on cognitive
tests and dementia prevalence are due to differences in pre-morbid ability, rather than to
differences in the rate of cognitive decline.343
It should be stressed, however, that these conclusions are based as much on a lack of
information, as on research findings showing no relationship. The results of research have
been inconclusive, as well as difficult to interpret because of the different types of study,
variety of measures of social class and different types of dementia examined. Also,
importantly, associations between socio-economic status and the incidence of cognitive
decline or dementia have been little examined. The literature in this area is limited, with
few longitudinal studies specifically examining social class having been carried out. Studies
in the US have taken education as a proxy measure of social class, but the meaning of
education has been interpreted in a number of ways.
EDUCATION
A number of studies have examined associations between educational level (years of
education or age of leaving education) and the prevalence or incidence of cognitive decline
and dementia. Gilleard has commented (p33) that, “if findings do indeed reflect a real and
substantial relationship between learning in early life and mental decline in later life, the
social and medical implications are profound”.108 As he points out, since future cohorts of
older people in Western countries are likely to have had a higher level of education than
older people now have had, a lower incidence of cognitive impairment and dementia might
be predicted in the future (by contrast with increasing numbers in developing countries).
Education and the risk of cognitive decline
There is considerable evidence linking educational level with the level of cognitive function
in later life.  A number of studies, including the recent MRC Cognitive Function and Ageing
Study (MRC CFAS)10 have found that lower cognitive function in old age is clearly
associated cross-sectionally with lower educational level.350-353 Similarly, findings from the
Nun study have shown that that nuns who were poorly educated had higher rates of severe
cognitive impairment (as well as reduced motor function, greater impairment in activities of
daily living, and higher mortality rates).354-356 The relationship between educational level and
cognitive impairment in later life has been widely debated.10 Mortality has been suggested
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as a possible confounding factor, since both current cognitive function,110 and childhood
IQ,357 have been shown to be related to survival.
The relationship between educational level and cognitive decline has been little examined,
but the Cambridge City Over-75 Cohort Study data has found that a greater decline in the
memory subscale was associated with less education.55 The findings from a recent Finnish
study have suggested that any association between education and cognitive decline might
be modified by the presence or absence of the APOE 4 allele, although larger studies are
felt to be needed.145
Education and the risk of dementia
Since 1990, studies from a number of countries have indicated potential associations
between lower educational level and the prevalence or incidence of dementia of various
types.22;347;358 Some longitudinal studies, particularly the Framingham study,353 have shown a
relationship between lower educational level and the risk of vascular dementia. In a review
of the literature, Gilleard has noted that it is reasonably well established that limited
education, low paid occupation and lower socio-economic status all contribute to the risk
of vascular disease, and by implication to the risk of vascular dementia.108 Commentators
have concluded that any increased risk of vascular dementia associated with low education
can be seen as occurring indirectly.56;108;359
In addition, a number of studies, including the EURODEM pooled analyses,22 the Canadian
Study of Health and Aging,13 and the work of Stern,347 have found an association between
limited educational experience and Alzheimer's disease,124;205;360 or dementia generally.122;361
Recent findings from large longitudinal studies such as the Rotterdam study,362;363 and the
PAQUID project124 have supported these conclusions. The results of the EURODEM pooled
analyses have also suggested that low levels of education might increase the risk of
Alzheimer's disease, more strongly in women.22
Not all empirical work has shown an association between education and dementia,
however, and those reviewing the literature have expressed various views about the
strength of the evidence. Although some have claimed that the strength and consistency of
the association, as well as the partly established dose-response relationship, indicates that
higher education is associated with a lower risk of developing dementia,364 others have been
more cautious.56;108 Van Duijn has argued that the finding that highly educated subjects had
a lower risk for all types of dementia (for example the work of Katzman358) was based on
prevalence studies, so that the results might be explainable by survival and selection bias.56
The findings from incidence studies examining Alzheimer's disease or dementia have been
seen as inconsistent.56;108 Gilleard has concluded that, while educational background has
been found consistently to influence mental state performance (and hence the probability
of a diagnosis of dementia), the evidence for an aetiological link between educational
background and dementia is ambiguous at best, and in many studies non-existent.108
Interpretation of findings
Reviewers of the literature have noted a number of issues which need to be taken into
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consideration in interpreting research evidence examining links between education and
dementia. First, the inclusion of a large institutional population (who might be significantly
less well educated) could introduce serious problems of bias. If this were the case, any
finding of links with education would have to be questioned.108 Gilleard has also argued
that it is essential to control for age, since older people have inevitably received less
education than younger generations. The confounding effects of age might lead to the
effects of education being exaggerated.108 Gilleard has observed that, in some studies,353
although not in others,365 the relative risk of dementia in less educated people declined
when age was controlled for.
Many commentators have also drawn attention to the nature of the diagnostic tools for
identifying cognitive decline and dementia, pointing out that it can be difficult to distinguish
between low and declining cognitive function,41 and that it is well known that scores in
cognitive assessments are highly correlated with education.108;114;366 They have noted that the
relationship between education and dementia appears to be strongest when the diagnostic
criteria emphasise ‘cognitive impairment’, and to be least evident in long-term studies based
on clinically verified cases.108;366 Some commentators have pointed out that educated people
might perform more competently on neuropsychological and mental state tests for
Alzheimer's disease (as well as on those for cognitive function)114 leading to a possible over-
diagnosis of dementia in poorly educated populations, and an under-diagnosis in well-
educated populations.108;366 Stern has made the point that the use of cognitive tests makes it
difficult to establish whether educational experience is a risk factor for Alzheimer's disease,
because educational attainment can influence performance on diagnostic tests.347
Not only does ‘education’ have a number of meanings, but educational level might be
associated with a number of factors, biological and environmental; e.g. level of income,
level of stress or depression, adequacy of nutrition or tendency to physical illness. The
findings of a possible relationship between low educational level and dementia have been
interpreted in various ways.
Environmental interpretation: socio-economic status
Some commentators have argued that any association between lower educational level and
the incidence of dementia might be explained by other factors associated with low socio-
economic status such as peri-natal nutritional difficulties,62 or by lifestyle factors such as
alcohol consumption and occupational exposures,354 rather than by education itself.
Mortimer has made the point that low education has been found to be a risk factor for
other signs of ‘accelerated ageing’.62 Evidence from one small study has suggested that
lower education and / or poverty might diminish cognitive reserve or resistance to
Alzheimer's disease, rather than higher education providing a ‘protective effect’.367
Biological interpretations: the ‘brain reserve’ hypothesis
The data suggesting that less well educated individuals appear to be more susceptible to
late-onset dementia has often been interpreted environmentally, but recently the link with
education has tended to be explained in terms of the protective or compensatory effects of
‘brain reserve’.14 There is a view that individuals will exhibit dementia only if their cognitive
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or neurological reserve capacity falls below a specific threshold, i.e. a critical volume of brain
tissue.354 From the ‘brain reserve hypothesis’, the brains of individuals vary in their resistance
to cognitive decline or dementia. A higher capacity can provide a ‘buffer’, hence delaying
(rather than preventing) the manifestation of dementia or Alzheimer's disease.10;26;364
Katzman has proposed that the protective effects of education could be seen as related to
neuronal reserve, such that those with higher levels of education may be more resistant to
the effects of dementia.358 Orrell and Sahakian have noted that education can be seen either
as protecting against neurodegeneration (by delaying the pathological process of decline)
or as delaying the onset of clinical symptoms.359 ‘Brain reserve’ has been explained in terms
of early or innate capacity or intelligence, enhancement by mental stimulation or training,
or a combination of the two.14
Education as a marker for innate intelligence
Some studies have tried to examine whether premorbid intelligence, rather than education,
reduces the risk of dementia or cognitive decline. Higher cognitive function in early life is
known to predict higher cognitive function in later life.50;368;369 One UK study has indicated
that those with higher baseline ability and more education (but also higher social class) are
relatively protected from age-related decline in certain verbal abilities.370
Jorm has noted that there is some evidence that brain size might be a protective factor for
Alzheimer's disease.14 The findings from one study have suggested that larger brain or head
size appears to be associated with a reduced risk of Alzheimer's disease.371 Another
neuropathological study found that individuals who had Alzheimer's disease changes at
autopsy, but were not demented during life, had bigger brains.372 These findings have been
replicated in the Nun study.373
There is also some evidence that premorbid, early life or childhood intelligence, as
measured by a single test, is a better predictor of subsequent dementia than
education.343;374;375 Whalley and colleagues have reported that, in a large study which
examined the records of intelligence test scores for children born in Scotland and tested in
1932, an association with poor mental ability in childhood was found with late onset
dementia, which became significant by age 72 years.92 (The authors have interpreted their
data as support for the role of childhood mental ability in modifying the link between age-
related brain changes and late-onset dementia. They have noted, however, that
explanatory mechanisms are unknown, and that other factors, including environmental
factors, which contribute to individual differences in mental abilities at age 11 years might
also contribute to late-life differences in susceptibility.)  
Education as acquired protection
Others have seen education as providing mental stimulation or an enriching experience.26
Intellectual stimulation promotes brain growth in animals,376 and it has been suggested that
mental activity might modulate the natural history of neurodegenerative disease in humans,
hence delaying the onset of dementia.377 Education has been considered as building or
enhancing a potential functional reserve, and suggested mechanisms include improved
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neuronal networking,359 or ‘enhanced synaptic complexity’,358 and improved cerebral blood
flow.14 From this view, because of improved neuronal networks, people might continue to
benefit from cognitive abilities, even when the neuronal networks begin to deteriorate due
to the biological processes of dementia or decline.359;366
Support for the ‘brain reserve’ hypothesis
The findings from some neuropathological studies appear to support the ‘education
hypothesis’. The long term Nun study has found that lower idea density in early adulthood
was associated with poorer cognitive functioning in old age, and was also related to
Alzheimer's disease pathology in nuns who had died, findings which might support the role
of premorbid intelligence, or cognitive ability and neurological development in early life.354
Other findings from the same study have indicated that formal education seems to be
associated with a delay in the expression of dementia, even in individuals with clear
evidence of the pathology of Alzheimer’s disease.373 Another study has found an association
between lower education and age-related cortical atrophy.378 However, further longitudinal
studies are felt to be needed.354;378
In addition, findings from the Seattle Longitudinal Study have indicated that the higher the
base levels on a given ability, the more likely it is that significant decline will occur, (and
that this inverse relationship appears to be strongest in the oldest age-group).48 The more
rapid decline in memory in Alzheimer's disease patients with higher educational (and
occupational) attainment has been seen as lending support to the view that the
discontinuity between the degree of pathology and the observed clinical severity is
mediated through some form of protective ‘reserve’.379
Implications for prevention
Protective interventions require an understanding of the processes underlying any possible
association between lower educational level and late-onset dementia, and commentators
have noted that such mechanisms are unclear.347;359 The point has been made that the
findings of an association between higher education in early life and a reduced risk of
dementia or cognitive decline in later life might indicate that increased neuronal branching
and connectivity related to learning are protective, or might mean that individuals with
early higher intellect have ‘further to fall’.380 It has also been noted that people with a
higher premorbid intellect might tend to seek more stimulating environments, which in
turn might help to prevent a decline in cognitive skills.381 Gatz, in reporting the problems in
carrying out a twin study, has gone further, noting the difficulties in resolving a variety of
alternative explanations of the meaning of ‘low education’.382 Gatz has concluded that any
support for a ‘cognitive reserve’ hypothesis can only be equivocal. The point has been
made, therefore, even if there is evidence for an inverse correlation between educational
attainment and an increased risk of dementia, there is no clear lead to preventive action.
One reason for this conclusion is that poverty – for which education may be a marker –
may be associated with a number of potential ‘risk factors’.37
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SUMMARY
• Factors relating to social context or class have a significant effect on health and on the
incidence of a number of disorders.
• Lower socio-economic status (as measured by income or occupation) has been linked to
lower cognitive function in later life.
• Lower socio-economic status is known to be associated with an increased risk of vascular
disease, and, hence, potentially with an increased risk of vascular dementia.
• Little is known, however, about the relationship between lower socio-economic status
and the risk of cognitive decline or dementia. Few longitudinal studies examining social
class or poverty as a factor have been carried out. In the US, education has been taken as
a proxy measure of social class, but education can have a number of meanings.
• Occupation can be a marker for a number of factors, in addition to social class (e.g.
exposure to toxic substances).
• Lower educational level is known to be associated with lower cognitive function later in
life, but there has been little examination of the nature of this association, or of links with
cognitive decline.
• There is evidence that lower educational level is associated with an increased risk of
vascular dementia.
• The findings from studies examining links between lower educational level and an
increased risk of dementia of all types or Alzheimer's disease are mixed. Some studies
have found evidence of an association, but others have not.
• Education has often been taken as a measure of innate intelligence or mental stimulation,
either or both of which have been viewed as serving to enhance ‘brain reserve’. It has
been suggested that brain reserve might protect the brain from degeneration, or might
mitigate against the effects, hence delaying a diagnosis of dementia or cognitive decline.
• Because of the many meanings of education, implications for prevention are unclear.
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CHAPTER FIFTEEN
PHYSICAL, MENTAL
AND SOCIAL ACTIVITY
There has been increasing interest in the effect of personal and lifestyle factors on the
development of age-related cognitive decline and dementia. This chapter examines the evidence
for seeing physical activity, mental activity, social involvement and support, depression and
stress, as risk factors or protective factors for cognitive decline and dementia.  
It has been suggested that personal and lifestyle differences, as well as individual and cohort
differences in adaptation, might explain some of the differences in the maintenance of
cognitive function in old age.48 The point has also been made that the effect on cognitive
function of factors connected with retirement, for example, is unknown.189 Keefover and
Rankin have argued that a shift to a less demanding or stimulating environment with
expectations of a less challenging role, as well as the loss of friends who can share activities,
could represent a threat to cognitive vitality in old age.26
Factors such as physical, mental and social activity may be potentially modifiable to an
extent,50 although not necessarily by the individual. For example, if associations with the
incidence of cognitive decline or dementia are confirmed, there might be important
implications for social policy, relating to work-family relations and housing, as well as to
retirement.26;383 In investigating these risk factors, however, there can be particular
difficulties in quantifying the ‘strength of exposure’, as well as in examining at what stage
of life the factor might have most impact. Drawing conclusions about the relative
importance can therefore be problematic.  
PHYSICAL HEALTH, PHYSICAL ACTIVITY, AND PULMONARY FUNCTION
Physical health
The evidence for seeing certain disorders as ‘risk factors’ for dementia and cognitive decline
has been outlined in previous chapters of this report. The effects of various factors
classically associated with ‘ill health’ (and particularly those linked with vascular disease)
have also been discussed. Some studies have taken a rather different approach, and have
tried to examine whether ‘physical health’ itself, or fitness, might have a protective effect,
particularly in relation to cognitive decline in later life.384
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Reviewing the literature in 1991, Salthouse concluded that (contrary to intuition and
popular opinion) there was little evidence that declines in cognitive performance associated
with increased age were mediated by declines in health status.385 Findings from an
Australian cross-sectional study which examined a variety of subjective and objective health
measures and a number of measures of intelligence and memory, have lent support to this
view.384 The authors have concluded that cognitive decline can be seen as largely due to
neuropathology rather than to the secondary effect of other medical conditions. 
On the other hand, Schaie, reporting the findings from the Seattle Longitudinal Study,
has stressed that the absence of chronic disease is positively associated with the
maintenance of intellectual abilities with age.116 Similarly, the HOPE study in Edinburgh
found that the decline in cognitive function over four years in healthy old people was
non-significant.106 The findings from another small study have indicated that, in the
healthiest group, although lifetime risks of cognitive impairment are similar to the
general population, onset is later.386
Ventilatory capacity or pulmonary function
Pulmonary function, as measured by the rate of forced expiratory volume in litres in one
second (FEV1) has received considerable examination as an influence on cognitive
function.189 The Honolulu-Asia Aging Study (HAAS), which examined over 8000 Japanese-
American men, found a significant positive association between FEV1 performance at
baseline and cognitive performance 25 years later (i.e. better pulmonary function predicted
better cognitive function).387 White and colleagues have concluded that that low FEV1
should be seen as a potential risk factor for cognitive impairment.189 They have noted that
behaviour such as smoking and exercise can affect pulmonary function considerably, as can
air quality, and have suggested that it is possible that accelerated ageing of the lung might
predict accelerated ageing of the brain.
Physical exercise
Participation in physical activity has been associated with reduced risk of mortality, as well
as with maintenance of functional ability among older people.388 Since physical exercise
minimises the risk of cardio-vascular incidents, high blood pressure and coronary heart
disease,388;389 such activity might be expected to reduce the risk of vascular dementia. It has
also been suggested that, insofar as physical health influences cognitive function, physical
exercise can be expected to contribute to this influence.390 Conversely, a relatively sedentary
lifestyle might contribute to a deterioration in cognitive proficiency.26 It is thought that
physical exercise can increase the blood flow to the brain, and that this might promote
nerve cell growth.50 Some studies of animals have shown that those which are physically
active develop new neurones in the hippocampus, compared with inactive animals.50
The relationship between physical activity and cognitive decline in later life, in the long
term, has been little examined.26 However, some recent research, mainly in the US, has
examined the effects on cognitive function or performance (in the short term) of current
physical activity (mainly vigorous exercise), often in conjunction with mental activity,391 or
social activity.392;393 One recent study, for example, found that mental tasks in executive
control improved in a group of healthy older adults taking aerobic exercise compared with
a control group.394 Reviewers of the literature have noted that there is some evidence that,
94 Risk Factors for Dementia and Cognitive Decline
CHAPTER FIFTEEN PHYSICAL, MENTAL AND SOCIAL ACTIVITY
in relatively healthy older people, sustained regular exercise might confer at least some
protection against an age-related deterioration in reaction time (or the processing speed
component of cognitive function),26;390 but that there is insufficient evidence to base
conclusions about the impact of physical activity on other cognitive processes.26 Large, well-
controlled longitudinal studies directed at identifying effective behavioural change for older
adults have been called for.390
MENTAL STIMULATION AND ACTIVITY
Mental activity has been found to have an effect on cognitive function. Older adults living
in the community have shown significant improvement in performance on a number of
mental abilities, including various aspects of memory, inductive reasoning, spatial
orientation and perceptual speed, as a result of relatively brief behavioural interventions.395
It has been found also that older people who participate in activities that use cognitive
skills, such as working memory and reasoning, are better able than non-participants to
perform other tasks using similar skills.26 These observations have lent credence to the view
that you ‘use it or lose it’.26 Some commentators have argued that links between dementia
and education (when seen in terms of mental stimulation) lend support to this view.359 
The goals of intervention (mental stimulation or training) can be seen in terms of
remediation (correcting a problem), enrichment or prevention of problems,396 and there is
interest in whether mental exercise in mid-life or in old age might protect against cognitive
decline or even dementia. Reviewers of the literature have concluded that there is evidence
that mental stimulation can help to improve memory performance, so that it is possible
that such stimulation might help to preserve cognitive function or stave off decline in old
age.50;359 Orrell and Sahakian359 cite the work of Yesavage,397 which indicates that stimulation
programmes may be effective in reducing memory problems associated with normal
ageing. In addition, Schaie has reported that the findings from the Seattle Longitudinal
Study (SLS) have suggested that high levels of motor-cognitive and attitudinal flexibility
appear to be conducive to the maintenance of function in early old age.48
There is also some evidence from case-control studies of links between lower levels of
mental activity in the recent and more distant past, and an increased risk of Alzheimer’s
disease.136;391 Two longitudinal studies have reported similar results.  Findings from the Nun
study have suggested that frequent participation in cognitively stimulating activities was
associated with a reduced risk of Alzheimer's disease,398 and data from the Kungsholmen
Project have indicated that physical activity, emotional/structural support and intellectual
stimulation seemed to decrease the risk of dementia.399
Some commentators have argued, however, that caution should be exercised in ascribing
causality, since people in the early stages of developing dementia might be less likely than
others to be cognitively active or to take part in stimulating activities.400 A recent report
from the Einstein Aging Study went some way towards clarifying this issue by excluding
individuals with possible preclinical dementia at the study baseline from their analyses.401
The association between participation in ‘cognitive leisure’ activities and reduced risk of
dementia persisted after these individuals had been excluded. Although further research
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(e.g. controlled trials) is felt to be needed to establish whether increased cognitive activity
can protect against Alzheimer's disease,400 the point has been made that - while there might
be much variation in the capacity to benefit - if mental stimulation could delay the onset of
the clinical symptoms of dementia to any extent, it would be worthwhile.359 It has been
emphasised, however, that, in considering the feasibility of intervention, the reasons for the
problem – such as memory loss – have to be established.396 Hence, although training might
offer remediation when older people have experienced decline, and enhancement when
there was no decline, training might be ineffective where people have preclinical or mild
dementia, since the condition is associated with a markedly reduced ability to acquire and
recall new information.395 (This difference in responsiveness to training interventions has
been suggested as a way of differentiating between normal ageing and dementia.402)
PSYCHOSOCIAL FACTORS
Until recently, the relationship between psychosocial factors and the development of
cognitive decline and dementia had been little examined,392 but as interest in risk factors has
widened, these factors are receiving increasing attention.25 In one early study in Sweden,
Persson and Skoog investigated a number of ‘psychosocial risk factors’.403 Although the
findings were preliminary, the authors have suggested that greater exposure to such risk
factors in early life might contribute to the development of dementia in old age. There are
questions about how psycho-social factors should be defined and measured, and which
potential factors should be examined.  Some studies have investigated social activity and
support; others have examined psychological factors such as depression and stress.
Social activity, involvement and support
There is a wealth of data indicating that engagement in meaningful and productive
activities, within the context of socially supportive networks, can have a protective effect on
morbidity and mortality from many causes in later life.383;404 Those reporting associations
between mental activity and a reduced risk of cognitive decline and dementia have often
speculated on the protective role of social activity or involvement. The association has been
seen as biologically plausible, since interactions between mother and infant rodents have
been found to influence cognitive decline and hippocampal cell loss in later life.383 In
humans, early work on enriched environments showed that increasing social interactions, as
well as dealing with a complex physical environment, can lead to improved cognition, and
more recent work on neuronal recovery has similarly indicated the critical role of social
environment.383 A number of recent studies have extended findings about marital status
and living arrangements to examine the putative role of social activity, social involvement,
networks and support in reducing the incidence of cognitive decline and dementia.383
Findings from the MacArthur Study of Successful Aging in the US have indicated that
staying in close touch with people and remaining involved in meaningful activities
predicted ‘successful ageing’,404 a large part of the definition of which was in terms of
cognitive success.50 Greater baseline emotional support was a significant predictor of better
cognitive functioning at a 7.5 year follow-up, controlling for baseline cognitive function
and known sociodemographic, behavioural, psychological and health status predictors of
cognitive ageing.25 In a review of the literature on cognitive decline, Keefover and Rankin
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have concluded that the complexity of the environment appears to have a proportionately
invigorating influence on intellectual proficiency, even in later life.26
Findings from some recent longitudinal studies have suggested that social involvement
might also protect against dementia. Data from the PAQUID study in France indicated that
regular participation in social or leisure activities was associated with a lower risk of
subsequent dementia.393 Similarly, findings from the Kungsholmen project in Sweden have
suggested that a poor or limited social network might increase the risk of dementia, though
the authors have noted that risks rose substantially only where there were no close ties
across several domains.405 Diversity of relations appeared to be critical.383 A US study also
found that the risk of dementia was decreased in subjects with high leisure activities.392
Berkman has concluded that the recent findings are consistent and potentially important,
although causal mechanisms may be unclear.383 One view is that it might be plausible that
social engagement could promote cognitive health, since the challenge of participating in
complex personal exchanges might contribute to a protective ‘reserve’.383;392 Reviewing the
literature, Jorm has concluded that there is some evidence, from both psychological and
physiological studies, that activity in general - during old age rather than over the life span
- may have some preventative effects on both cognitive decline and dementia.343 A lack of
physical, mental and social activity could have a negative impact on mental health. 
Nevertheless, commentators have noted that questions remain unanswered, and that longer
follow-up periods are needed for several reasons: to confirm the findings, to investigate at
what point in life the effect of social interaction is important, to clarify protective
mechanisms, and also to ensure that social withdrawal is not influenced by cognitive
decline.383 It has been demonstrated, for example, that people with dementia have less
contact with friends, neighbours and community groups than do non-sufferers,406 and it has
been noted that this group may also be more likely to exhibit symptoms of depression.
Psychological factors: depression and stress
Some studies have examined the links between dementia or cognitive decline, and
depression, psychiatric history more generally, and stress. Snowdon has explained that
research carried out at the Mayo clinic, Minnesota (US) has found that an optimistic or
positive outlook is associated with longevity. Findings from the Nun study, although the
data is limited, have appeared to confirm this association.88
Depression
Depression may be associated with significant cognitive deficits, and may be a feature of, or an
early sign of Alzheimer's disease.407 There has been interest, however, in whether depression
earlier in life could be a risk factor for subsequent dementia or cognitive decline.14;56;408
Cognitive impairment often co-exists with depression. One view is that mood exerts an
effect on cognitive proficiency,26 but there are contradictory views about which condition
should be seen as primary.407 Both conditions are generally seen as reversible. Although
some commentators have stated that neither depression, nor the cognitive conditions
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sometimes associated with depression, are age related,26 others have argued that
vulnerability to depression, like cognitive impairment, increases with age.51
There is some evidence that previous psychiatric history can be associated with an
increased risk of late life dementia,409-412 although not all studies have found this.413 A recent
study of twins has suggested that a history of psychiatric illness, especially depression, may
be associated with an increased risk of Alzheimer's disease,414 and a meta-analysis of early
case-control studies found that people with late-onset Alzheimer's disease were more likely
to have had a history of medically treated depression (although no association was found
with either anti-depressant treatment or adverse life events).415 The findings from
prospective studies have been mixed, with some finding that depression pre-dates
dementia or cognitive decline and others not.14 One meta-analysis, however, found that
depression was associated with an increased risk of subsequent dementia and cognitive
decline in both case-control and prospective studies.408 Jorm has noted that, in general, the
duration of follow-up has not been long enough to rule out depression as a clinical feature
of the disease, but has concluded that there is sufficient evidence to take seriously the
possibility that depression is a risk factor for dementia and cognitive decline.408
A number of possible explanations have been suggested, including a common biological
basis of vulnerability to depression and cognitive disorders,51 links with dietary factors,51
overlapping neuropathology,14 or mild cognitive deficits with depression lowering the
threshold for the clinical manifestation of Alzheimer's disease.14 In a comprehensive review
of the epidemiological evidence from case-control and prospective studies, Jorm has
considered six hypotheses: (1) depression treatments are a risk factor for dementia, (2)
dementia and depression share common risk factors, (3) depression is a prodrome of
dementia, (4) depression is an early reaction to cognitive decline, (5) depression affects the
threshold for manifesting dementia, and (6) depression is a causal factor in dementia.408 He
has concluded that there is limited support for hypotheses 3, 4, 5 and 6, which warrant
further research.  
Stress
Stress and key hormones secreted during stress are now viewed as being relevant to many
aspects of health. For example, in old age, the stress response may be directly linked to
heart attack or stroke.41 The work of Sapolsky has shown that glucocorticoids (the adrenal
steroids secreted during stress) can have adverse effects on the nervous system, if secreted
in excess.416;417 This evidence mostly relates to rodents, but there is evidence that, in
humans, chronic stress can impair mental performance, and that prolonged exposure to
stress hormones (e.g. cortisol) has an adverse effect on the hippocampus.50;416 Chronic stress
is known to contribute to depression and anxiety disorders, conditions which interfere with
normal memory processing, particularly – perhaps - as people age.50 Stress has also been
associated with factors such as high blood pressure.112 Another suggested mechanism is that
high levels of cortisol could damage the immune system, which may be involved in brain
ageing. There is a view that ageing is best seen in terms of a loss of adaptive capacity, and
that the responses of older individuals to stress are greater than those of younger people.41
Persson and Skoog have suggested that observed associations between psychosocial risk
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factors and the development of late onset dementia found in a Swedish study could be
explained by stress as a possible link (although they have acknowledged that other
interpretations are possible).403 On the other hand, a study of former World War II prisoners-
of-war found no evidence that they were at increased risk of Alzheimer's disease, despite
their higher prevalence of anxiety and depressive disorders decades after the war.243
SUMMARY
• Research is beginning to examine relationships between physical, mental and social
activity – in mid-life and in old age – and the incidence of cognitive decline and
dementia. If associations are found, there may be implications for social policy, e.g. in
relation to retirement.
• The findings from some studies have indicated that the maintenance of cognitive
function in old age is associated with good physical health. Other research has not found
this, however.
• There is some evidence that pulmonary function (FEV1) in mid-life predicts cognitive
function in old age, although the mechanisms are unknown.
• Physical exercise has been linked with a reduced risk of vascular disease. However, links with
the incidence of cognitive decline and dementia have been little examined by research.
• There is some evidence that mental activity can enhance or maintain cognitive function,
or protect against a degree of decline, although there are wide variations. Further
research is felt to be needed to establish whether cognitive activity could protect against
long-term cognitive decline or dementia.
• There is also some evidence that social activity, involvement and support can help to
maintain cognitive function. Preliminary findings which suggest a reduced susceptibility
to dementia are felt to warrant further investigation.
• Although there is some evidence that some forms of ‘activity’ seem to have a preventive
effect on cognitive decline, caution has been expressed about ascribing a protective role
to ‘activity’, since those experiencing cognitive decline might be less likely to be active.
• There is felt to be enough evidence to take seriously the possibility that depression is a
risk factor for dementia and cognitive decline.
• There has been increasing interest in the role of stress in cognitive functioning, because
of the link with stroke, because prolonged exposure to a stress hormone (cortisol) is
known to affect mental performance, and because ageing can be viewed in terms of a
loss of adaptive capacity.
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DISCUSSION
This chapter summarises the findings from research examining risk factors for dementia and
cognitive decline. It considers what the evidence suggests about the nature of dementia and
cognitive decline and the relationship between the two. The limitations of existing research are
discussed, as well as some limitations and critiques of the focus on primary prevention. Starting
from the concept of ‘healthy ageing’, the chapter considers the feasibility of ‘compression of
morbidity’. It concludes by outlining the conclusions that can be drawn about public health
strategies for preventing dementia and cognitive decline.
Research examining risk factors for dementia, particularly Alzheimer's disease, is being
carried out in a number of countries. Early work consisted of case-control studies, but large
longitudinal studies, some multi-centre, are now ongoing, and results are beginning to
emerge. Risk factors are generally seen in terms of possibility or probability, since it is
recognised that they do not operate in isolation. There may often be no single cause of
dementia or cognitive decline, therefore, and no single ‘solution’. Where epidemiological
and other research has indicated the putative protective role of certain interventions (e.g.
reduction of hypertension, vitamin supplements, NSAIDs), clinical trials are beginning to
examine whether there are benefits for people with mild cognitive impairment, or who are
asymptomatic. There is an increasing interest in examining risk factors for cognitive decline.
In considering what the findings from research indicates about possible strategies of
‘prevention’, a number of key questions have still to be answered. These include: What
weight should be given to specific factors, such as age? How do the findings from research
relate to, or add to, hypotheses about causal mechanisms or processes? What does research
evidence suggest about the nature of cognitive decline and dementia and the relationship
between the two? To what extent is modification of specific risk factors feasible or ethical?
When might intervention measures be appropriate? This chapter addresses these questions,
after summarising the findings from existing research.
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SUMMARY OF RESEARCH EVIDENCE: RISK FACTORS FOR DEMENTIA
AND COGNITIVE DECLINE
Risk factors for cognitive decline
Cognitive function declines with age, although such decline is not inevitable and not
always progressive. A range of risk and protective factors has been examined by research.
There are differing views about the extent to which physical health should be seen as
protective, with some studies finding that the absence of chronic disease is associated with
the maintenance of intellectual abilities with age,116;404 but others not.385 Small has
summarised the risk factors identified by recent research as follows: genetic factors, female
sex, APOE 4 genotype, medical co-morbidities, hypertension, heart disease, diabetes,
elevated low-density lipoprotein cholesterol level, elevated homocysteine level, transient
ischaemic attacks, head trauma, environmental exposure to toxins (particularly lead),
lifestyle choices, smoking, substance abuse including alcohol and illicit drugs, psychological
/psychosocial factors, low educational achievement, lack of physical activity, lack of social
interaction / leisure activities, excessive response to stress (elevated cortisol levels).50 From a
psychological perspective, findings from the Seattle Longitudinal Study have suggested that
protective factors include: living in favourable economic circumstances, involvement in
complex or intellectually stimulating activities, higher levels of education, a flexible
personality in middle age, having a spouse functioning at a high level of cognitive abilities,
maintenance of high levels of perceptual processing speed, above average success in life,
high satisfaction with accomplishments and a perception of intellectual competence.116
In relation to strategies of prevention, lifestyle measures, such as stress reduction, physical
activity, healthy diet, mental activity and psychosocial activity, have been recommended,
rather than unproven treatments or large doses of supplements, since age associated
cognitive decline is not seen as a disease.50;51;376;418 Small has concluded that, ‘what is healthy
for the body is healthy for the brain’,50 and the Institute for the Study of Ageing and the
International Longevity Center, USA have offered the following recommendations:376;418
• Pursue lifelong learning and memory training
• Engage in physical activity
• Keep working at a job and/or participating in social activities
• Practice stress reduction techniques
• Get help for sleeping disorders
• Seek treatment for depression
• Maintain a nutritious, low fat diet
• Effectively control medical problems such as high blood pressure, diabetes and
high cholesterol.
Risk factors for vascular dementia
Some vascular dementia might be preventable to the extent that susceptibility to
cerebrovascular disease can be modified, whether by public health measures or by
management of putative risk factors and the promotion of potential protective factors. The
control of hypertension (above certain limits, and taking care to avoid hypotension) by
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medication is now accepted, and has been shown to be effective in the primary prevention
of cerebrovascular disease for those at high risk.20;28;66 At the same time, lifestyle changes
which lower blood pressure have been seen as advisable at all levels of blood pressure,
across the population as a whole.66
Risk factors for dementia of the Alzheimer type
Dementia of the Alzheimer type is generally seen as a multi-factorial syndrome, whose risk
factors are ubiquitous.56 Reviewers of the epidemiological literature have concluded that, at
the moment, the only risk factors for Alzheimer's disease confirmed beyond reasonable doubt
are old age, a family history of dementia (particularly for early onset dementia), Down’s
syndrome and the APOE 4 genotype.14 There is recent evidence of an association between
vascular disease and its factors and the risk of Alzheimer's disease.12 The evidence for other risk
or protective factors is felt to be inconclusive and to need further investigation,37;56;133 and it
has been suggested that other causal factors may remain to be identified.62 Cross-cultural
studies and trends over time have yielded few clues.56 The mechanisms underlying the
development of dementia of the Alzheimer type are not yet understood,61 and some
commentators have argued that examining interactions between factors (e.g. genetic and
environmental) might offer the best hope of understanding the aetiology.56
None of the known risk factors for Alzheimer's disease is felt to give scope for preventive
action.14 Also, because of the links with age and – perhaps - genetic factors, the potential
for primary prevention may always be relatively limited. Research suggests that it would be
prudent to avoid - where possible - head injury, a deficiency of folate or vitamin 12 (which
can result from a high alcohol intake or from malnutrition), and an excess of cholesterol,
although the nature of the connection between these and other candidate ‘risk factors’ and
Alzheimer's disease remains unclear. However, the association with vascular factors suggests
that some dementia of the Alzheimer type might be preventable to an extent. Clinical trials
of potentially beneficial interventions are felt to be worthwhile.
THE NATURE OF DEMENTIA AND COGNITIVE DECLINE
The causal mechanisms underlying the development of dementia and cognitive decline are
not fully understood, but there is increasing knowledge about changes in the brain
associated with ageing,41 or with biological mechanisms. Cognitive research examining
decline, and epidemiological studies of risk factors, have been seen as usefully adding to
knowledge about what is ‘normal’ and ‘pathological’ ageing,26;395 and about the nature of
cognitive decline and dementia. The point has been made, for example, that evidence from
empirical work shows that the idea of a dichotomy between vascular dementia and
Alzheimer's disease is no longer tenable.19
There is a continuing debate about the nature of cognitive decline, and about the
relationship with dementia. One question concerns whether cognitive decline and
dementia should be seen as part of a continuum or as different conditions; i.e. to what
extent are there similar or distinct processes involved – one leading to slow decline and the
other to severe decline?42;44;49;395 It has been suggested that, if Alzheimer's disease can be
seen as an extreme variant of normal ageing, then the focus of study should be on the
ageing process, rather than on disease.41
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One view is that dementia is a disorder distinct from cognitive decline. Christensen and
O’Brien have noted that there is evidence, although it is not conclusive, to suggest that the
deficits in dementia might be qualitatively, as well as quantitatively, distinct from those in
normal ageing.44 Age-related cognitive decline takes place across various domains, whereas
in Alzheimer's disease there is a sequential decline across specific cognitive domains.55
Some cognitive decline can be avoided or remedied with training, but dementia is not
amenable to these measures.395
On the other hand, a number of commentators have claimed that the processes leading to
dementia can be seen as similar to, although more severe than, those resulting in cognitive
decline.19;44;55 Brayne and colleagues have suggested that the evidence which shows that
cognitive decline, like dementia, becomes increasingly common with advancing age,
indicates that dementia may be regarded as one extreme of the continuum of cognitive
decline.85 In a similar way, Willis has argued that, since the earliest decline in both normal
age-related decline and pathological ageing occurs with respect to the higher-order
executive level abilities (fluid and crystallised intelligence), and since the proportion of older
adults experiencing decline in these abilities increases with age (even though there is
evidence of wide individual differences),402 the relationship can be seen as hierarchical.395
Christensen and O’Brien have concluded that the findings from risk factor research have
suggested that, except for rare, early-onset cases of dementia (involving specific single
genes) there is no clear evidence that the risk factors associated with Alzheimer's disease are
not also predictors of normal ageing.44 In their view, dementia could, therefore, be seen as
the final stage of ‘normal’ biological ageing.
LIMITATIONS OF RESEARCH
A number of commentators have drawn attention to some limitations of epidemiological
research examining risk factors. Since the findings are not just of academic interest, but
might suggest ways in which the onset of dementia or cognitive decline might be delayed
or even prevented, it has been emphasised that the evidence must be adequate.11;19
Methodological shortcomings of early case-control studies, such as the low statistical power
and the possibility of bias,56;62 have been noted earlier in this report. Large longitudinal
studies are now ongoing, and the point has been made that early suggestions about factors
could be superseded as more understanding is gained.11
Reviewers of the literature have stressed that findings from empirical work so far have
tended to highlight how much remains to be understood. Hence, there is felt to be
considerable scope for further research, both in the sense of ‘factors’ that might be
examined, and in research questions. Dementia is often seen as having multiple causes, and
it has been suggested that possible interactions between risk factors, including genetic,
environmental and vascular factors, should be investigated.11;19;56 More work is also felt to be
needed in quantifying risk, particularly genetic risk.19;56 Commentators have pointed out that
the findings from research, together with new technological possibilities, raise a number of
new questions, such as – for example - how much of the risk of Alzheimer's disease is due
to genetics, age or other factors, and hence how much risk is modifiable. 
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Existing empirical work has largely been carried out from medical and epidemiological
perspectives, and there has been little examination so far of environmental factors such as
social class or poverty. There may be links between socio-economic status and other factors,
such as diet or education. If social factors were found to be important, then the implication
is that approaches to ‘prevention’ should include social or structural change.
The findings from current research are also limited in the sense that few conclusions can be
drawn about causality, or about methods of prevention. Several commentators have
emphasised that, since there might be various ways in which the findings from epidemiological
research could be interpreted, and since the processes underlying the development of
dementia and cognitive decline are not fully understood, care should be taken in ascribing
causality.43;61 There continue to be many gaps in knowledge and unanswered questions. Little is
known about the nature of dementia and cognitive decline, and the nature of ageing, about
causal mechanisms of decline, or about the effectiveness of interventions.
LIMITATIONS AND CRITIQUES OF A FOCUS ON PRIMARY PREVENTION
There have also been critiques of a focus on ‘risk factors’ and primary prevention strategies,
although from a number of perspectives. Some commentators have criticised an over-
emphasis on individual, or biological ‘risk factors’. There are concerns, for example, about
an over-emphasis on genetic explanations for the causes of disease (or ‘genetic
determinism’). One BMJ editorial has emphasised that the main contributors to disease or
impairment - malnutrition, poor water and sanitation systems, unsafe sex, tobacco and
alcohol, physical inactivity, occupation, drug misuse, and air pollution – are unlikely to be
affected by knowledge of genetics.419 From this view, a recourse to ‘simplistic’ genetic
explanations can marginalise more difficult – often political – questions, which are relevant
to public health.419 Others, on the other hand, have argued that the growing evidence that
genetic factors are involved in disease expression has served to strengthen support for a
specific biological aetiology, hence focusing attention on individual, biological factors,
rather than those which are social or environmental.420 Gilleard and Higgs have contended
that a focus on ‘types’ of dementia, and on the family history of Alzheimer's disease, has
provided the beginnings of a notion that there are people ‘at risk’ of the condition.420
Individual risk factors can imply individual blame, and Katzman, for example, has argued
that a discussion of risk factors should focus on populations, rather than on individuals.39
A search for risk factors associated with dementia has also been criticised for promoting the
view that a primary prevention strategy (i.e. by modifying risk) is realisable, whether by
lifestyle management or by medical intervention, thus omitting any consideration of the
role of age in disease causation.94;420 Some have seen dementia as an almost inevitable
corollary of ageing. For example, Blumenthal has noted that the production of amyloid
(which is implicated in dementia, diabetes and myocardial fibrillation) is a phenomenon
prevalent in old age.94 He has argued that strategies based on risk factors will not eliminate
the diseases of senescence, since the same or other diseases will later emerge.  
Another argument is that the very laudable attempts to publicise the risk of dementia, and
to investigate risk factors, may have the effect of creating anxiety and fear of dementia
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among older people and informal care-givers.421 It has also been suggested that the
increasing interest in links between cognitive decline and dementia may result in the
stigmatisation of those with mild cognitive impairment, and the pathologising of this
condition (which is not necessarily progressive).422
Finally, some have argued that a focus on primary prevention involves a shift in priorities
away from those affected and from service provision.94;420 An epidemiological approach has
been seen as diverting attention from the fact that an increasing prevalence of age-related
disorders might imply a greater provision of care, whether in terms of treatment (secondary
prevention) or improved support to ameliorate social and psychological as well as biological
effects (tertiary prevention).
PUBLIC HEALTH, HEALTHY AGEING AND THE COMPRESSION OF MORBIDITY
With increasing longevity and a predicted rise in the numbers of older people, there is
concern to find ways in which the health of older people might be maintained for longer,
both for their own sake and for more general benefit. Questions about the extent to which
the goal of ‘healthy ageing’ is possible and – if so - how this might be achieved, have raised
wider questions about how and why individuals age, and about the relationship between
ageing and disease. Healthy ageing might come about or be achieved ‘naturally’ or
through ‘strategies’, and by various means, such as by changes to the environment or to
behaviour, or by interventions such as treatment.  
There has been interest in whether ageing itself might be slowed,16;41;423 but also in the
extent to which ageing might be separated from disease.  If the rate of disease progression
could be slowed and/or the onset of disease occurrence delayed or prevented, this could
result in ‘healthy ageing’ or ‘compression of morbidity’.424 Individuals would have the same
life expectancy, but they would remain healthier for longer. On the other hand, it has been
pointed out that measures to improve health might, instead, extend life expectancy,
leaving the period of morbidity unchanged,16 or even lengthened.37 A more pessimistic
scenario is that other current trends, such as increasing alcohol consumption or obesity,
might serve to increase the risk of disorders, resulting in a lengthened period of morbidity.
At the moment, the potential for the ‘compression of morbidity’ is largely unknown.
PUBLIC HEALTH STRATEGIES FOR PRIMARY PREVENTION
‘Healthy ageing’ can have a number of dimensions. Fillitt and Butler have argued that, in
line with the current emphasis on preventive medicine and health maintenance, one goal
(which would be reflected in health programmes) ought to be the promotion of robust
cognitive health in later life.425 There is general agreement that – despite concerns about
priorities, about raising anxiety, and about feasibility - it is right and important to try to
delay the onset, or prevent the occurrence, of dementia and also cognitive decline, by
primary precention methods, and to allocate resources to investigate risk factors.42;386 If there
are risk factors that are modifiable, and if the means of modification are known, then some
prevention of dementia, by primary prevention measures, may be feasible.  
In moving from a knowledge of risk factors to considering primary prevention strategies,
however, there are important practical and philosophical issues to be taken into
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account.11;19;36 These include: How certain is it that an intervention will lower risk? To what
degree? To all equally? To whom might intervention be beneficial, rather than harmful?
When might intervention be most beneficial? To be beneficial, any intervention should be
effective in modifying risk and – perhaps – cost-effective.  Interventions should also be
feasible and acceptable. How might benefit, feasibility and acceptability be measured?
Whose responsibility is it to reduce risk – since there may be implications for individuals, for
policy-makers and public health, or for both?19 (For example, what is the best way to lower
vascular risk?) What are the implications for ethics and human rights?19
Since the anticipated benefit of any intervention, or prevention strategy, must outweigh
possible harm, there are a number of ethical issues to be considered.11 First, the evidence base
must be adequate. There are also issues of safety. Any intervention may have consequences or
side effects and hence may carry a risk. In relation to primary prevention measures, there are
concerns about prescribing – or offering - medication for people who are healthy or
asymptomatic.11 In addition, knowledge of increased risk might be of questionable benefit,
especially if information is uncertain or not easily understood, or if no effective treatment is
available. Screening can provoke anxiety. Concerns have also been expressed about
confidentiality, especially about the way that genetic information could be used.
Views about the importance of ‘prevention’, about priorities, or about definitions of a problem,
can differ between individuals or groups, and can conflict even within individuals. Interventions
must be voluntary, and different individuals might judge benefit, risk and harm in different ways.
The point has also been made that ideas about what is important can be cultural, as well as
individual; they can be specific to a generation and can change.396 For example, as noted earlier,
there are questions about the effectiveness of health promotion campaigns in changing
behaviour, and about the acceptability of screening, e.g. for vascular risk factors.
Strategies for primary prevention are based on either ‘population’ or ‘high-risk’ approaches.37
They include lifestyle change, reduction in exposure to risk, ‘treatment’ (e.g. medical and
dietary supplements), vaccination and family planning. What does the evidence from studies
of risk factors suggest about the scope for reducing the incidence of dementia or cognitive
decline by primary prevention methods?
WHAT IS THE SCOPE FOR THE PRIMARY PREVENTION OF DEMENTIA AND
COGNITIVE DECLINE?
Population-based strategies
There is little evidence of differences in risk between different populations, which might
suggest environmental factors or protective measures. In relation to limiting exposure to
hazards in the physical environment, evidence does suggest that any workable measures to
reduce brain injury or head trauma could be useful, although the numbers affected are
small.37 There is no evidence to support measures to limit exposure to toxins in the
environment. Findings of studies examining education do not lead to any suggestions for
prevention, partly because of the different meanings of ‘education’. Although socio-
economic status has been linked with health status, as yet there has been little examination
of links with dementia and cognitive decline.
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There is a body of research connecting a ‘healthy lifestyle’ (stress reduction, avoidance of
harmful stimulants, exercise, a diet low in cholesterol and high in vitamins, maintenance of
social activity) with protection against chronic disabling disease generally.50 Such a lifestyle
is being promoted for everyone, and has been advocated for older people.376;418 (Older
people may be seen as a ‘population’.) There is some evidence that elements of a ‘healthy
lifestyle’ might offer some protection against age associated cognitive decline. Also, to the
extent that elements of a healthy lifestyle protect against vascular disease, there is evidence
to suggest some lowering of the risk of vascular dementia, and perhaps dementia generally.
There is also some evidence to link low alcohol consumption, and a diet adequate in
vitimanins and (perhaps) rich in fish oil with a reduced risk of dementia. However, there is a
general problem with suggesting protective measures such as dietary changes or
supplements (and of course medication or vaccination) because of the possibility of harm.
Hence measures such as oestrogen and NSAIDs cannot be recommended.  Debates about
individual versus social responsibility are particularly relevant in considering population-
based measures of prevention.
Strategies targeted at ‘high-risk’ groups
Research examining risk factors has suggested the possible benefit of certain protective
measures targeted towards specific ‘high-risk’ groups. For example, dietary supplements
may be beneficial for those with hyperhomocysteinaemia, statins may be beneficial for
those with high cholesterol, and anti-hypertensive medication may be beneficial for those
with high blood pressure. Although at the moment, the evidence about whether, and if so
to what extent, such ‘protective’ measures reduce the risk of dementia (or long-term
cognitive decline) is limited, all of the above interventions (along with NSAIDs) have been
felt to be worth further investigation by clinical trials.
Cooper (p898) has suggested that high-risk measures might focus on “a strongly positive
family history and the presence of medical conditions known to be associated with brain
pathology”.37 Individuals with certain genetic mutations constitute ‘high-risk’ groups,
although - because genetic make-up is not modifiable - the only potential preventive
strategy at the moment rests on the possibilities presented by vaccination. However, if in
the future genetic polymorphisms are found to interact with other modifiable (biological or
environmental) risk factors, there may be possibilities for targeted intervention measures.
Other high-risk groups, and appropriate interventions, may be indicated by further research
(e.g. into links between depression and dementia). People experiencing cognitive decline
may also be at higher risk of dementia, although in this case, interventions have been in
terms of secondary prevention.37 The issue of whether ‘older people’ should be seen as a
‘high-risk’ group raises a number of questions; for example, at what age might ‘risk’ be felt
to be increased, or might intervention be appropriate. 
Questions have also been raised about how those at ‘high-risk’ might be identified, and
about the feasibiloity and acceptability of screening, which might form part of the
preventive method. These concerns about screening (e.g. for vascular risk) have been noted
earlier in this report. At the moment, APOE genotyping may not be used for screening for
Alzheimer’s disease,19;41 although some commentators have predicted that, despite ethical
concerns, there will eventually be susceptibility testing (of people who are asymptomatic).42
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Regarding the prospects intervention (either for drug therapy or for the modification of risk
of dementia), Eastwood and colleagues have argued that, in considering what can be
learned from clinical trials, there are a number of difficulties in study design to be
resolved.19 For example: Should the primary outcome measures to judge efficacy be in
terms of function or imaging? How should the likely size effect of a given treatment be
estimated? How should the study population be stratified? How should the issue of
informed consent be addressed? These authors have suggested that there should be a first
stage of smaller exploratory trials to gather data on efficacy, driven by hypotheses
generated from longitudinal surveys, followed by larger, more pragmatic trials, which will
have wide inclusion criteria and which will look at effectiveness, acceptability, compliance
and cost. Their view is that the latter might not be warranted for some time.19
When might intervention measures be appropriate?
Any intervention measure to prevent the occurrence of a condition or delay its onset can
only be effective when there is the potential for change, whether this is in terms of
modifying risk or arresting the disease (or ageing) process. In the case of dementia, it is
widely felt that, by the time clinical symptoms are apparent, it may be too late for any
measures of prevention to be effective.41 They will be more likely to succeed when the
process of neurological deterioration is in its early stages.61 However, the ‘early stages’ at
which it might be felt right or beneficial to intervene have not yet been identified, since
the mechanisms by which dementia develops, and when risk factors operate, are still
largely unknown.42;61
There is some evidence that certain risk factors, measured in mid-life, predict later cognitive
decline, and some have suggested that the degenerative processes may begin in mid-life.426
For example, the 1998 Alzheimer's Association Research Grants Program has noted
evidence that initial neurodegenerative changes of Alzheimer's disease can occur up to 40
years before the first clinical symptoms appear.42 (The focus of their research programme is
on early detection, with the purpose of delaying the onset of symptoms for those at high
risk.) With the ‘baby-boomer’ generation approaching retirement, interest has focused on
whether there are interventions in mid-life which might avert or delay the onset of
dementia and cognitive decline. It has been suggested that the prevention of Alzheimer's
disease ought to be a concern of middle-aged people.42
SUMMARY
• Cognitive function declines with age, although such decline is not inevitable and
not always progressive. A ‘healthy lifestyle’, and measures to mental and social, as
well as physical health, have been recommended as potentially protective against
cognitive decline.
• The risk factors for vascular dementia are relatively well understood; these include
cerebro-vascular disease and risk factors for vascular disorders. The risk of vascular
dementia may be reduced by lowering the risk of vascular disease, e.g. through the
control of hypertension.
• At the moment, the only risk factors for Alzheimer's disease confirmed beyond reasonable
doubt are old age, a family history of dementia (particularly for early onset dementia),
Down’s syndrome and the APOE 4 genotype. The evidence for other risk factors is
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inconclusive. None of the known risk factors for Alzheimer's disease is felt to give scope
for preventive action. Also, because of the links with age and  – perhaps –- genetic
factors, the potential for primary prevention may always be relatively limited. However,
an association with vascular factors suggested by recent research has caused the
dichotomy between vascular dementia and (‘degenerative’) Alzheimer's disease to be
questioned, and has indicated that there may be some scope for prevention.  
• Although the causal mechanisms underlying the development of dementia and cognitive
decline are not fully understood, with increasing knowledge about the brain and the
findings from epidemiological studies of risk factors, progress is being made. There is felt
to be considerable potential for further research.
• Evidence suggests that there is often no single cause of dementia or cognitive decline,
and hence no single solution, but that there may be some limited scope for intervention.
Clinical trials of potentially benefical interventions are felt to be worthwhile.
• One key issue may be the relationship between age-related cognitive decline and
dementia. Some commentators (although not others) have suggested that the evidence
from risk factor research tends to support the view that cognitive decline and dementia
of the Alzheimer type should be seen as a continuum rather than as qualitatively different
conditions. If this is the case, then changes associated with ageing are of interest. 
• Reviewers of the literature have noted a number of limitations of current research. It has
been emphasised that the evidence base must be adequate before considering strategies
of prevention.
• Some environmental risk factors, particularly social class, have been little examined
by research.  
• A focus on primary prevention has been criticised for an over-emphasis on individual and
biological ‘risk factors’, for promoting the view that such prevention strategies are
feasible and ignoring the role of age, and for increasing anxiety and pathologising mild
cognitive impairment. A focus on primary prevention has also been seen as shifting
priorities and diverting attention from solutions of care and the needs of those affected.
• One approach to a public health goal of ‘healthy ageing’ is to consider the extent to
which ‘compression of morbidity’ is achievable, by delaying the onset of certain
conditions or preventing their occurrence.  
• In moving from knowledge about risk factors to strategies of intervention, there are a
number of practical and philosophical issues to be taken into account. These include
questions of ethics, responsibility, feasibility and acceptability.
• At the moment, targeted strategies (based on ‘high-risk’ groups) seem to offer more
potential than those based on populations, with the further investigation of potential
protective measures felt to be worthwhile. Questions remain about screening as a
method of identifying those at high risk.
• An important issue is when strategies of intervention might be most effective or
beneficial. Some evidence that ‘mid-life’ risk factors may predict later cognitive decline,
and that initial neurodegenerative changes of Alzheimer's disease may occur up to 40
years before the first clinical symptoms, suggests that mid-life preventive measures might
be worthwhile.
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CONCLUSION
Given the increasing numbers of older people in most western populations, there is
concern about the anticipated rise in the prevalence of ageing-related disorders such as
dementia. It has been predicted, for example, that by 2040 one in every fifty people in
Scotland could be living with this disorder. At one time, dementia and cognitive decline
were seen as inevitable consequences of ageing. Now, however, as more is known about
ageing and about the brain, possible means of prevention are being investigated. Although
treatment may slow the progress of dementia some cases, the condition cannot be reversed
or cured. There has been growing interest, therefore, in finding out whether there are ways
in which the incidence (as well as the prevalence) of dementia might be reduced, since
delaying the onset could dramatically reduce the numbers affected.  
Although little is known at the moment about the mechanisms which result in cognitive
decline and dementia, or about when the degenerative processes begin, progress is being
made. Considerable research efforts are being expended in investigating possible methods
of prevention. Epidemiological studies across the world are investigating possible risk and
protective factors for dementia (especially Alzheimer's disease), and more recently
cognitive decline. The findings from large longitudinal studies and clinical trials are
beginning to emerge, although many of the conclusions are tentative. Some intervention
trials have been instigated.  
Cognitive decline is not always progressive, and some research findings have indicated that
a ‘healthy lifestyle’, and measures to maintain physical, mental and social health might be
beneficial in maintaining cognitive function in later life, at least in the short term. Risk
factors for vascular dementia are relatively well understood, and some dementia with
vascular causes may be preventable by reducing the risk of vascular disease by the control
of hypertension. At the moment, the only risk factors for Alzheimer's disease confirmed
beyond reasonable doubt are old age, a family history of dementia, Down’s syndrome and
the APOE 4 genotype. The evidence for other risk factors is inconclusive. However, an
association with vascular factors has been suggested by recent research, suggesting that
there might be some scope for prevention. At the moment, none of the known risk factors
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for dementia of the Alzheimer type is felt to give scope for preventative action. Also, because
of the relative importance (it seems at the moment) of age and – perhaps – genetic factors,
it may be that the possibilities for primary prevention of Alzheimer's disease by reducing risk
will always be limited (compared with cardio-vascular disease, for example). Nevertheless,
clinical trials of potentially beneficial interventions are felt to be worthwhile.  
The conclusion to be drawn from a review of the literature, therefore, is that at present there
are very few immediate prospects for effective action to reduce the incidence of dementia in
Scotland, particularly dementia of the Alzheimer type. However, prospects may be beginning
to improve. Research into risk factors and potential interventions is ongoing, and there is
much that remains to be investigated. For example, a number of environmental factors, such
as social class or poverty, have been little examined as yet. More factors may be found, and
much more will be learned about – for example - the relative importance of different factors,
the ways in which and the extent to which these factors interact, and the extent to which
they can be modified. Progress is being made. The hope is that new knowledge, together
with the increased understanding about ageing and the brain, will contribute to a better
understanding about the nature and the causes of cognitive decline and dementia. This in
turn may suggest possible methods of primary prevention.
Research findings tend to suggest that there is no one single ‘cause’ of dementia or cognitive
decline and, hence, that there is no one single ‘solution’. Age is an important contributory
factor, so that – unless ageing itself can be slowed – there is a limit to the extent to which
dementia and cognitive decline can be prevented altogether. At the same time, the findings
from research suggest that there are ways in which some risk might be reduced; there is
some scope for action. Measures to reduce the risk of vascular disease and stroke, such as
management of hypertension, avoiding excess cholesterol, stopping smoking, taking
moderate exercise, as well as reducing poverty, can help to reduce the risk of dementia of
vascular origin. It would also be prudent to avoid, where possible, severe head injury and
nutritional deficiency (which can occur with eating disorders or alcoholism). Eating a healthy
diet, staying socially involved and keeping mentally alert may also be beneficial. The main
message, therefore, is that ‘every little helps’ and may be worthwhile.
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APPENDIX
USEFUL REFERENCES AND WEBSITES
Alzheimer’s Scotland – Action on dementia
www.alzscot.org
The Dementia Services Development Centre, which is part of the Applied Social Science
Department, Faculty of Human Sciences at the University of Stirling, assists in the
development and improvement of services for people with dementia and their carers (but
not directly to carers).
www.stir.ac.uk/Departments/HumanSciences/AppSocSci/DS
Scottish statistics: see ISD webpage
http://www.show.scot.nhs.uk/isd/joint_futures/mental_health/mental_health_dem.htm
The Alzheimer's Association is the largest national voluntary health organization
supporting Alzheimer research and care.
http://www.alz.org
Alzheimer’s Research Forum gives details of research
http://www.alzforum.org
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